Anti-PSMA antibodies, variants thereof and uses thereof
By designing antibodies or antigen-binding fragments that specifically bind PSMA, the problem of antibody stability and effectiveness is solved, and efficient targeted treatment for prostate cancer and other tumors is achieved.
Patent Information
- Application Number
- CN202380024354.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-28
- Publication Date
- 2024-11-15
AI Technical Summary
The stability of protein drugs such as antibodies is affected by a variety of factors, resulting in degradation and reduced activity, affecting the effectiveness and safety of drugs.
Provides antibodies or antigen-binding fragments thereof that specifically bind PSMA, including specific light and heavy chain variable region sequence variants, by optimizing amino acid sequences to improve the stability and effectiveness of the antibody, and bind bispecific or multispecific Sex antibodies are designed to target the diagnosis and treatment of prostate cancer and other solid tumors.
It improves the stability and effectiveness of the antibody, enhances the affinity and target specificity for PSMA, improves the effect of treating prostate cancer and other tumors, and reduces the impact on normal tissues.
Smart Images

Figure CN118974097A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 325,330, filed on March 30, 2022. The contents of that application are incorporated herein by reference in their entirety.
[0003] Sequence Listing References
[0004] This application incorporates by reference the sequence listing submitted in computer readable form as file SeqList_168276.00301, which was created on March 27, 2023 and contains 81,222 bytes. Technical Field
[0005] The present application relates to improved anti-PSMA antibodies and methods of use thereof. Background Art
[0006] Prostate-specific membrane antigen (PSMA) has been confirmed to be a specific marker of prostate epithelial cells, which lays the foundation for the development of precision medicine targeting prostate cancer. Histological studies have shown that almost all prostate cancers express PSMA, and cancers with higher malignancy or metastasis, or resistance to androgen deprivation therapy, usually express higher PSMA (Ananias, HJ, et al. (2009) Prostate, 69 (10): 1101-8; Wright, GL, Jr., et al. (1995) Urol Oncol, 1 (1): 18-28; Wright, GL, Jr., et al. (1996) Urology, 48 (2): 326-34; Sweat, SD, et al. (1998) Urology, 52 (4): 637-40). It is noteworthy that the expression level of PSMA in normal tissues is 100 to 1000 times lower than that in tumors (Sokoloff, RL, et al. (2000) Prostate, 43 (2): 150-7), and these normal tissues are generally not easily accessible to circulating antibodies (Troyer, JK et al. (1995) Int J Cancer, 62 (5): 552-8), which further ensures the safety of PSMA-targeted imaging and treatment. In addition to the prostate, PSMA is also highly expressed in the new vasculature in many solid tumors, but not in normal blood vessels (Sokoloff, RL, et al. (2000) Prostate, 43 (2): 150-7). Therefore, PSMA is not only an ideal marker for prostate cancer, but also an ideal marker for targeted therapy of the new vasculature of other solid tumors.
[0007] Antibodies are the most effective tumor targeting tools because they can specifically recognize tumor-associated or tumor-specific antigens expressed on tumor cells, which has opened up avenues for antibody-based precision medicine, including tumor-targeted imaging and therapy, such as optical, PET, SPECT or MRI imaging for early tumor detection, antibody-drug conjugates and radiotherapy, bispecific or multispecific antibodies, chimeric antigen receptor T cell or NK cell therapy for cancer treatment.
[0008] However, the stability of protein drugs such as antibodies is adversely affected by many different factors. Protein degradation and subsequent reduction in protein activity is a recurring problem in the pharmaceutical industry. Therefore, there remains a need for antibodies as therapeutic agents with improved stability. Summary of the invention
[0009] The present disclosure addresses the above needs in multiple aspects. In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof or variant thereof that specifically binds to PSMA (eg, human PSMA). In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region (LCVR) comprising three light chain complementary determining regions (LCDRs) (LCDR1, LCDR2, and LCDR3), wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13 or SEQ ID NO:41, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; and / or (ii) a heavy chain variable region (HCVR) comprising three heavy chain complementary determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33 or SEQ ID NO:49, wherein the variant comprises one or more conservative amino acid substitutions in LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, or HCDR3.
[0010] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:25, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0011] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0012] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:41, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0013] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:49.
[0014] In some embodiments, the light chain variable region comprises one or more of the amino acid sequences of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, and SEQ ID NO:69.
[0015] In some embodiments, the heavy chain variable region comprises one or more of the amino acid sequences of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, and SEQ ID NO:68.
[0016] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:5, or comprises the amino acid sequence of SEQ ID NO:5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:21, or comprises the amino acid sequence of SEQ ID NO:21.
[0017] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:70, or comprises the amino acid sequence of SEQ ID NO:70; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:72, or comprises the amino acid sequence of SEQ ID NO:72.
[0018] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:71, or comprises the amino acid sequence of SEQ ID NO:71; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:73, or comprises the amino acid sequence of SEQ ID NO:73.
[0019] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:5, or comprises the amino acid sequence of SEQ ID NO:5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:74, or comprises the amino acid sequence of SEQ ID NO:74.
[0020] In some embodiments, the light chain variable region and the heavy chain variable region comprise the LCVR and HCVR amino acid sequence pairs of SEQ ID NO:5 and SEQ ID NO:21, SEQ ID NO:70 and SEQ ID NO:72, SEQ ID NO:71 and SEQ ID NO:73, or SEQ ID NO:5 and SEQ ID NO:74.
[0021] In some embodiments, the antibody or antigen-binding fragment thereof or variant thereof comprises a heavy chain / light chain sequence pair of SEQ ID NO:75 and SEQ ID NO:77, SEQ ID NO:76 and SEQ ID NO:78, SEQ ID NO:69 and SEQ ID NO:68, or SEQ ID NO:75 and SEQ ID NO:79.
[0022] In some embodiments, the antibody or antigen-binding fragment thereof or variant thereof comprises at least one of the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:37.
[0023] In some embodiments, the antibody or antigen-binding fragment thereof is selected from IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE; or has a wild-type or aglycosylated immunoglobulin constant region and / or variable region of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE.
[0024] In some embodiments, the antibody or antigen-binding fragment thereof is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, a mixture of monoclonal and / or polyclonal antibodies, a human antibody, a humanized antibody, or a chimeric antibody.
[0025] In some embodiments, the antibody or antigen-binding fragment thereof or variant thereof is conjugated to a cytotoxic agent, a drug, a growth inhibitory agent, a toxin, an enzyme, a tag, a label, a radioisotope, or a nanoparticle.
[0026] In another aspect, the present disclosure also provides bispecific or multispecific antibodies or antigen-binding fragments thereof that bind to two or more different epitopes on the same or different antigens. In some embodiments, one of the epitopes is on human prostate-specific membrane antigen (PSMA), and the bispecific or multispecific antibody comprises a light chain variable region and / or a heavy chain variable region of an antibody or antigen-binding fragment thereof or variant thereof as described herein.
[0027] On the other hand, the present disclosure further provides a separated chimeric antigen receptor (CAR). In some embodiments, CAR comprises an antibody or antigen binding fragment thereof described herein, or a variant thereof, a transmembrane domain, and an intracellular signaling domain comprising one or more stimulatory domains.
[0028] Also included within the scope of the present disclosure are (a) nucleic acid molecules encoding polypeptide chains of antibodies or antigen-binding fragments thereof or variants thereof, bispecific or multispecific antibodies or antigen-binding fragments thereof, or CARs as described herein; (b) vectors comprising nucleic acid molecules as described herein; and (c) cells comprising nucleic acid molecules or vectors as described herein.
[0029] In another aspect, the present disclosure provides a method for preparing an antibody or an antigen-binding fragment thereof. In some embodiments, the method comprises (i) obtaining a cell as described herein; (ii) culturing the cell in a culture medium under conditions that allow expression of a polypeptide encoded by a nucleic acid molecule and assembly of the antibody or its fragment; and (iii) purifying the antibody or fragment from the cultured cell or the culture medium of the cell.
[0030] In another aspect, the present disclosure additionally provides a composition comprising an antibody or antigen-binding fragment thereof, or a variant thereof, of the bispecific or multispecific antibody or antigen-binding fragment thereof, CAR, nucleic acid molecule, vector or cell described herein, and optionally a pharmaceutically acceptable carrier.
[0031] In another aspect, the present disclosure additionally provides a kit comprising an antibody or antigen-binding fragment thereof or variant thereof, a bispecific or multispecific antibody or antigen-binding fragment thereof, a CAR, a nucleic acid molecule, a vector, a cell or a composition described herein.
[0032] In another aspect, the present disclosure also provides use of the composition described herein for the preparation of a medicament for the diagnosis, prevention, treatment, or a combination thereof of a condition caused by a proliferative disease associated with the expression of PSMA in a subject.
[0033] In another aspect, the present disclosure further provides a method for preventing or treating a proliferative disease associated with PSMA expression in a subject. In some embodiments, the method comprises administering to the subject an effective amount of an antibody or antigen-binding fragment thereof, or variant thereof, a bispecific or multispecific antibody or antigen-binding fragment thereof, a CAR, a nucleic acid molecule, a vector, a cell, or a composition described herein.
[0034] In some embodiments, the method further comprises administering a second agent or treatment to the subject. In some embodiments, the second agent or treatment comprises an anticancer agent. In some embodiments, the second agent or treatment is administered to the subject before, after, or simultaneously with an antibody or antigen-binding fragment thereof, or variant thereof, a bispecific or multispecific antibody or antigen-binding fragment thereof, a CAR, a nucleic acid molecule, a vector, a cell, or a composition as described herein.
[0035] In another aspect, the present disclosure also provides a method for identifying a subject as having a disease or condition associated with PSMA expression. In some embodiments, the method comprises: (a) providing a tissue sample from a subject; (b) contacting the tissue sample with the antibody, or antigen-binding fragment thereof, or variant thereof; and (c) determining that the antibody, or antigen-binding fragment thereof, or variant thereof binds to the tissue sample, wherein binding of the antibody, or antigen-binding fragment thereof, or variant thereof to the tissue sample indicates the presence of a disease or condition associated with PSMA expression in the subject.
[0036] In yet another aspect, the present disclosure also provides an imaging method targeting PSMA. The method comprises administering an antibody or an antigen-binding fragment thereof or a variant thereof or a composition to a subject in need thereof, wherein the antibody or an antigen-binding fragment thereof or a variant thereof is linked to an agent. In some embodiments, the agent comprises a photoactivator, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, a fluorescent peptide, an imaging contrast agent, an enzyme, a nuclear magnetic resonance active agent, or a nanoparticle.
[0037] In some embodiments, the disease comprises cancer. In some embodiments, the cancer comprises prostate cancer.
[0038] In some embodiments, the subject is a mammal, such as a human.
[0039] The above overview is not intended to limit every aspect of the present disclosure, and additional aspects are described in other sections, such as the detailed description below. The entire document is intended to be described as a unified disclosure, and it should be understood that all combinations of features described herein are within the scope of consideration, even if the combinations of features are not found together in the same sentence or paragraph or section of the document. Other features and advantages of the present invention will become apparent from the detailed description below. However, it should be understood that the detailed description and specific examples, although indicating specific embodiments of the present disclosure, are given only by way of illustration, because various changes and modifications within the spirit and scope of the present disclosure will be apparent to those skilled in the art based on the detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] The following detailed description of the preferred embodiments of the present invention will be better understood when read in conjunction with the accompanying drawings. In order to illustrate the present invention, currently preferred embodiments are shown in the accompanying drawings. However, it should be understood that the present invention is not limited to the precise arrangement and means of the embodiments shown in the accompanying drawings.
[0041] Figure 1 Depicted are experimental results of measuring affinity for PSMAb and PSMAbLm by capture ELISA. The data showed that the affinity of PSMAbLm was approximately 2.3 times higher than that of PSMAb (Kd = 0.0479 nM (PSMAbLm) vs. Kd = 0.1088 nM (PSMAb)).
[0042] Figure 2ADCC activity of PSMAb-WT, PSMAb-AF, and PSMAbLm-AF on target cells is depicted. ADCC was studied using CD16-Jurkat reporter cells with PSMA+ CHO cells as targets. Abbreviations: PSMAb-WT: wild-type PSMAb with normal glycosylation; PSMAb-AF: defucosylated PSMAb; PSMAbLm-AF: defucosylated PSMAb with N=>S mutation in the CDR3 region of the light chain.
[0043] Figure 3A and Figure 3B Binding of PSMAb and PSMAbLm on LnCaP cells is depicted. Figure 3A Cell populations are shown, and Figure 3B The mean fluorescence intensity for each antibody concentration is shown.
[0044] Figure 4A , Figure 4B , Figure 4C and Figure 4D Internalization of PSMAb and PSMAbLm into LnCaP cells is depicted. FIG. 4A to FIG. 4C Shown are cell populations with internalized antibodies at antibody concentrations ranging from 0.001 nM to 0.009 nM, 0.027 nM to 0.247 nM, and 0.74 nM to 6.67 nM, respectively. Figure 4D Statistical fluorescence mean intensity of cells with different concentrations of internalized antibodies is shown. DETAILED DESCRIPTION
[0045] The present disclosure relates to compositions and methods for treating and / or preventing cancer, based in part on the discovery of optimized antibodies or antigen-binding fragments thereof that specifically bind to an epitope in the extracellular domain of PSMA (e.g., human PSMA).
[0046] In one aspect, the present disclosure provides antibodies or antigen-binding fragments thereof that bind to PSMA. The disclosed anti-PSMA antibodies or antigen-binding fragments thereof have superior stability and effectiveness compared to the parent antibody. Bispecific antibodies, antibody drug conjugates, PSMA-targeted imaging agents, chimeric antigen receptors, cells expressing chimeric antigen receptors, and the like are also within the scope of the present disclosure.
[0047] In some embodiments, the present disclosure provides a composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to the extracellular domain of PSMA. The antibody or its antigen-binding fragment can be formulated as a therapeutic and diagnostic composition targeting PSMA present in the new vasculature of prostate cancer and / or other solid tumors. In one embodiment, the composition may include an antibody drug conjugate (ADC), wherein the antibody or antibody or its antigen-binding fragment targets the drug to the tumor location. In one embodiment, the composition comprises a bispecific antibody. In some embodiments, the bispecific antibody comprises a first antigen-binding arm that specifically binds to PSMA and a second antigen-binding arm that binds to a T cell antigen (e.g., CD3). In one embodiment, the composition is a chimeric antigen receptor comprising an antibody or its antigen-binding fragment that specifically binds to PSMA.
[0048] On the other hand, the present disclosure also provides isolated nucleic acids encoding antibodies or antigen-binding fragments thereof, bispecific antibodies or chimeric antigen receptors as disclosed herein. Cells modified to express antibodies or antigen-binding fragments thereof, bispecific antibodies or chimeric antigen receptors disclosed herein, and cell cultures comprising the cells are also within the scope of the present disclosure.
[0049] The present disclosure additionally provides methods for treating or preventing cancer, including but not limited to prostate cancer. In some embodiments, the method comprises administering to a subject an effective amount of a composition comprising an antibody or antigen binding fragment thereof that specifically binds to PSMA. In some embodiments, the method comprises administering to a subject an antibody or antigen binding fragment thereof, a bispecific antibody, or a chimeric antigen receptor. In one embodiment, the method comprises administering to a subject an effective amount of a composition comprising an isolated nucleic acid encoding an antibody or antigen binding fragment thereof, a bispecific antibody, or a chimeric antigen receptor. In one embodiment, the method comprises administering to a subject a cell modified to express an antibody or antigen binding fragment thereof, a bispecific antibody, or a chimeric antigen receptor.
[0050] The present disclosure further provides methods for detecting cancer in a subject. In some embodiments, the method comprises administering to the subject a targeted imaging agent comprising an antibody or antigen binding fragment thereof that specifically binds to PSMA. In some embodiments, the antibody or antigen binding fragment thereof can be conjugated to any imaging agent to provide a targeted imaging agent for use in various imaging modalities, including but not limited to PET, SPECT, MRI, or optical imaging.
[0051] Antibody
[0052] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to an epitope in the extracellular portion of PSMA. In some embodiments, the extracellular portion of PSMA comprises the amino acid sequence of SEQ ID NO:1.
[0053] The disclosed antibodies or antigen-binding fragments thereof are based in part on the optimization of the anti-PSMA antibodies described in WO2017180713A1. The optimization includes a mutation of the "NG" sequence to "SG" in the CDR3 of the light chain. Importantly, such optimization eliminates the potential deamidation of asparagine (Asn or N). It also imparts several excellent properties to the disclosed antibodies or antigen-binding fragments thereof, including improved stability and effectiveness, without negatively affecting antigen binding affinity. For example, the affinity of the optimized intact antibody represented by PSMAbLm shows the same or even slightly higher affinity than its parent antibody PSMAb (e.g., Kd = 0.049 nM for PSMAbLm compared to Kd = 0.1088 nM for the antibody of WO2017180713A1).
[0054] The disclosed antibodies or antigen-binding fragments are not limited to the mutation of the "NG" sequence in the CDR3 of the light chain to "SG". The disclosed antibodies or antigen-binding fragments also include any possible mutations, which include one or a combination of mutations listed below: any mutation of Asn in the CDR3 of the light chain, including but not limited to mutation to Ala, Arg, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Gly in the CDR3 of the light chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val.
[0055] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, said any possible mutations containing one or a combination of the following mutations to remove the potential deamidation site of "NS" in FR3 of the heavy chain: any mutation of Asn in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Ser in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Thr, Trp, Tyr or Val.
[0056] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, which contain one or a combination of the following mutations to remove the potential deamidation site of "NT": any mutation of Asn in the CDR2 of the light chain, including but not limited to mutation to Ala, Arg, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Thr in the CDR2 of the light chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Trp, Tyr or Val.
[0057] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, said any possible mutations containing one or a combination of the following mutations to remove the potential deamidation site of "NT" in FR3 of the heavy chain: any mutation of Asn in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Thr in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Trp, Tyr or Val.
[0058] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, which contain one or a combination of the following mutations to remove the potential isomerization motif of "DG" in the CDR2 of the heavy chain: any mutation of Asp in the CDR2 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Gly in the CDR2 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val.
[0059] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, which contain one or a combination of the following mutations to remove the potential isomerization motif of "DS" in the CDR3 of the light chain: any mutation of Asp in the CDR3 of the light chain, including but not limited to mutation to Ala, Arg, Asn, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Ser in the CDR3 of the light chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Thr, Trp, Tyr or Val.
[0060] The disclosed antibodies or antigen-binding fragments also comprise any possible mutations, said any possible mutations containing one or a combination of the following mutations to remove the potential isomerization motif of "DS" in FR3 of the heavy chain: any mutation of Asp in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; and / or any mutation of Ser in FR3 of the heavy chain, including but not limited to mutation to Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Thr, Trp, Tyr or Val.
[0061] Antibody drug conjugates (ADCs) are also provided in the present disclosure. ADCs are a platform strategy for the delivery of antigen-specific toxicity equipped antibodies. The basic principle is to couple an antibody (usually a tumor-targeted antibody) with a super-toxic drug to selectively kill tumor cells in a targeted manner while sparing normal tissues. Drugs used in ADCs are mainly divided into two types; one is microtubule inhibitors, such as auristatin (MMAE, MMAF) (Stephan, JP, et al. (2008) Bioconjug Chem, 19(8):1673-83; Younes, A., et al. (2010) N Engl J Med, 363(19):1812-21; Okeley, NM, et al. (2010) Clin Cancer Res, 16(3):888-970) and maytansinoids (DM1 and DM4) (Lambert, JM et al. (2014). J Med Chem, 57(16):6949-64; Bender, B., et al. (2014) AAPS J, 16(5):994-1008; Raufi, A., AS. Ebrahim et al. (2014) AAPS J, 16(5):994-1008; al. (2013) Cancer Manag Res, 5: 225-33); another type is double-stranded DNA cleavage agents, such as calicheamicin. Due to their extreme toxicity, some drugs cannot be used alone as chemotherapeutic agents; instead, they must be coupled to antibodies to reduce side effects and improve therapeutic efficacy.
[0062] Bispecific or multispecific antibodies are also within the scope of the present disclosure. Bispecific monoclonal antibodies (BsMAbs, BsAbs) are another strategy for preparing powerful anti-tumor weapons using novel antibodies. BsAbs are artificial proteins that are composed of fragments of two different monoclonal antibodies and are therefore bound to two different types of antigens. The most widely used application of this method is in cancer immunotherapy, where BsMAbs are engineered to simultaneously bind to cytotoxic cells (using receptor-like CD3) and targets (such as tumor cells to be destroyed) (Muller D et al. (2010) BioDrugs, 24 (2): 89-98; Chames Pl et al. (2009) MAbs, 1 (6): 539-47). Bispecific T cell adapters (BiTEs) and dual affinity retargeting (DARTs) are examples of small fragment BsAbs. A variety of larger BsAbs have also been developed, such as knob-in-hole IgG, CrossMab, TrioMab, DVD Ig (Kontermann RE et al. (2015) Drug Discov Today, 20 (7) 838-47). In BsAb, one arm can be a T cell or NK cell activating antibody, such as anti-CD3 or anti-CD16 antibody, and the other arm can be a tumor targeting antibody; or the two arms target different tumor markers for synergistic inhibition of tumor growth.
[0063] The present disclosure further provides a composition comprising a chimeric antigen receptor (CAR). For example, in some embodiments, the composition is a cell genetically modified to express CAR. For example, in some embodiments, T cells or NK cells are genetically engineered to produce CAR on their surface, which allows T cells or NK cells to recognize specific proteins (antigens) on tumor cells. ScFv is the most commonly used receptor for this engineering modification, and has been successfully used in clinical cancer treatment (Grupp SA et al. (2013) N Engl J Med, 368 (16): 1509-18; Porter DL et al. (2011) N Engl J Med, 365 (8): 725-33). ScFv is fused with an intracellular signaling domain via a hinge and a transmembrane domain. Such molecules respond to the recognition of scFv by its target and cause activation of T cells or NK cells. When T cells or NK cells express such CAR, they recognize and kill target cells expressing target antigens. Several CARs targeting tumor-associated antigens have been developed, and adoptive transfer approaches using such CAR-expressing T cells are currently in clinical trials for the treatment of various cancers.
[0064] In one embodiment, the antibody or antigen-binding fragment thereof comprises a high affinity anti-PSMA scFv Mut-gy1 comprising the amino acid sequence of SEQ ID NO:3.
[0065] In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 5. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR1 comprising the amino acid sequence of SEQ ID NO: 7. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 9. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR2 comprising the amino acid sequence of SEQ ID NO: 11. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 13. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR3 comprising the amino acid sequence of SEQ ID NO: 15. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 17. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR4 comprising the amino acid sequence of SEQ ID NO:19.
[0066] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 21. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR1 comprising the amino acid sequence of SEQ ID NO: 23. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR2 comprising the amino acid sequence of SEQ ID NO: 27. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR3 comprising the amino acid sequence of SEQ ID NO: 31. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR4 comprising the amino acid sequence of SEQ ID NO: 35. In one embodiment, the antibody or antigen-binding fragment thereof comprises a scFv linker comprising the amino acid sequence of SEQ ID NO:37.
[0067] For example, in one embodiment, the antibody or antigen-binding fragment thereof comprises a scFv denoted herein as Mut-gy1. In one embodiment, the antibody or antigen-binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 3. In one embodiment, Mut-gy1 comprises a light chain and a heavy chain, the light chain comprising the amino acid sequence of SEQ ID NO: 5 and the heavy chain comprising the amino acid sequence of SEQ ID NO: 21. In one embodiment, Mut-gy1 comprises VL FR1, VL CDR1, VL FR2, VL CDR2, VL FR3, VL CDR3, VL FR4, VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VHCDR3 and / or VH FR4, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO:7; the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VL FR2 comprises the amino acid sequence of SEQ ID NO:11; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL FR3 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17; the VL FR4 comprises the amino acid sequence of SEQ ID NO:19; the VH FR1 comprises the amino acid sequence of SEQ ID NO:23; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:24. NO: 25; the VH FR2 comprises the amino acid sequence of SEQ ID NO: 27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 29; the VH FR3 comprises the amino acid sequence of SEQ ID NO: 31; the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 33; and / or the VH FR4 comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, the antibody or antigen-binding fragment thereof comprises a scFv linker comprising the amino acid sequence of SEQ ID NO: 37.
[0068] In one embodiment, the antibody or antigen-binding fragment thereof comprises one or more mutations. For example, in one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR2 comprising the amino acid sequence of SEQ ID NO: 39, wherein SEQ ID NO: 39 comprises a V→A point mutation relative to SEQ ID NO: 11. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 41, wherein SEQ ID NO: 41 comprises a G→E point mutation relative to SEQ ID NO: 13. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VL FR4 comprising the amino acid sequence of SEQ ID NO: 43, wherein SEQ ID NO: 43 comprises a V→A point mutation relative to SEQ ID NO: 19. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 45, wherein SEQ ID NO: 45 comprises an S→F point mutation relative to SEQ ID NO: 25. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR3 comprising the amino acid sequence of SEQ ID NO: 47, wherein SEQ ID NO: 47 comprises an I→V point mutation relative to SEQ ID NO: 31. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 49, wherein SEQ ID NO: 49 comprises a D→G point mutation relative to SEQ ID NO: 33. In one embodiment, the antibody or antigen-binding fragment thereof comprises a VH FR4 comprising the amino acid sequence of SEQ ID NO: 51, wherein SEQ ID NO: 51 comprises a G→E point mutation relative to SEQ ID NO: 35.
[0069] In one embodiment, the antibody or antigen-binding fragment thereof comprises an scFv represented herein as Mut-gy1-st. In one embodiment, Mut-gy1-st comprises VL FR2, VH CDR1 and VH FR4, wherein the VL FR2 comprises the amino acid sequence of SEQ ID NO: 39; the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 45, and the VH FR4 comprises the amino acid sequence of SEQ ID NO: 51. In one embodiment, Mut-gy1-st comprises VL FR1, VL CDR1, VLFR2, VL CDR2, VL FR3, VL CDR3, VL FR4, VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VHCDR3 and / or VH FR4, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO:7; the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VL FR2 comprises the amino acid sequence of SEQ ID NO:39; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL FR3 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17; the VL FR4 comprises the amino acid sequence of SEQ ID NO:19; the VH FR1 comprises the amino acid sequence of SEQ ID NO:23; the VH CDR1 comprises the amino acid sequence of SEQ ID NO: NO:45; the VH FR2 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:29; the VH FR3 comprises the amino acid sequence of SEQ ID NO:31; the VH CDR3 comprises the amino acid sequence of SEQ ID NO:33; and / or the VH FR4 comprises the amino acid sequence of SEQ ID NO:51. In some embodiments, the antibody or antigen-binding fragment thereof comprises a scFv linker comprising the amino acid sequence of SEQ ID NO:37.
[0070] In one embodiment, the composition comprises an antibody fragment comprising an scFv represented herein as Mut-gy1-2. In one embodiment, Mut-gy1-2 comprises VL CDR2, VL FR4, VH CDR1 and VH FR3, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 41; the VL FR4 comprises the amino acid sequence of SEQ ID NO: 43; the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 45, and the VH FR3 comprises the amino acid sequence of SEQ ID NO: 47. In one embodiment, Mut-gy1-2 comprises VL FR1, VL CDR1, VL FR2, VL CDR2, VL FR3, VLCDR3, VL FR4, VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VH CDR3 and / or VH FR4, wherein the VLFR1 comprises the amino acid sequence of SEQ ID NO:7; the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VLFR2 comprises the amino acid sequence of SEQ ID NO:11; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:41; the VL FR3 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17; the VL FR4 comprises the amino acid sequence of SEQ ID NO:43; the VH FR1 comprises the amino acid sequence of SEQ ID NO:23, and the VH CDR1 comprises the amino acid sequence of SEQ ID NO: NO:45; the VH FR2 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:29; the VH FR3 comprises the amino acid sequence of SEQ ID NO:47; the VH CDR3 comprises the amino acid sequence of SEQ ID NO:33; and / or the VH FR4 comprises the amino acid sequence of SEQ ID NO:35. In some embodiments, the antibody or antigen-binding fragment thereof comprises a scFv linker comprising the amino acid sequence of SEQ ID NO:37.
[0071] In one embodiment, the composition comprises an antibody fragment comprising an scFv represented herein as Mut-gy1-3. In one embodiment, Mut-gy1-3 comprises a VH CDR1 and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 45 and the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 49. In one embodiment, Mut-gy1-3 comprises VL FR1, VL CDR1, VL FR2, VL CDR2, VL FR3, VL CDR3, VL FR4, VH FR1, VH CDR1, VH FR2, VH CDR2, VH FR3, VH CDR3 and / or VH FR4, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO:7; the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; the VL FR2 comprises the amino acid sequence of SEQ ID NO:11; the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; the VL FR3 comprises the amino acid sequence of SEQ ID NO:15; the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17; the VL FR4 comprises the amino acid sequence of SEQ ID NO:19; the VH FR1 comprises the amino acid sequence of SEQ ID NO:23; the VH CDR1 comprises the amino acid sequence of SEQ ID NO:24. NO:45; the VH FR2 comprises the amino acid sequence of SEQ ID NO:27; the VH CDR2 comprises the amino acid sequence of SEQ ID NO:29; the VH FR3 comprises the amino acid sequence of SEQ ID NO:31; the VH CDR3 comprises the amino acid sequence of SEQ ID NO:49; and / or the VH FR4 comprises the amino acid sequence of SEQ ID NO:35. In some embodiments, the antibody or antigen-binding fragment thereof comprises a scFv linker comprising the amino acid sequence of SEQ ID NO:37.
[0072] In one embodiment, the scFv described herein can be engineered into another fragment antibody or a full-length antibody, wherein the fragment antibody refers to Fab, Fab', (Fab')2, Fv, scFv-Fc, scFv-CH2, scFv-CH3 or a full-length antibody.
[0073] In some embodiments, the antibody or antigen-binding fragment thereof comprises a Mut-gy1-2 scFv, which is denoted herein as PSMAbLm. In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 68. In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain having a signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 55.
[0074] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57. In one embodiment, the antibody comprises a heavy chain constant region of SEQ ID NO:59.
[0075] In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 69. In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain having a signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 61 or SEQ ID NO: 63. In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 65. In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain constant region of SEQ ID NO: 67.
[0076] In one aspect, the present disclosure provides antibodies or antigen-binding fragments thereof or variants thereof that specifically bind to PSMA (eg, human PSMA). In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region (LCVR) comprising three light chain complementarity determining regions (LCDRs) (LCDR1, LCDR2, and LCDR3), wherein LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13 or SEQ ID NO:41, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; and / or (ii) a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33 or SEQ ID NO:49, wherein the variant comprises one or more conservative amino acid substitutions in LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, or HCDR3.
[0077] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:25, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0078] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0079] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:41, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:33.
[0080] In some embodiments, LCDR1 comprises the amino acid sequence of SEQ ID NO:9, LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and LCDR3 comprises the amino acid sequence of SEQ ID NO:17; HCDR1 comprises the amino acid sequence of SEQ ID NO:45, HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and HCDR3 comprises the amino acid sequence of SEQ ID NO:49.
[0081] In some embodiments, the light chain variable region comprises one or more of the amino acid sequences of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, and SEQ ID NO:69.
[0082] In some embodiments, the heavy chain variable region comprises one or more of the amino acid sequences of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, and SEQ ID NO:68.
[0083] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:5, or comprises the amino acid sequence of SEQ ID NO:5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:21, or comprises the amino acid sequence of SEQ ID NO:21.
[0084] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:70, or comprises the amino acid sequence of SEQ ID NO:70; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:72, or comprises the amino acid sequence of SEQ ID NO:72.
[0085] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:71, or comprises the amino acid sequence of SEQ ID NO:71; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:73, or comprises the amino acid sequence of SEQ ID NO:73.
[0086] In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:5, or comprises the amino acid sequence of SEQ ID NO:5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to the amino acid sequence of SEQ ID NO:74, or comprises the amino acid sequence of SEQ ID NO:74.
[0087] In some embodiments, the light chain variable region and the heavy chain variable region comprise the LCVR and HCVR amino acid sequence pairs of SEQ ID NO:5 and SEQ ID NO:21, SEQ ID NO:70 and SEQ ID NO:72, SEQ ID NO:71 and SEQ ID NO:73, or SEQ ID NO:5 and SEQ ID NO:74.
[0088] In some embodiments, the antibody or antigen-binding fragment thereof or variant thereof comprises a heavy chain / light chain sequence pair of SEQ ID NO:75 and SEQ ID NO:77, SEQ ID NO:76 and SEQ ID NO:78, SEQ ID NO:69 and SEQ ID NO:68, or SEQ ID NO:75 and SEQ ID NO:79.
[0089] In some embodiments, the antibody or antigen-binding fragment thereof or variant thereof comprises at least one of the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:37.
[0090] Representative sequences
[0091]
[0092] SEQ ID NO: 1 PSMA extracellular domain:
[0093] KSSNEATNITPKHNM:KAFLDELKAENIKKFLYNFTQIPHLAGT EQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPL YHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA
[0094] SEQ ID NO:2 Mut-gy1 scFv nucleotide sequence:
[0095] CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGTGTCATTATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTCTCATGTACACTGGTACCAGCAGGTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGAAACACCAATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGGTTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGCTGATTATTATTGTGCAACATGGGATGACAGTCTGAGTGGTGTAATATTCGGCGGAGGGACCAAGGTCACCGTCCTAGGCGGATCCTCTAGGTCAAGTTCCAGCGGCGGCGGTGGCAGCGGAGGCGGCGGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGCCCTGGCCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATCCACCCTCAGTGGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTACTATTGTGCTAAAGGCCTTACTTGGGGACTCGGTGACAATGATGCTCTCGATATCTGGGGCCCCGGGACCACGGTCACCGTCTCCTCA
[0096] SEQ ID NO:3 Mut-gy1 scFv Amino acid sequence:
[0097] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKVTVLGGSSRSSSSGGGGSGGGGEVQLVESGGALAKPGGSLRLSCAASGSTLSGYAf'IHWVRQAPGKGLEWVAVISY DGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKG LTWGLGDNDALDIWGPGTTVTVSS
[0098] SEQ ID NO:4 Mut-gy1 VL nucleotide sequence:
[0099] CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGTGTCATT
[0100] ATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTCTCATGTACACTGGTACCAGCAGGTTCCAGGAACAGCCCCCAAACTCCTCATCTATGGAAACACCAATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGGTTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGCTGATTATTATTGTGCAACATGGGATGACAGTCTGAGTGGTGTAATATTCGGCGGAGGGACCAAGGTCACCGTCCTA
[0101] SEQ ID NO:5 Mut-gy1 VL amino acid sequence:
[0102] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKVTVL
[0103] SEQ ID NO:6 Mut-gy1 VL FR1 nucleotide sequence:
[0104] CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCC AGGGCAGAGTGTCATTATCTCCTGCACTGGGAGC
[0105] SEQ ID NO:7 Mut-gy1 VL FR1 amino acid sequence:
[0106] QSVLTQPPSVSGAPGQSVIISCTGS
[0107] SEQ ID NO:8 Mut-gy1 VL CDR1 nucleotide sequence:
[0108] AGCTCCAACATCGGGGCAGGTTCTCAT
[0109] SEQ ID NO:9 Mut-gy1 VL CDR1 amino acid sequence:
[0110] SSNIGAGSH
[0111] SEQ ID NO:10 Mut-gy1 VL FR2 nucleotide sequence:
[0112] GTACACTGGTACCAGCAGGTTCCAGGAACAGCCCCCAAACT CCTCATCTAT
[0113] SEQ ID NO:11Mut-gy1 VL FR2 amino acid sequence:
[0114] VHWYQQVPGTAPKLLIY
[0115] SEQ ID NO:12 Mut-gy1 VL CDR2 nucleotide sequence:
[0116] GGAAACACC
[0117] SEQ ID NO:13Mut-gy1 VL CDR2 amino acid sequence:
[0118] GNT
[0119] SEQ ID NO:14 Mut-gy1 VL FR3 nucleotide sequence:
[0120] AATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGGTTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGCTGATTATTATTGT
[0121] SEQ ID NO:15 Mut-gy1 VL FR3 amino acid sequence:
[0122] NRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYC
[0123] SEQ ID NO:16 Mut-gy1 VL CDR3 nucleotide sequence:
[0124] GCAACATGGGATGACAGTCTGAGTGGTGTAATA
[0125] SEQ ID NO: 17Mut-gy1 VL CDR3 amino acid sequence
[0126] ATWDDSLSGVI
[0127] (ASN to Ser substitution is in bold)
[0128] SEQ ID NO: 18: Mut-gy1 VL FR4 nucleotide sequence
[0129] TTCGGCGGAGGGACCAAGGTCACCGTCCTA
[0130] SEQ ID NO:19 Mut-gy1 VL FR4 amino acid sequence:
[0131] FGGGTKVTVL
[0132] SEQ ID NO:20 Mut-gy1 VH nucleotide sequence:
[0133] GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCCTGGCCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATCCACCCTCAGTGGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTACTATTGTGCTAAAGGCCTTACTTGGGGACTCGGTGACAATGATGCTCTCGATATCTGGGGCCCCGGGACCACGGTCACCGTCTCCTCA
[0134] SEQ ID NO:21 Mut-gy1 VH amino acid sequence:
[0135] EVQLVESGGALAKPGGSLRLSCAASGSTLSGYAMHWVRQAPG KGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPGTTVTVSS
[0136] SEQ ID NO:22 Mut-gy1 VH FR1 nucleotide sequence:
[0137] GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCCTGGCCAAGCC TGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCT
[0138] SEQ ID NO:23 Mut-gy1 VH FR1 amino acid sequence:
[0139] EVQLVESGGALAKPGGSLRLSCAAS
[0140] SEQ ID NO:24 Mut-gy1 VH CDR1 nucleotide sequence:
[0141] GGATCCACCCTCAGTGGCTATGCT
[0142] SEQ ID NO:25 Mut-gy1 VH CDR1 amino acid sequence:
[0143] GST LSGYA
[0144] SEQ ID NO:26 Mut-gy1 VH FR2 nucleotide sequence:
[0145] ATGCACTGGGTCCCGCCAGGCTCCAGGCAAGGGGCTGGAGTG GGTGGCAGTT
[0146] SEQ ID NO:27 Mut-gy1 VH FR2 amino acid sequence:
[0147] MHWVRQAPGKGLEWVAV
[0148] SEQ ID NO:28 Mut-gy1 VH CDR2 nucleotide sequence:
[0149] ATATCATATGATGGAAGCAATAAA
[0150] SEQ ID NO:29Mut-gy1 VH CDR2 amino acid sequence:
[0151] ISYDGSNK
[0152] SEQ ID NO:30 Mut-gy1 VH FR3 nucleotide sequence:
[0153] TACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTACTATTGT
[0154] SEQ ID NO:31 Mut-gy1 VH FR3 amino acid sequence:
[0155] YYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYC
[0156] SEQ ID NO 32 Mut-gy1 VH CDR3 nucleotide sequence:
[0157] GCTAAAGGCCTTACTTGGGGACTCGGTGACAATGATGCTCTC GATATC
[0158] SEQ ID NO:33 Mut-gy1 VH CDR3 amino acid sequence:
[0159] AKGLTWGLGDNDALDI
[0160] SEQ ID NO:34 Mut-gy1 VH FR4 nucleotide sequence:
[0161] TGGGGCCCCGGGACCACGGTCACCGTCTCCTCA
[0162] SEQ ID NO:35 Mut-gy1 VH FR4 amino acid sequence:
[0163] WGPGTTVTVSS
[0164] SEQ ID NO:36 Mut-gy1 scFv linker nucleotide sequence:
[0165] GGCGGATCCTCTAGGTCAAGTTCCAGCGGCGGCGGTGGCAG CGGAGGCGGCGGT
[0166] SEQ ID NO:37 Mut-gy1 scFv linker amino acid sequence:
[0167] GGSSRSSSSGGGGSGGGG
[0168] SEQ ID NO:38 Mut-gy1 VL FR2 nucleotide sequence (variant):
[0169] GTACACTGGTACCAGCAGGCTCCAGGAACAGCCCCCAAACT CCTCATCTAT
[0170] SEQ ID NO:39 Mut-gy1 VL FR2 amino acid sequence (variant):
[0171] VHWYQQAPGTAPKLLIY(V=>A)
[0172] SEQ ID NO:40 Mut-gy1 VL CDR2 nucleotide sequence (variant):
[0173] GAAAACACC
[0174] SEQ ID NO:41 Mut-gy1 VL CDR2 amino acid sequence (variant):
[0175] ENT(G=>E)
[0176] SEQ ID NO:42 Mut-gy1 VL FR4 nucleotide sequence (variant)
[0177] TTCGGCGGAGGGACCAAGGCCACCGTCCTA
[0178] SEQ ID NO:43 Mut-gy1 VL FR4 amino acid sequence (variant):
[0179] FGGGTKATVL(V=>A)
[0180] SEQ ID NO:44 Mut-gy1 VH CDR1 nucleotide sequence (variant):
[0181] GGATTCACCCTCAGTGGCTATGCT
[0182] SEQ ID NO:45 Mut-gy1 VH CDR1 amino acid sequence (variant):
[0183] GFTLSGYA(S=>F)
[0184] SEQ ID NO:46: Mut-gy1 VH FR3 nucleotide sequence (variant)
[0185] TACTACGCAGACTCCGTGAAGGGCCGATTCACCGTCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGA GACCTGAGGACACGGCTGTGTACTATTGT
[0186] SEQ ID NO:47 Mut-gy1 VH FR3 amino acid sequence (variant):
[0187] YYADSVKGRFTVSRDNSKNTLFLQMNSLRPEDTAVYYC(I=>V)
[0188] SEQ ID NO:48 Mut-gy1 VH CDR3 nucleotide sequence (variant):
[0189] GCTAAAGGCCTTACTTGGGGACTCGGTGACAATGATGCTCTC GGTATC
[0190] SEQ ID NO:49 Mut-gy1 VH CDR3 amino acid sequence (variant):
[0191] AKGLTWGLGDNDALGI(D=>G)
[0192] SEQ ID NO:50: Mut-gy1 VH FR4 nucleotide sequence (variant):
[0193] TGGGGCCCCGAGACCACGGTCACCGTCTCCTCA
[0194] SEQ ID NO:51 Mut-gy1 VH FR4 amino acid sequence (variant):
[0195] WGPETTVTVSS(G=>E)
[0196] SEQ ID NO:52: PSMAbLm heavy chain nucleotide sequence:
[0197] ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGCCCTGGCCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCCTCAGTGGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCGTCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTACTATTGTGCTAAAGGCCTTACCTGGGGACTCGGTGACAATGATGCTCTCGATATCTGGGGCCCCGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
[0198] SEQ ID NO:53 PSMAbLm Amino acid sequence:
[0199] MEFGLSWVFLVALLRGVQCEVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTVSRDNSKNTLFLQMNSLRPEDTAVYYCAKG LTWGLGDNDALDIWGPGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0200] SEQ ID NO:54 PSMAbLm heavy chain signal peptide nucleotide sequence:
[0201] ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTA AGAGGTGTCCAGTGT
[0202] SEQ ID NO:55 PSMAbLm heavy chain signal peptide amino acid sequence:
[0203] MEFGLSWVFLVALLRGVQC
[0204] SEQ ID NO:56 PSMAbLm heavy chain variable region nucleotide sequence:
[0205] GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCCTGGCCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCCTCAGTGGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCGTCTCCAGAGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTGTACTATTGTGCTAAAGGCCTTACCTGGGGACTCGGTGACAATGATGCTCTCGATATCTGGGGCCCCGGGACCACGGTCACCGTCTCCTCA
[0206] SEQ ID NO:57 Amino acid sequence of the variable region of the heavy chain of PSMAbLm:
[0207] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTVSRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPGTTVTVSS
[0208] SEQ ID NO:58 Nucleotide sequence of the constant region of the heavy chain of PSMAbLm:
[0209] GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAG GAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
[0210] Amino acid sequence of the constant region of the heavy chain of SEQ ID NO:59 PSMAbLm:
[0211] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0212] Nucleotide sequence of the light chain of SEQ ID NO:60 PSMAbLm:
[0213] ATGGCCTGGTCTCCTCTCCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCCCAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGTGTCATTATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTCTCATGTACACTGGTACCAGCAGGTTCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAACACCAATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGGTTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGCTGATTATTATTGTGCAACATGGGATGACAGTCTGAGTGGTGTAATATTCGGCGGAGGGACCAAGGCCACCGTCCTAGGTCAGCC CAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATGA
[0214] SEQ ID NO: 61 Amino acid sequence of the light chain of PSMAbLm:
[0215] MAWSPLLLTLLAHCTGSWAQSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYENTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSG VIFGGGTKATVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0216] SEQ ID NO:62 PSMAbLm light chain signal peptide nucleotide sequence:
[0217] ATGGCCTGGTCTCCTCTCCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCC
[0218] SEQ ID NO:63 PSMAbLm light chain signal peptide amino acid sequence:
[0219] MAWSPLLLTLLAHCTGSWA
[0220] SEQ ID NO:64 PSMAbLm light chain variable region nucleotide sequence:
[0221] CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGTGTCATTATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTCTCATGTACACTGGTACCAGCAGGTTCCAGGAACAGCCCCCAAACTCCTCATCTATGAAAACACCAATC GGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGGTTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGCTGATTATTGTGCAACATGGGATGACAGTCTGAGTGGTGTAATATTCGGCGGAGGGACCAAGGCCACCGTCCTA
[0222] SEQ ID NO:65 PSMAbLm light chain variable region amino acid sequence:
[0223] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYENTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKATVL
[0224] SEQ ID NO:66 PSMAbLm light chain constant region nucleotide sequence:
[0225] GGTCAGCCCAAGGCTGCCCTCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTG GAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
[0226] SEQ ID NO:67 PSMAbLm light chain constant region amino acid sequence:
[0227] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0228] SEQ ID NO:68 Amino acid sequence of PSMAbLm heavy chain without signal peptide:
[0229] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTVSRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0230] Amino acid sequence of the light chain of PSMAbLm without signal peptide: SEQ ID NO: 69
[0231] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYENTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCA TWDDSLSGVIFGGGTKATVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0232] Amino acid sequence of Mut-gy1-st VL: SEQ ID NO: 70
[0233] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQAPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKVTVL
[0234] SEQ ID NO:71 Mut-gy1-2 VL amino acid sequence:
[0235] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYENTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKATVL
[0236] SEQ ID NO:72Mut-gy1-st VH amino acid sequence:
[0237] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPETTVTVSS
[0238] SEQ ID NO:73Mut-gy1-2 VH amino acid sequence:
[0239] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTVSRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPGTTVTVSS
[0240] SEQ ID NO:74 Mut-gy1-3 VH amino acid sequence:
[0241] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALGIWGPGTTVTVSS
[0242] SEQ ID NO:75 Amino acid sequence of PSMAb1Lm light chain without signal peptide (from Mut-gy1):
[0243] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQVPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKV TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0244] SEQ ID NO:76 Amino acid sequence of PSMAb1stLm light chain without signal peptide (from Mut-gy1-st):
[0245] QSVLTQPPSVSGAPGQSVIISCTGSSSNIGAGSHVHWYQQAPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSGSLAITGLQPEDEADYYCATWDDSLSGVIFGGGTKV TVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0246] SEQ ID NO: 77 Amino acid sequence of PSMAb1Lm heavy chain without signal peptide (from Mut-gy1):
[0247] EVQLVESGGALAKPGGSLRLSCAASGSTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0248] SEQ ID NO: 78 Amino acid sequence of the heavy chain of PSMAb1stLm without signal peptide (from Mut-gy1-st):
[0249] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALDIWGPETTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0250] Amino acid sequence of the light chain of PSMAb3Lm without signal peptide (from Mut-gy1-3): SEQ ID NO:79
[0251] EVQLVESGGALAKPGGSLRLSCAASGFTLSGYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMNSLRPEDTAVYYCAKGLTWGLGDNDALGIW GPGTTVTVSSASTKGPSVFPLAPSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0252] In some embodiments, the term "epitope" refers to a region of an antigen that binds to an antibody. It is a region of an antigen that is recognized by a first antibody, wherein the binding of the first antibody to the region prevents the binding of a second antibody or other bivalent molecule to the region. The region includes a specific core sequence or a sequence that is selectively recognized by a class of antibodies. Typically, an epitope is formed by a localized surface structure that can be formed by a continuous or non-continuous amino acid sequence.
[0253] In another embodiment, the terms "selectively recognize," "selectively bind," or "selectively recognizes" means that the antibody or other bivalent molecule binds to an epitope at least 2-fold, 2-fold to 5-fold, or greater than 5-fold stronger than the binding of the bivalent molecule to an unrelated epitope, or at least 2-fold, 2-fold to 5-fold, or greater than 5-fold stronger than the binding of an unrelated bivalent molecule to the epitope, as determined by techniques known in the art and described herein, e.g., ELISA and cold displacement assays.
[0254] In some embodiments, the term "antibody" refers to the structure of the natural biological form of the antibody. In most mammals (including humans and mice), this form is a tetramer and consists of two identical immunoglobulin chain pairs, each pair having a light chain and a heavy chain, each light chain comprising immunoglobulin domains VL and CL, and each heavy chain comprising immunoglobulin domains VH, Cγ1, Cγ2, Cγ3 and Cγ4. In each pair, the light chain and heavy chain variable regions (VL and VH) are jointly responsible for binding antigens, and the constant regions (CL, Cγ1, Cγ2, Cγ3 and Cγ4, particularly Cγ1, Cγ2 and Cγ3) are responsible for antibody effector functions. In some mammals (e.g., in camels and llamas), full-length antibodies can be composed of only two heavy chains, each of which comprises immunoglobulin domains VH, Cγ2 and Cγ3. "Immunoglobulin (Ig)" herein means a protein consisting of one or more polypeptides, which are substantially encoded by immunoglobulin genes. Immunoglobulins include, but are not limited to, antibodies. Immunoglobulins can have a variety of structural forms, including but not limited to full-length antibodies, antibody fragments, and single immunoglobulin domains, including but not limited to VH, Cγ1, Cγ2, Cγ3, Cγ4, VL, and CL.
[0255] Depending on the amino acid sequence of the constant region of their heavy chains, intact antibodies can be assigned to different "classes". There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these antibodies can be further divided into "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant regions corresponding to the different classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.
[0256] In some embodiments, the term "antibody" or "antigen binding fragment" refers to a complete molecule and a functional fragment thereof, such as Fab, scFv-Fc bivalent molecule, F(ab')2 and Fv, respectively, which is capable of specifically interacting with a desired target. In some embodiments, the antigen binding fragment includes:
[0257] (1) Fab, a fragment containing a monovalent antigen-binding fragment of an antibody molecule, can be produced by digesting an intact antibody with papain to produce a complete light chain and a portion of one heavy chain;
[0258] (2) Fab', a fragment of an antibody molecule, which can be obtained by treating an intact antibody with pepsin followed by reduction to produce an intact light chain and a portion of a heavy chain; two Fab' fragments are obtained per antibody molecule;
[0259] (3) (Fab')2, a fragment of an antibody which can be obtained by treating an intact antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds;
[0260] 4) Fv, a genetically engineered fragment comprising the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and
[0261] (5) Single-chain antibody (scFv), a genetically engineered molecule containing the variable region of a light chain and the variable region of a heavy chain connected by a suitable polypeptide linker as a genetically fused single-chain molecule.
[0262] (6) scFv-Fc, which is produced by fusing a single-chain Fv (scFv) to the hinge region of an immunoglobulin (Ig) (e.g., IgG and Fc region).
[0263] In one embodiment, the antibody provided herein is a monoclonal antibody. In another embodiment, the antigen binding fragment provided herein is a single-chain Fv (scFv), a bispecific antibody, a tandem scFv, a scFv-Fc bivalent molecule, Fab, Fab', Fv or F(ab')2.
[0264] In one embodiment, the term "bivalent molecule" or "BV" refers to a molecule that is capable of binding to two separate targets simultaneously. A bivalent molecule is not limited to having two and only two binding domains, and can be a multivalent molecule or a molecule composed of linked monovalent molecules. The binding domains of a bivalent molecule can selectively recognize the same epitope or different epitopes located on the same target or on targets from different species. The binding domains can be linked in any of a variety of ways, including but not limited to disulfide bonds, peptide bridges, amide bonds, and other natural or synthetic linkages known in the art (Spatola et al., "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983) (general review); Morley, JS, "Trends Pharm Sci" (1980) pp. 463-468 (general review); Hudson et al., Int J Pept Prat Res (1979) 14, 177-185; Spatola et al., Life Sci (1986) 38, 1243-1249; Hann, MM, J Chem Soc Perkin Trans I (1982) 307-314; Almquist et al., J Med Chem (1980) 23, 1392-1398; Jennings-White et al., Tetrahedron Lett (1982) 23, 2533; Szelke et al., European Application EP 45665; Chemical Abstracts 97, 39405 (1982); Holladay, et al., Tetrahedron Lett (1983) 24, 4401-4404; and Hruby, VJ, Life Sci (1982) 31, 189-199).
[0265] The sequence alignment method that can be used to realize required sequence alignment includes but is not limited to paired alignment method or multiple sequence alignment method, as those skilled in the art will understand.Sequence alignment can be stored in multiple text-based file formats.In one embodiment, this is by using conversion program and program package in some embodiments, for example ReadSeq, EMBOSS and Bioberl, BioRuby convert any format, for example FASTA or GenBank, SwissProt, Entrez and EMBL format realize.Should be appreciated that those skilled in the art can use any program or storage medium to convert, revise, score, update and / or store sequence as required, as those skilled in the art will understand.
[0266] In some embodiments, the term "sequence alignment" includes the use of any program or method as understood by the skilled artisan for aligning nucleic acid or amino acid sequences to produce results that can be easily detected, evaluated, and subjected to mathematical and statistical calculations. In one embodiment, methods for sequence or structure alignment are well known in the art and include alignments based on sequence and structural homology, as will be understood by those skilled in the art.
[0267] In one embodiment, the term "homology", "homolog" or "homologous" refers to sequence identity, or structural identity, or functional identity. By using the term "homology" and other similar forms, it should be understood that any molecule, whether nucleic acid or peptide, which functions similarly, and / or contains sequence identity, and / or is structurally conserved so that it is close to the reference sequence, is considered to be part of the present invention. In another embodiment, in any case, the term "homology", "homolog" or "homologous" means that the sequence referred to, whether it is an amino acid sequence or a nucleic acid sequence, shows at least 86% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence shows at least 90% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence shows at least 92% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence shows at least 95% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence shows at least 95% or higher identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence shows at least 97% or higher identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence exhibits 97% to 100% identity to the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence exhibits 100% identity to the indicated sequence. Similarly, in one embodiment, reference to the identity of a particular sequence includes direct identity, as well as homology to a sequence defined herein.
[0268] Therefore, in one embodiment, the term "non-homologous" refers to an amino acid sequence or nucleic acid sequence that has no more than 85% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 75% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 65% to 74% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 55% to 64% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 45% to 54% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 35% to 44% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 35% to 44% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 15% to 34% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 5% to 14% identity with the indicated sequence. In another embodiment, the amino acid sequence or nucleic acid sequence has no more than 0.1% to 4% identity to the indicated sequence.In another embodiment, the term "non-homologous" can be used interchangeably with the term "low sequence similarity".
[0269] In one embodiment, the light chain contains CDR1, CDR2 and CDR3 sequences that are listed above or have greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; e.g., having mutations, deletions or insertions of 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid.
[0270] In one embodiment, the light chain contains FR1, FR2 and FR3 sequences that are listed above or have greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; e.g., having mutations, deletions or insertions of 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid.
[0271] In one embodiment, the heavy chain contains CDR1, CDR2 and CDR3 sequences that are listed above or have greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; e.g., having mutations, deletions or insertions of 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid.
[0272] In one embodiment, the heavy chain contains FR1, FR2 and FR3 sequences that are listed above or have greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; for example, having mutations, deletions or insertions of 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid.
[0273] In one embodiment, the complete antibody is one of the IgG1, IgG2, IgG3 or IgG4 types. In another embodiment, the Mut-gy1 scFv is engineered into an IgG1 complete antibody.
[0274] In one embodiment, the complete antibody has a constant region that is λ, κ, or a mutation thereof. In another embodiment, the Mut-gy1 scFv is engineered into a complete antibody using the CL2 constant region.
[0275] In one embodiment, the heavy chain comprises the constant region of SEQ ID NO: 59, or a sequence having greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; e.g., having 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid mutations, deletions or insertions.
[0276] In one embodiment, the light chain comprises the constant region of SEQ ID NO: 67, or a sequence having greater than 70%, e.g., greater than 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology; e.g., having 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid mutations, deletions or insertions.
[0277] In one embodiment, there may or may not be a linker between the signal peptide and the variable region, between the variable region and the constant region of the heavy chain and / or light chain. An example of such a linker is encoded by a restriction enzyme cleavage site.
[0278] In one embodiment, the antibody or its antigen binding fragment is displayed on the surface of yeast cells. In another embodiment, the antibody or its antigen binding fragment is coated on the surface of nanoparticles. In another embodiment, the antibody or its antigen binding fragment is displayed on the surface of mammalian cells, such as T cells, NK cells or other human or other mammalian cells. In another embodiment, the antibody or its antigen binding fragment is produced as a secreted protein by yeast, E. coli or mammalian cells.
[0279] In one embodiment, the terms "binds", "binding" or grammatical equivalents refer to compositions that have an affinity for each other. "Specific binding" is where the binding between two molecules is selective. A specific example of specific binding is the binding that occurs between an antibody and an antigen. Generally, specific binding occurs when the dissociation constant (KD) is less than about 1×10 -5 M or less than about 1×10- 6 M or 1×10 -7 When M is used, specific binding can be distinguished from non-specific binding, which can be detected, for example, by ELISA, immunoprecipitation, co-precipitation (with or without chemical cross-linking), two-hybrid assays, etc. Appropriate controls can be used to distinguish between "specific" and "non-specific" binding.
[0280] In some embodiments, the antibody or its antigen-binding fragment has a modification. The modification is a modification as further defined below. In some embodiments, the modification is an N-terminal modification. In another embodiment, the modification is a C-terminal modification. In another embodiment, the modification is in the middle of the protein. In one embodiment, the secretable form of the antibody or antigen-binding fragment comprises an N-terminal modification that allows binding to an immunoglobulin (Ig) hinge region. In another embodiment, the Ig hinge region is from, but is not limited to, an immunoglobulin hinge region. In some embodiments, the modification is a direct modification on the antibody or its antigen-binding fragment. In other embodiments, the modification is an indirect modification bridged by one or more other peptides, proteins, chemicals, carbohydrates or even a second antibody.
[0281] Additional post-translational modifications encompassed by the invention include, for example, N-linked or O-linked sugar chains, processing of the N-terminus or C-terminus, attachment of chemical moieties to the amino acid backbone, chemical modifications of the N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue due to expression in prokaryotic host cells.
[0282] In one embodiment, the term "polypeptide" generally refers to an antibody, antigen-binding fragment or variant of the invention.
[0283] In one embodiment, the polypeptide of the present invention comprises amino acid substitution. In one embodiment, amino acid substitution is conservative. "Conservative amino acid substitution" is an amino acid substitution in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In another embodiment, amino acid substitution is not a conservative amino acid substitution that results in enhanced activity of a mutant polypeptide compared to a native polypeptide.
[0284] The antibodies or antigen-binding fragments of the present invention can be produced by any synthetic or recombinant method, such as those well known in the art. The antibodies or antigen-binding fragments of the present invention can be further modified by techniques known in the art to alter biophysical or biological properties. For example, the polypeptide can be modified to increase its stability to proteases, or to modify its lipophilicity, solubility, or binding affinity to its natural receptor.
[0285] In some embodiments, antibody fragments can be prepared by proteolysis of antibodies or by expressing DNA encoding the fragment in Escherichia coli or mammalian cells (e.g., Chinese hamster ovary cell culture or other protein expression systems). In some embodiments, antibody fragments can be obtained by digesting complete antibodies with pepsin or papain by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment represented as F(ab')2. The fragment can be further cleaved with a thiol reducing agent and optionally a blocking group of a sulfhydryl group produced by the cleavage of a disulfide bond to produce a 3.5S Fab' monovalent fragment. Alternatively, enzymatic cleavage using pepsin directly produces two monovalent Fab' fragments and an Fc fragment. These methods are described in, for example, U.S. Patent Nos. 4,036,945 and 4,331,647 of Goldenberg, and the references contained therein, which are incorporated herein by reference in their entirety. See also Porter, RR, Biochem. J., 73: 119-126, 1959. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of the fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen recognized by the intact antibody.
[0286] In one embodiment, the "variant" of a polypeptide, antibody or protein of the present invention refers to an amino acid sequence that is changed by one or more amino acids relative to a reference polypeptide, antibody or protein. In the present invention, the variant of a polypeptide retains the antibody binding properties of a reference protein. In another embodiment, a "variant" refers to an antigen binding fragment of the present invention. In another embodiment, a variant is a variant of an antigen binding fragment that retains target or marker specificity. Variants may have "conservative" changes, in which the substituted amino acids have similar structural or chemical properties (e.g., leucine is replaced with isoleucine). In another embodiment, the variant has conservative amino acid substitutions at one or more predicted non-essential amino acid residues. In another embodiment, a "conservative amino acid substitution" is a substitution in which an amino acid residue is substituted by an amino acid residue with a side chain of similar charge, wherein, in other embodiments, the opposite is the case of a "non-conservative substitution". Families of amino acid residues with side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, for example, by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be conventionally expressed, and the function and / or biological activity of the encoded protein can be determined using the techniques described herein or by conventional modification techniques known in the art. Similar minor variations can also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without eliminating immunoreactivity can be found through computer programs well known in the art, such as DNASTAR software.
[0287] In one embodiment, the term "framework region" or "FR" is those variable domain residues other than the hypervariable region residues. The framework region has been precisely defined. See, for example, Kabat, EA et al., Sequences of Proteins of Immunological Interest, USDept. Health and Human Services, National Institutes of Health, USA (5th ed. 1991). Each variable domain generally has four FRs identified as FR1, FR2, FR3 and FR4. In some embodiments, "FR" also refers to an antibody variable region comprising amino acid residues adjacent to or close to the CDR region but outside the CDR region, that is, a region that directly interacts with the antigen, as a recognition element of the antibody molecule in the antibody variable region. In one embodiment, the term "framework region" is intended to mean each domain of the framework separated by CDR. In some embodiments, the sequences of the framework regions of different light or heavy chains are relatively conserved within species. The combined heavy and light chain framework regions of antibodies are used to position and align CDRs to correctly bind to antigens.
[0288] In one embodiment, the term "CDR" or "complementarity determining region" refers to the amino acid residues that contain non-contiguous antigen binding sites found in the variable regions of heavy and light chain polypeptides. In other embodiments, the term "CDR" will include regions such as Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991) and Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987) and Maccallum et al., J. Mol. Biol. 262: 732-745 (1996). Based on sequence variability, the amino acids of the CDRs of the variable domains were originally defined by Kabat, consisting of amino acid residues 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the human heavy chain variable domain (VH) and amino acid residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the human light chain variable domain (VL), using the Kabat numbering system for antibody amino acid residues. See Kabat et al., sequences of proteins of immunological interest, USDept. Health and Human Services, NIH, USA (5th ed. 1991). Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987) proposed another definition of CDRs based on residues contained in the three-dimensional structural loops of the variable domain region, which were found to be important in antigen binding activity. Chothia et al. defined CDR as consisting of amino acid residues 26-32 (H1), 52-56 (H2) and 95-102 (H3) in the human heavy chain variable region (VH), and amino acid residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the human light chain variable region (VL). Combining the CDR definitions of Kabat and Chothia, based on Kabat's numbering system, CDR consists of amino acid residues 26-35B (H1), 50-65 (H2) and 95-102 (H3) in human VH and amino acid residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in human VL.
[0289] In some embodiments, when used with reference to an antibody or its heavy or light chain, "variable region" refers to the amino terminal portion of the antibody that binds the antigen to the molecule, rather than the constant region. The term is intended to include functional fragments thereof that maintain a portion of all binding functions of the entire variable region. Thus, the term "heterologous variable region binding fragment" is intended to mean at least one heavy chain variable region and at least one light chain variable region or a functional fragment thereof assembled into a heterologous complex. Heterologous variable region binding fragments include, for example, functional fragments such as Fab, F(ab)2, Fv, single-chain Fv (scfv), etc. Such functional fragments are well known to those skilled in the art. Therefore, the use of these terms in describing the functional fragments of heterologous variable regions is to correspond to definitions well known to those skilled in the art. Such terms are described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989); Malec. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, R A. (ed.), New York: VCHPublisher, Inc.); Huston et al., Cell Biophysics, 22: 189-224 (1993); Ph. ickthun and Skerra, Meth. Enzymol., 178:497-515 (1989) and Day, ED, Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990).
[0290] In one embodiment, the polypeptide of the invention is an isoform of an isolated polypeptide. In one embodiment, an "isoform" refers to a form of a molecule, e.g., a protein or polypeptide of the invention, that differs only slightly from another isoform of the same protein or polypeptide. In one embodiment, the isoforms are produced by different but related genes, or in another embodiment, they are produced from the same gene by alternative splicing. In another embodiment, the isoforms are caused by a single nucleic acid polymorphism.
[0291] In one embodiment, the isolated polypeptide of the present invention is a fragment of a natural protein. In one embodiment, a "fragment" refers to a protein or polypeptide that is shorter than a full-length protein or polypeptide or contains fewer amino acids. In another embodiment, a fragment refers to a nucleic acid that is shorter than a full-length nucleic acid or contains fewer nucleic acids. In another embodiment, the fragment is an N-terminal fragment. In another embodiment, the fragment is a C-terminal fragment. In one embodiment, the fragment of the present invention is an internal sequence portion of a protein, peptide or nucleic acid. In another embodiment, the fragment is a functional internal sequence portion of a protein, peptide or nucleic acid. In another embodiment, the fragment is a functional internal sequence portion within a protein, peptide or nucleic acid. In another embodiment, the fragment is an N-terminal functional fragment. In one embodiment, the fragment is a C-terminal functional fragment.
[0292] In one embodiment, the term "functional fragment" refers to a fragment that retains a certain degree of biological activity compared to the wild type, even though it is a modified form of a native or wild type antibody or polypeptide. Compared to the wild type, this degree of activity can be moderate to high, where "activity" refers to its natural biophysical or biochemical properties, e.g., binding capacity, affinity, half-life, etc.
[0293] In one embodiment, the isolated polypeptide of the present invention comprises a derivative of a polypeptide of the present invention. In some embodiments, a "derivative" is understood to refer to a full-length portion of the native sequence of the protein in question. In some embodiments, a "derivative" may further comprise (at its end and / or within its own sequence) a non-native sequence, that is, a sequence that does not form a part of the native protein in question. The term "derivative" also includes within its scope a molecular species produced by bonding a chemical group to the amino residue side chain of a native protein or its fragment, wherein the chemical group does not form a part of the naturally occurring amino acid residue present in the native protein.
[0294] Methods for preparing antibodies and antibody fragments are known in the art (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).
[0295] Antibodies can be produced by immunizing various animals, including mice, rats, rabbits, goats, primates, humans, and chickens, with target antigens containing anti-PSMA epitopes of the invention, such as PSMA or peptide fragments of PSMA. In one embodiment, the antibodies or antigen-binding fragments are purified prior to immunizing the animals. In one embodiment, the antibodies or antigen-binding fragments of the invention can be purified by methods known in the art, such as gel filtration, ion exchange, affinity chromatography, and the like. Affinity chromatography or any of a variety of other techniques known in the art can be used to isolate polyclonal or monoclonal antibodies from serum, ascites, or hybridoma supernatants.
[0296] By "purified" is meant that the monoclonal antibody is separated from at least some proteins normally associated with the monoclonal antibody, and preferably is separated from all cellular material other than proteins.
[0297] Chemically modified derivatives of the antibodies of the invention are also provided, which may provide additional advantages, such as increased solubility, stability, in vivo or in vitro circulation time of the polypeptide, or reduced immunogenicity (see U.S. Patent No. 4,179,337). The chemical moiety used for derivatization may be selected from water-soluble polymers, such as polyethylene glycol, ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, etc. The antibody may be modified at random positions within the molecule, or at predetermined positions within the molecule, and may include one, two, three or more linked chemical moieties.
[0298] The polymer can have any molecular weight and can be branched or unbranched. For polyethylene glycol, the molecular weight is about 1 kDa to about 100 kDa (the term "about" means that in the preparation of polyethylene glycol, some molecules will be heavier or lighter than the molecular weight) for ease of handling and manufacturing. Other sizes can be used depending on the desired therapeutic properties (e.g., the duration of the desired sustained release, the effect of biological activity, the ease of handling, the degree or lack of antigenicity, and other known effects of polyethylene glycol on therapeutic proteins or analogs). For example, the polyethylene glycol can have a molecular weight of about 200 kDa, 500 kDa, 1000 kDa, 1500 kDa, 2000 kDa, 2560 kDa, 3000 kDa, 3500 kDa, 4000 kDa, 4500 kDa, 5000 kDa, 5500 kDa, 6000 kDa, 6500 kDa, 7000 kDa, 7500 kDa, 8000 kDa, 8500 kDa, 9000 kDa, 9500 kDa, 10,000 kDa, 10,500 kDa, 11,000 kDa, 11,500 kDa, 12,000 kDa, 12,500 kDa, 13,000 kDa, 13,500 kDa, 14,000 kDa, 14,500 kDa In some embodiments, the present invention relates to an average molecular weight of a, 15,000 kDa, 15,500 kDa, 16,000 kDa, 16,500 kDa, 17,000 kDa, 17,500 kDa, 18,000 kDa, 18,500 kDa, 19,000 kDa, 19,500 kDa, 20,000 kDa, 25,000 kDa, 30,000 kDa, 35,000 kDa, 40,000 kDa, 50,000 kDa, 55,000 kDa, 60,000 kDa, 65,000 kDa, 70,000 kDa, 75,000 kDa, 80,000 kDa, 85,000 kDa, 90,000 kDa, 95,000 kDa or 100,000 kDa.
[0299] As described above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Pat. No. 5,643,575; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72 (1996); Vorobje et al., Nucleosides Nucleic acids 18:2745-2750 (1999); and Caliceti et al., Bioconjug. Chem. 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.
[0300] Considering the effect on the functional or antigenic domain of the antibody, the polyethylene glycol molecule (or other chemical moiety) should be attached to the antibody. Many attachment methods are available to those skilled in the art, for example, EP 0 401 384, which is incorporated herein by reference (PEG conjugation to G-CSF); see also Malik et al., Exp. Hematol. 20: 1028-1035 (1992) (reporting the use of trifluoroethanesulfonyl chloride to PEGylate GM-CSF). For example, polyethylene glycol can be covalently bound to amino acid residues through reactive groups (e.g., free amino or carboxyl groups). Reactive groups are those groups to which activated polyethylene glycol molecules can bind. Amino acid residues with free amino groups can include, for example, lysine residues and N-terminal amino acid residues; those with free carboxyl groups can include aspartic acid residues, glutamic acid residues, and C-terminal amino acid residues. Sulfhydryl groups can also be used as reactive groups for attaching polyethylene glycol molecules. In some embodiments, attachment is at an amino group, such as attachment at the N-terminus or a lysine group.
[0301] As described above, polyethylene glycol can be attached to a protein (e.g., an antibody) by linking to any one of a number of amino acid residues. For example, polyethylene glycol can be covalently linked to a lysine, histidine, aspartic acid, glutamic acid, or cysteine residue of a protein. One or more reaction chemistries can be used to attach polyethylene glycol to a specific amino acid residue of a protein (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) or to more than one type of amino acid residue of a protein (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine, and combinations thereof).
[0302] Glycosylation variants
[0303] In some embodiments, the antibodies provided herein are altered to increase or decrease the degree of glycosylation of the antibody. The addition or deletion of glycosylation sites of the antibody can be conveniently accomplished by altering the amino acid sequence to create or remove one or more glycosylation sites.
[0304] For example, aglycosylated antibodies (i.e., antibodies lacking glycosylation) can be prepared. Glycosylation can be altered, for example, to increase the affinity of the antibody for an antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more glycosylation sites in the antibody sequence. For example, one or more amino acid substitutions can be made, resulting in the elimination of one or more variable region framework glycosylation sites, thereby eliminating glycosylation at the site. Such aglycosylation can increase the affinity of the antibody for an antigen. Such methods are described in further detail in U.S. Patent Nos. 5,714,350 and 6,350,861 to Co et al.
[0305] Glycosylation of the constant region at N297 can be prevented by mutating the N297 residue to another residue (eg, N297A) and / or by mutating an adjacent amino acid (eg, 298) thereby reducing glycosylation at N297.
[0306] Additionally or alternatively, antibodies with altered types of glycosylation can be prepared, such as hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNac structures. Such altered glycosylation patterns have been shown to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished, for example, by expressing the antibody in a host cell with an altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells that express the recombinant antibodies described herein, thereby producing antibodies with altered glycosylation. For example, EP 1,176,195 by Hanai et al. describes a cell line with a functionally disrupted FUT8 gene encoding a fucosyltransferase, such that antibodies expressed in such a cell line display hypofucosylation. PCT Publication WO 03 / 035835 by Presta describes a Chinese hamster ovary cell line variant, Led 3 cells, which has a reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in reduced fucosylation of antibodies expressed in the host cells (see also Shields, RL et al. (2002) J. Biol. Chem. 277:26733-26740). PCT Publication WO 99 / 54342 by Umana et al. describes a cell line engineered to express a glycoprotein modifying glycosyltransferase (e.g., β(1,4)-N-acetylglucosamine transferase III (GnTIII)), such that antibodies expressed in the engineered cell line exhibit increased bisecting GlcNac structures, which results in increased ADCC activity of the antibodies (see also Umana et al. (1999) Nat. Biotech. 17:176-180).
[0307] Fc region variants
[0308] The variable region of the antibodies described herein can be linked (e.g., covalently linked or fused) to an Fc, e.g., an IgG1, IgG2, IgG3, or IgG4 Fc, which can be any allotype or isoallotype, e.g., for IgG1: Glm, Glm1(a), Glm2(x), Glm3(f), Glm17(z); for IgG2: G2m, G2m23(n); for IgG3: G3m, G3m2l(gl), G3m28(g5), G3ml l(b0), G3m5(bl), G3ml3(b3), G3ml4(b4), G3m10(b5), G3ml5(s), G3ml6(t), G3m6(c3), G3m24(c5), G3m26(u), G3m27(v); and for K: Km, Km1, Km2, Km3 (see, e.g., Jefferies et al. (2009) mAbs 1:1). In some embodiments, the antibody variable regions described herein are linked to an Fc that binds to one or more activating Fc receptors (FcγI, FcγIIa, or FcγIIIa), thereby stimulating ADCC and can cause T cell depletion. In some embodiments, the antibody variable regions described herein are linked to an Fc that causes depletion.
[0309] In some embodiments, the antibody variable region described herein can be connected to an Fc comprising one or more modifications, typically to change one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or antigen-dependent cellular toxicity. In addition, the antibodies described herein can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or modified to change its glycosylation to change one or more functional properties of the antibody. The numbering of residues in the Fc region is that of the EU index of Kabat.
[0310] The Fc region includes domains from immunoglobulins, preferably constant regions of human immunoglobulins, including fragments, analogs, variants, mutants or derivatives of constant regions. Suitable immunoglobulins include IgG1, IgG2, IgG3, IgG4 and other species such as IgA, IgD, IgE and IgM. The constant region of an immunoglobulin is defined as a naturally occurring or synthetically produced polypeptide homologous to the C-terminal region of an immunoglobulin, and may include a CH1 domain, hinge, CH2 domain, CH3 domain or CH4 domain alone or in combination. In some embodiments, the antibody of the present invention has an Fc region different from wild-type IgA1. Antibodies may have an Fc region from IgG (e.g., IgG1, IgG2, IgG3 and IgG4) or other species such as IgA2, IgD, IgE and IgM. Fc may be a mutant form of IgA1.
[0311] The constant region of immunoglobulins is responsible for many important antibody functions, including Fc receptor (FcR) binding and complement fixation. There are five major types of heavy chain constant regions, classified as IgA, IgG, IgD, IgE, IgM, each with characteristic effector functions specified by the isotype. For example, IgG is divided into four subclasses, known as IgG1, IgG2, IgG3 and IgG4.
[0312] Ig molecules interact with various types of cell receptors. For example, IgG molecules interact with three types of Fcγ receptors (FcγRs) specific for IgG class antibodies, namely FcγRI, FcγRII and FcγRIII. The important sequences for IgG to bind to FcγR receptors have been reported to be located in the CH2 and CH3 domains. The serum half-life of an antibody is affected by the ability of the antibody to bind to FcR.
[0313] In some embodiments, the Fc region is a variant Fc region, e.g., an Fc sequence that has been modified (e.g., by amino acid substitution, deletion, and / or insertion) relative to a parent Fc sequence (e.g., an unmodified Fc polypeptide that is subsequently modified to produce a variant) to provide desired structural features and / or biological activity. For example, modifications can be made in the Fc region to produce an Fc variant that (a) has increased or decreased ADCC, (b) has increased or decreased CDC, (c) has increased or decreased affinity for C1q, and / or (d) has increased or decreased affinity for Fc receptors relative to the parent Fc. Such Fc region variants typically include at least one amino acid modification in the Fc region. Combination amino acid modifications are considered particularly desirable. For example, a variant Fc region may include, for example, two, three, four, five, etc. substitutions at specific Fc region positions identified herein.
[0314] Variant Fc regions may also include sequence changes in which the amino acids involved in disulfide bond formation are removed or replaced by other amino acids. Such removal can avoid reactions with other cysteine-containing proteins present in the host cells used to produce the antibodies described herein. Even when cysteine residues are removed, single-chain Fc domains can still form dimeric Fc domains that are non-covalently held together. In other embodiments, the Fc region may be modified to make it more compatible with the selected host cell. For example, the PA sequence near the N-terminus of a typical native Fc region may be removed, which may be recognized by digestive enzymes (e.g., proline imino peptidase) in Escherichia coli. In other embodiments, one or more glycosylation sites in the Fc domain may be removed. Typically, glycosylated residues (e.g., asparagine) may confer a cell lysis reaction. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine). In other embodiments, sites that participate in interaction with complement (e.g., Clq binding sites) may be removed from the Fc region. For example, the EKK sequence of human IgG1 may be deleted or substituted. In some embodiments, sites that affect binding to Fc receptors can be removed, preferably sites other than the rescue receptor binding site. In other embodiments, the Fc region can be modified to remove the ADCC site. ADCC sites are known in the art; see, e.g., Molec. Immunol. 29(5):633-9 (1992) about ADCC sites in IgG1. Specific examples of variant Fc domains are disclosed, e.g., in WO 97 / 34631 and WO 96 / 32478.
[0315] In one embodiment, the hinge region of Fc is modified so that the number of cysteine residues in the hinge region is changed, for example, increased or decreased. The method is further described in U.S. Patent No. 5,677,425 of Bodmer et al. The number of cysteine residues in the hinge region of Fc is changed to, for example, promote the assembly of light chain and heavy chain or increase or reduce the stability of the antibody. In one embodiment, the Fc hinge region of the antibody is mutated to reduce the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment so that the antibody has impaired staphylococcal protein A (SpA) binding relative to the native Fc-hinge domain staphylococcal protein A (SpA) binding. The method is further described in detail in U.S. Patent No. 6,165,745 of Ward et al.
[0316] In other embodiments, the Fc region is altered to change the effector function of the antibody by replacing at least one amino acid residue with a different amino acid residue. For example, one or more amino acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320, and 322 can be replaced by different amino acid residues so that the antibody has a changed affinity for the effector ligand, but retains the antigen binding ability of the parent antibody. The effector ligand that changes affinity can be, for example, an Fc receptor or the CI component of complement. This method is further described in detail in U.S. Pat. Nos. 5,624,821 and 5,648,260 to Winter et al.
[0317] In another example, one or more amino acids selected from amino acid residues 329, 331, and 322 can be replaced with a different amino acid residue such that the antibody has altered CIq binding and / or reduced or eliminated CDC. This approach is described in further detail in U.S. Patent No. 6,194,551 to Idusogie et al.
[0318] In another example, one or more amino acid residues between amino acid positions 231 and 239 are altered to thereby alter the ability of the antibody to fix complement. This approach is described in further detail in PCT Publication WO 94 / 29351 to Bodmer et al.
[0319] In another example, the Fc region can be modified to increase ADCC and / or to increase affinity for Fcγ receptors by modifying one or more amino acids at the following positions: 234, 235, 236, 238, 239, 240, 241, 243, 244, 245, 247, 248, 249, 252, 254, 255, 256, 258, 262, 263, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 291 2, 293, 294, 295, 296, 298, 299, 301, 303, 305, 307, 309, 312, 313, 315, 320, 322, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 433, 434, 435, 436, 437, 438 or 439. Exemplary substitutions include 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D and 332E. Exemplary variants include 239D / 332E, 236A / 332E, 236A / 239D / 332E, 268F / 324T, 267E / 268F, 267E / 324T and 267E / 268F7324T. Other modifications for enhancing FcγR and complement interactions include, but are not limited to, substitutions 298A, 333A, 334A, 326A, 247I, 339D, 339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 305I and 396L. These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20:685-691.
[0320] Fc modifications that increase binding to Fcγ receptors include amino acid modifications at one or more of the following amino acid positions in the Fc region: 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 279, 280, 283, 285, 298, 289, 290, 292, 293, 294, 295, 296, 298, 301 , 303, 305, 307, 312, 315, 324, 327, 329, 330, 335, 337, 3338, 340, 360, 373, 376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439, wherein the numbering of the residues in the Fc region is according to the EU index as in abat (WO 00 / 42072).
[0321] Other Fc modifications that can be performed on Fc are for reducing or eliminating the combination with FcγR and / or complement proteins, thereby reducing or eliminating those modifications of the effector functions such as ADCC, antibody-dependent cellular phagocytosis (ADCP) and CDC mediated by Fc. Exemplary modifications include but are not limited to substitutions, insertions and deletions at positions 234, 235, 236, 237, 267, 269, 325 and 328, wherein numbering is according to the EU index. Exemplary substitutions include but are not limited to 234G, 235G, 236R, 237K, 267R, 269R, 325L and 328R, wherein numbering is according to the EU index. Fc variants may include 236R / 328R. Other modifications used to reduce FcγR and complement interactions include substitutions 297A, 234A, 235A, 237A, 318A, 228P, 236E, 268Q, 309L, 330S, 331S, 220S, 226S, 229S, 238S, 233P and 234V, and removal of glycosylation at position 297 by mutation or enzymatic means or by production in organisms that do not glycosylate the protein (e.g., bacteria). These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20: 685-691.
[0322] Optionally, the Fc region may comprise non-naturally occurring amino acid residues at additional and / or alternative positions known to those skilled in the art (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; 6,194,551; 7,317,091; 8,101,720; WO00 / 42072; WO01 / 58957; WO02 / 06919; WO04 / 016750; WO04 / 029207; WO04 / 035752; WO04 / 074455; WO04 / 099249; WO04 / 063351; WO05 / 070963; WO05 / 040217; WO05 / 092925 and WO06 / 020114).
[0323] Fc variants that enhance the affinity for inhibitory receptor FcγRIIb can also be used. Such variants can provide Fc fusion proteins with immunomodulatory activity associated with FcγRIIb cells (including, for example, B cells and monocytes). In one embodiment, relative to one or more activating receptors, Fc variants provide selectively enhanced affinity for FcγRIIb. Modifications for changing binding to FcγRIIb include one or more modifications selected from the following positions: 234, 235, 236, 237, 239, 266, 267, 268, 325, 326, 327, 328 and 332, according to the EU index. Exemplary substitutions for enhancing affinity of FcγRIIb include, but are not limited to, 234D, 234E, 234F, 234W, 235D, 235F, 235R, 235Y, 236D, 236N, 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, and 332E. Exemplary substitutions include 235Y, 236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y. Other Fc variants used to enhance binding to FcγR11b include 235Y / 267E, 236D / 267E, 239D / 268D, 239D / 267E, 267E / 268D, 267E / 268E, and 267E / 328F.
[0324] The affinity and binding properties of the Fc region to its ligand can be determined by a variety of in vitro assays known in the art (based on biochemical or immunological assays), including but not limited to equilibrium methods (e.g., ELISA or radioimmunoassay) or kinetics (e.g., BIACORE analysis), as well as other methods such as indirect binding assays, competitive inhibition assays, fluorescence resonance energy transfer (FRET), gel electrophoresis, and chromatography (e.g., gel filtration). These and other methods can utilize labels on one or more of the components being examined and / or employ various detection methods, including but not limited to color development, fluorescence, luminescence, or isotope labeling. A detailed description of binding affinity and kinetics can be found in Paul, WE, ed., 25 Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999), which focuses on antibody-immunogen interactions.
[0325] In some embodiments, the antibody is modified to increase its biological half-life. Various methods are possible. For example, this can be accomplished by increasing the binding affinity of the Fc region to FcRn. For example, one or more of the following residues can be mutated: 252, 254, 256, 433, 435, 436, as described in U.S. Patent No. 6,277,375. Specific exemplary substitutions include one or more of the following: T252L, T254S and / or T256F. Alternatively, in order to increase the biological half-life, the antibody can be modified in the CH1 or CL region to contain a salvage receptor binding epitope containing two loops of the CH2 domain taken from the Fc region of IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022 of Presta et al. Other exemplary variants that increase binding to FcRn and / or improve pharmacokinetic properties include substitutions at positions 259, 308, 428, and 434, including, e.g., 259I, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al, 2004, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 286A, 305A, 307A, 307Q, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields et al, Journal of Biological Chemistry,2001,276(9):6591-6604), 252F, 252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P, 3 11S, 433R, 433S, 433I, 433P, 433Q, 434H, 434F, 434Y, 252Y / 254T / 256E,, 433K / 434F / 436H, 308T / 309P / 311S(Dall Acqua et al.Journal ofImmunology,2002,169:5171-5180,Dall'Acqua et al.,2006,Journal of Biological Chemistry 281: 23514-23524). Other modifications for modulating FcRn binding are described in Yeung et al., 2010, J Immunol, 182: 7663-7671.In some embodiments, a hybrid IgG isotype with a specific biological property can be used. For example, an IgG1 / IgG3 hybrid variant can be constructed by replacing the amino acid from IgG3 at the position where the IgG1 position in CH2 and / or CH3 district is different from two isotypes. Therefore, a hybrid variant IgG antibody can be constructed, which comprises one or more replacements, such as 274Q, 276K, 300F, 339T, 356E, 358M, 384S, 392N, 397M, 422I, 435R and 436F. In other embodiments described herein, an IgG1 / IgG2 hybrid variant can be constructed by replacing the amino acid from IgG1 at the position where the IgG2 position in CH2 and / or CH3 district is different from two isotypes. Therefore, a hybrid variant IgG antibody can be constructed, which comprises one or more replacements, such as one or more following amino acid replacements: 233E, 234L, 235L, 236G (referring to inserting glycine at position 236) and 321H.
[0326] In addition, the binding sites for FcγR1, FcγRII, FcγRIII and FcRn on human IgG1 have been mapped, and variants with improved binding have been described (see Shields, RL et al. (2001) J. Biol. Chem. 276: 6591-6604). Specific mutations at positions 256, 290, 298, 333, 334 and 339 were shown to improve binding to FcγRIII. In addition, the following combination mutants were shown to improve FcγRIII binding: T256A / S298A, S298A / E333A, S298A / K224A and S298A / E333A / K334A, which have been shown to show enhanced FcγRIIIa binding and ADCC activity (Shields et al., 2001). Other IgG1 variants with enhanced binding to FcγRIIIa have been identified, including variants with S239D / I332E and S239D / I332E / A330L mutations, which showed the greatest increase in affinity for FcγRIIIa, decreased binding to FcγRIIb, and potent cytotoxic activity in cynomolgus monkeys (Lazar et al., 2006). Triple mutations were introduced into antibodies such as alemtuzumab (CD52 specific), trastuzumab (HER2 / neural specific), rituximab (CD20 specific), and cetuximab (EGFR-specific), which translated into greatly enhanced ADCC activity in vitro, and the S239D / I332E variant showed enhanced ability to deplete B cells in monkeys (Lazar et al., 2006). In addition, IgG1 mutants containing L235V, F243L, R292P, Y300L and P396L mutations have been identified, which show enhanced binding to FcγRIIIa and concomitant enhanced ADCC activity in transgenic mice expressing human FcγRIIIa in B cell malignancies and breast cancer models (Stavenhagen et al., 2007; Nordstrom et al., 2011). Other Fc mutants that can be used include: S298A / E333A / L334A, S239D / I332E, S239D / I332E / A330L, L235V / F243L / R292P / Y300L / P396L and M428L / N434S.
[0327] In some embodiments, an Fc is selected that has reduced binding to an FcγR. An exemplary Fc with reduced FcγR binding (eg, IgG1 Fc) comprises the following three amino acid substitutions: L234A, L235E, and G237A.
[0328] In some embodiments, an Fc is selected that has reduced complement fixation. An exemplary Fc with reduced complement fixation (eg, IgG1 Fc) has the following two amino acid substitutions: A330S and P331S.
[0329] In some embodiments, an Fc is selected that has substantially no effector function, ie, it has reduced binding to FcγRs and reduced complement fixation. An exemplary Fc with no effector (eg, IgG1 Fc) comprises the following five mutations: L234A, L235E, G237A, A330S, and P331S.
[0330] When using an IgG4 constant region, it is generally preferred to include the substitution S228P, which mimics the hinge sequence in IgG1 and thereby stabilizes the IgG4 molecule.
[0331] Fc mutations that increase serum half-life
[0332] In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 directed antibody comprises an amino acid modification that promotes an increase in the serum half-life of the antigen binding molecule. Mutations that increase the half-life of antibodies have been described. In one embodiment, the Fc region or Fc domain of one or both of the CD3 targeting heavy chain and the HIV antigen targeting heavy chain comprises a substitution of methionine to tyrosine at position 252 (EU numbering), a substitution of serine to threonine at position 254 (EU numbering), and a substitution of threonine to glutamate at position 256 (EU numbering). See, e.g., U.S. Patent No. 7,658,921. This type of mutant, called a "YTE mutant," exhibits a 4-fold increase in half-life relative to the wild-type form of the same antibody (DalFAcqua, et al., J Biol Chem, 281: 23514-24 (2006); Robbie, et al., Antimicrob Agents Chemotherap., 57(12):6147-6153(2013)). In certain embodiments, the Fc region or Fc domain of one or both of the CD3 targeting heavy chain and the HIV antigen targeting heavy chain comprises an IgG constant region comprising one, two, three or more amino acid substitutions at amino acid residues at positions 251 to 257, 285 to 290, 308 to 314, 385 to 389 and 428 to 436 (EU numbering). Alternatively, the M428L and N434S ("LS") substitutions may increase multispecific antigen binding. In other embodiments, one or both of the CD3 targeting heavy chain and the HIV antigen targeting heavy chain have an Fc region or Fc domain comprising M428L and N434S substitutions (EU numbering). In other embodiments, one or both of the CD3 targeting heavy chain and the HIV antigen targeting heavy chain have an Fc region or Fc domain comprising T250Q and M428L (EU numbering) mutations. In other embodiments, one or both of the CD3 targeting heavy chain and the HIV antigen targeting heavy chain have an Fc region or Fc domain comprising H433K and N434F (EU numbering) mutations.
[0333] Fc mutations that enhance effector activity
[0334] In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 directed antibody comprises post-translational and / or amino acid modifications that increase effector activity, for example, with improved FcγIIIa binding and increased antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 directed antibody comprises a DE modification in the Fc region (i.e., S239D and I332E by EU numbering). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 directed antibody comprises a DEL modification in the Fc region (i.e., S239D, I332E, and A330L by EU numbering). In some embodiments, the Fc region or Fc region of the anti-HIV gp120 directed antibody comprises a DEA modification in the Fc region (i.e., S239D, I332E, and G236A by EU numbering). In some embodiments, the Fc region or Fc domain of the anti-HIV gp120 directed antibody comprises a DEAL modification in the Fc region (i.e., S239D, I332E, G236A, and A330L by EU numbering). See, e.g., U.S. Pat. Nos. 7,317,091; 7,662,925; 8,039,592; 8,093,357; 8,093,359; 8,383,109; 8,388,955; 8,735,545; 8,858,937; 8,937,158; 9,040,041; 9,353,187; 10,184,000; and 10,584,176. Other amino acid modifications that increase effector activity (e.g., with improved FcγIIIa binding and increased antibody-dependent cellular cytotoxicity (ADCC)) include, but are not limited to (EU numbering) F243L / R292P / Y300L / V305I / P396L; S298A / E333A / K334A; or L234Y / L235Q / G236W / S239M / H268D / D270E / S298A on the first Fc domain and D270E / K326D / A330M / K334E on the second Fc domain. Amino acid mutations that increase C1q binding and complement-dependent cytotoxicity (CDC) include, but are not limited to (EU numbering) S267E / H268F / S324T or K326W / E333S. Fc region mutations that enhance effector activity are reviewed in, for example, Wang, et al., Protein Cell (2018) 9(1): 63-73; and Saunders, Front Immunol. (2019) 10: 1296. In other embodiments, the anti-HIV gp120 directed antibody or antigen-binding fragment thereof has modified glycosylation, which can be introduced, for example, post-translationally or by genetic engineering.In some embodiments, the anti-HIV gp120 directed antibody or antigen-binding fragment thereof is non-fucose modified, for example, at the glycosylation site present in the antibody or antigen-binding fragment thereof. Most approved monoclonal antibodies are of the IgG1 isotype, in which two N-linked biantennary complex oligosaccharides are bound to the Fc region. The Fc region exerts the effector function of ADCC through its interaction with leukocyte receptors of the FcγR family. A non-fucose modified monoclonal antibody is a monoclonal antibody that is engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose units.
[0335] Multivalent Antibodies
[0336] In one embodiment, the antibodies of the present disclosure may be monovalent or multivalent (e.g., bivalent, trivalent, etc.). As used herein, the term "valency" refers to the number of potential target binding sites associated with an antibody. Each target binding site specifically binds to a target molecule or a specific position or site on a target molecule. When the antibody is monovalent, each binding site of the molecule will specifically bind to a single antigen position or epitope. When the antibody comprises more than one target binding site (multivalent), each target binding site may specifically bind to the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes or positions on the same antigen). See, e.g., U.S. Patent Publication No. 2009 / 0130105. In each case, at least one binding site will comprise an epitope, motif, or domain associated with a DLL3 isoform.
[0337] In one embodiment, the antibody is a bispecific antibody in which the two chains have different specificities, as described in Millstein et al., 1983, Nature, 305:537-539. Other embodiments include antibodies with other specificities, such as trispecific antibodies. Other more complex compatible multispecific constructs and methods of making them are described in U.S. Patent Publication Nos. 2009 / 0155255 and WO94 / 04690 Suresh et al., 1986, Methods in Enzymology, 121:210; and WO96 / 27011.
[0338] As mentioned above, multivalent antibodies can immunospecifically bind to different epitopes of desired target molecules, or can immunospecifically bind to target molecules and heterologous epitopes, such as heterologous polypeptides or solid support materials. In some embodiments, multivalent antibodies can include bispecific antibodies or trispecific antibodies. Bispecific antibodies also include cross-linked or "heteroconjugate" antibodies. For example, one antibody in the heteroconjugate can be coupled to avidin, and the other is coupled to biotin. Such antibodies have been proposed, for example, for targeting immune system cells to unwanted cells (U.S. Patent No. 4,676,980) and for treating HIV infection (WO 91 / 00360, WO 92 / 200373 and EP 03089). Any convenient cross-linking method can be used to prepare heteroconjugate antibodies. Suitable cross-linking agents and many cross-linking techniques are well known in the art and are disclosed in U.S. Patent No. 4,676,980.
[0339] In some embodiments, antibody variable domains with desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences (e.g., an immunoglobulin heavy chain constant domain including at least part of the hinge, CH2, and / or CH3 regions) using methods well known to those of ordinary skill in the art.
[0340] In some embodiments, the isolated anti-HIV antibody is a bispecific antibody comprising a first antigen-binding arm that binds to a first antigen and a second antigen-binding arm that binds to a second antigen, wherein the first antigen and the second antigen are different, and wherein the first antigen-binding arm comprises the heavy chain amino acid sequence and the light chain amino acid sequence described in detail above.
[0341] In some embodiments, the second antigen is selected from CD3, FcyRI (CD64), FcyRII (CD32), FcyRIII (CD16); CD89, CCR5, CD4, CD8, CD28, CD137, CTLA-4, gp41, killer cell immunoglobulin-like receptor three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin-like receptor three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin-like receptor two I g domain and long cytoplasmic tail 1 (KIR2DL1), killer cell immunoglobulin-like receptor two Ig domain and long cytoplasmic tail 2 (KIR2DL2), killer cell immunoglobulin-like receptor two Ig domain and long cytoplasmic tail 3 (KIR2DL3), killer cell lectin-like receptor C1 (KLRC1), killer cell lectin-like receptor C2 (KLRC2), killer cell lectin-like receptor C3 (KLRC3), killer cell lectin-like receptor C4 (KLRC4), killer cell lectin-like receptor D1 (KLRD1), killer cell lectin-like receptor K1 (KLRK1), natural cytotoxicity triggering receptor 3 (NCR3 or NKp30), natural cytotoxicity triggering receptor 2 (NcR2 or NK-p44), natural cytotoxicity triggering receptor 1 (NCR1 or NK-p46), CD226 (DNAM-1), cytotoxic and regulatory T cell molecule (CRTAM or CD355), signaling lymphocyte activation molecule family member 1 (SLAMF1), CD48 (SLAMF2), lymphocyte The second epitope of Baculovirus antigen 9 (LY9 or SLAMF3), CD244 (2B4 or SLAMF4), CD84 (SLAMF5), SLAM family member 6 (SLAMF6 or NTB-A), SLAM family member 7 (SLAMF7 or CRACC), CD27 (TNFRSF7), semaphorin 4D (SEMA4D or CD100), CD160 (NK1), immune checkpoint proteins (e.g., PD-1, PD-L1, CTLA-4), and gp120.
[0342] Antibody derivatives
[0343] The antibodies provided herein can be further modified to contain additional non-proteinaceous parts known in the art and easily available. Suitable parts for antibody derivatization include but are not limited to water-soluble polymers. Non-limiting examples of water-soluble polymers include but are not limited to copolymers of PEG, ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers) and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol and mixtures thereof. Polyethylene glycol propionaldehyde has advantages in manufacturing due to its stability in water. Polymers can have any molecular weight and can be branched or non-branched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. Generally, the amount and / or type of polymer used for derivatization can be determined based on factors that require consideration, including, but not limited to, the specific properties or functions of the antibody to be improved, whether the antibody derivative will be used in treatment under defined conditions, etc.
[0344] In another embodiment, a conjugate of an antibody and a non-protein moiety is provided that can be selectively heated by exposure to radiation. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, and includes but is not limited to a wavelength that does not damage normal cells but heats the non-protein moiety to a temperature close to that at which the cells of the antibody-non-protein moiety are killed.
[0345] Another modification of the antibodies described herein is PEGylation. Antibodies can be PEGylated, for example, to increase the biological (e.g., serum) half-life of the antibody. In order to PEGylate an antibody, the antibody or a fragment thereof is typically reacted with PEG (e.g., a reactive ester or aldehyde derivative of PEG) under conditions where one or more PEG groups are attached to the antibody or antibody fragment. Preferably, PEGylation is performed by an acylation reaction or an alkylation reaction with a reactive PEG molecule (or a similar reactive water-soluble polymer). As used herein, the term "polyethylene glycol" is intended to encompass any form of PEG that has been used to derive other proteins, such as mono(C1-C1 10) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In some embodiments, the antibody to be PEGylated is a non-glycosylated antibody. Methods for PEGylating proteins are known in the art and can be applied to the antibodies described herein. See, for example, EP0154316 by Nishimura et al. and EP0401384 by Ishikawa et al.
[0346] The present disclosure also includes human monoclonal antibodies described herein coupled to a therapeutic agent, a polymer, a detectable label, or an enzyme. In one embodiment, the therapeutic agent is a cytotoxic agent. In one embodiment, the polymer is PEG.
[0347] Nucleic Acids
[0348] In one embodiment, the present disclosure also provides polynucleic acids, which comprise nucleic acid sequences encoding the polypeptide chains of the disclosed antibodies or antigen-binding fragments thereof or variants thereof, or alternatively consist of nucleic acid sequences encoding the polypeptide chains of the disclosed antibodies or antigen-binding fragments thereof or variants thereof. The present disclosure also includes polynucleic acids that hybridize to polynucleic acids complementary to nucleic acids having polynucleic acid sequences encoding the polypeptide chains of the disclosed antibodies or antigen-binding fragments thereof or variants thereof under high stringency hybridization conditions, or alternatively, under medium or low stringency hybridization conditions (e.g., as defined above).
[0349] In another embodiment, polynucleic acid is obtained, and the nucleic acid sequence of polynucleic acid can be determined by any method known in the art. Alternatively, polynucleic acid encoding antibodies (including molecules comprising antibody fragments or variants thereof or consisting of antibody fragments or variants thereof) is produced from nucleic acids of suitable sources. If clones containing nucleic acids encoding specific antibodies cannot be obtained, but the sequence of antibody molecules is known, nucleic acids encoding immunoglobulins can be chemically synthesized in natural or optimized codons for specific species, or from suitable sources (e.g., antibody cDNA libraries, or cDNA libraries generated from any tissue or cell expressing antibodies, or nucleic acids isolated from any tissue or cell expressing antibodies, preferably poly A+RNA, such as hybridoma cells expressing antibodies of the present invention), using synthetic primers that can hybridize with the 3' and 5' ends of the sequence by PCR amplification, or by cloning with oligonucleotide probes specific to specific gene sequences, to identify, for example, cDNA clones from cDNA libraries encoding antibodies. The amplified nucleic acids produced by PCR can then be cloned into reproducible cloning vectors using any method well known in the art.
[0350] In some embodiments, the term "nucleic acid" refers to polynucleic acids or oligonucleic acids, such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA) or its analogs. The term should also be understood to include, as equivalents, analogs of RNA or DNA made from nucleic acid analogs, and, as applicable to the embodiments, single (sense or antisense) and double-stranded polynucleic acids. The term includes oligonucleic acids composed of naturally occurring nucleobases, sugars and covalent internucleotide (skeleton) bonds, and oligonucleic acids with non-naturally occurring parts, which function similarly. Such modified or substituted oligonucleic acids are generally superior to native forms because they have desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid targets, and increased stability in the presence of nucleases.
[0351] As will be appreciated by those skilled in the art, fragments or derivatives of nucleic acid sequences or genes encoding proteins or peptides can still function in the same manner as the entire wild-type gene or sequence. Equally, the form of the nucleic acid sequence can have variations relative to the wild-type sequence, and despite these variations, the encoded protein or peptide or its fragment retains the wild-type function showing the same biological effect. Each of these represents a separate embodiment of the present invention.
[0352] Nucleic acids can be produced by any synthetic or recombinant method, such as those well known in the art. Nucleic acids can be further modified to alter biophysical or biological properties by techniques known in the art. For example, nucleic acids can be modified to increase their stability against nucleases (e.g., "end caps"), or to increase expression levels by codon optimization, or to modify their lipophilicity, solubility, or binding affinity to complementary sequences.
[0353] Methods for modifying nucleic acids to achieve specific purposes are disclosed in the art, for example, in Sambrook et al. (1989). In addition, the nucleic acid sequences of the present invention may include one or more portions of the nucleic acid sequence that do not encode the target protein. The present invention further provides DNA sequences that encode proteins similar to those encoded by the sequences described herein, but due to the degeneracy of the genetic code or allelic variation, they differ in the codon sequence (natural base changes in species populations, which may or may not result in amino acid changes), which may also encode the proteins of the present invention described herein. Changes in the DNA sequence, which are caused by point mutations or induced modifications (including insertions, deletions and substitutions) to enhance the activity, half-life or yield of the polypeptides encoded therein, are also included in the present invention.
[0354] The DNA encoding the antibody or antigen-binding fragment provided herein is easily separated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to the heavy chain and light chain of the encoded antibody). Once separated, the DNA can be placed in an expression vector, which is then transfected into a host cell (e.g., Escherichia coli cells, ape COS cells, Chinese hamster ovary (CHO) cells, yeast cells, or myeloma cells, which do not produce immunoglobulins in addition), to obtain the synthesis of the antibody in a recombinant host cell. The recombinant production of antibodies is described in more detail hereinafter.
[0355] In one embodiment, the nucleic acid molecule encoding scFv Mut-gy1 comprises the amino acid sequence of SEQ ID NO: 3. In one embodiment, the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:2.
[0356] In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a light chain, and the light chain comprises an amino acid sequence of SEQ ID NO: 5. For example, in one embodiment, the nucleic acid sequence encoding a light chain comprises a nucleotide sequence of SEQ ID NO: 4. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VL FR1, and the VL FR1 comprises an amino acid sequence of SEQ ID NO: 7. For example, in one embodiment, the nucleic acid sequence encoding VL FR1 comprises a nucleotide sequence of SEQ ID NO: 6. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VL CDR1, and the VL CDR1 comprises an amino acid sequence of SEQ ID NO: 9. For example, in one embodiment, the nucleic acid sequence encoding VL CDR1 comprises a nucleotide sequence of SEQ ID NO: 8. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VL FR2, and the VLFR2 comprises an amino acid sequence of SEQ ID NO: 11. For example, in one embodiment, the nucleic acid sequence encoding VL FR2 comprises a nucleotide sequence of SEQ ID NO: 10. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VL CDR2, and the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 13. For example, in one embodiment, the nucleic acid sequence encoding VL CDR2 comprises the nucleotide sequence of SEQ ID NO: 12. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VLFR3, and the VL FR3 comprises the amino acid sequence of SEQ ID NO: 15. For example, in one embodiment, the nucleic acid sequence encoding VL FR3 comprises the nucleotide sequence of SEQ ID NO: 14. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VL CDR3, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 17. For example, in one embodiment, the nucleic acid sequence encoding VL CDR3 comprises the nucleotide sequence of SEQ ID NO: 16. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VL FR4, and the VL FR4 comprises the amino acid sequence of SEQ ID NO: 19. For example, in one embodiment, the nucleic acid sequence encoding VL FR4 comprises the nucleotide sequence of SEQ ID NO: 18.
[0357] In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a heavy chain, the heavy chain comprising the amino acid sequence of SEQ ID NO: 21. For example, in one embodiment, the nucleic acid sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 20. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VH FR1, the VH FR1 comprising the amino acid sequence of SEQ ID NO: 23. For example, in one embodiment, the nucleic acid sequence encoding VH FR1 comprises the nucleotide sequence of SEQ ID NO: 22. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VH CDR1, the VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25. For example, in one embodiment, the nucleic acid sequence encoding VH CDR1 comprises the nucleotide sequence of SEQ ID NO: 24. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding VH FR2, the VH FR2 comprising the amino acid sequence of SEQ ID NO: 27. For example, in one embodiment, the nucleic acid sequence encoding VH FR2 comprises the nucleotide sequence of SEQ ID NO: 26. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VH CDR2 comprising an amino acid sequence of SEQ ID NO: 29. For example, in one embodiment, the nucleic acid sequence encoding a VH CDR2 comprises a nucleotide sequence of SEQ ID NO: 28. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VH FR3 comprising an amino acid sequence of SEQ ID NO: 31. For example, in one embodiment, the nucleic acid sequence encoding a VH FR3 comprises a nucleotide sequence of SEQ ID NO: 30. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VH CDR3 comprising an amino acid sequence of SEQ ID NO: 33. For example, in one embodiment, the nucleic acid sequence encoding a VH CDR3 comprises a nucleotide sequence of SEQ ID NO: 32. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a VH FR4 comprising an amino acid sequence of SEQ ID NO: 35. For example, in one embodiment, the nucleic acid sequence encoding a VH FR4 comprises a nucleotide sequence of SEQ ID NO: 34. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a scFv linker comprising the amino acid sequence of SEQ ID NO: 37. For example, in one embodiment, the nucleic acid sequence encoding the scFv linker comprises the nucleotide sequence of SEQ ID NO: 36.
[0358] For example, in one embodiment, the nucleic acid molecule encodes Mut-gy1. In one embodiment, the nucleic acid molecule encodes Mut-gy1, and the Mut-gy1 comprises the amino acid sequence of SEQ ID NO:3. For example, in one embodiment, the nucleic acid sequence encoding Mut-gy1 comprises the nucleotide sequence of SEQ ID NO:2. In one embodiment, the nucleic acid molecule encoding Mut-gy1 comprises a nucleotide sequence encoding a light chain and a nucleotide sequence encoding a heavy chain, the light chain comprising the amino acid sequence of SEQ ID NO:5 and the heavy chain comprising the amino acid sequence of SEQ ID NO:21. For example, in one embodiment, the nucleotide sequence encoding the light chain comprises the nucleotide sequence of SEQ ID NO:4, and the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO:20.
[0359] In one embodiment, the nucleic acid molecule encoding Mut-gy1 comprises: a nucleotide sequence encoding VL FR1, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO:7; a nucleotide sequence encoding VL CDR1, wherein the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9; a nucleotide sequence encoding VL FR2, wherein the VL FR2 comprises the amino acid sequence of SEQ ID NO:11; a nucleotide sequence encoding VL CDR2, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; a nucleotide sequence encoding VLFR3, which comprises the amino acid sequence of SEQ ID NO:15; a nucleotide sequence encoding VL CDR3, which comprises the amino acid sequence of SEQ ID NO:17; a nucleotide sequence encoding VL FR4, which comprises the amino acid sequence of SEQ ID NO:19; a nucleotide sequence encoding VH FR1, wherein the VH FR1 comprises the amino acid sequence of SEQ ID NO:23; a nucleotide sequence encoding VH CDR1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:25; a nucleotide sequence encoding VH a nucleotide sequence encoding a VH FR2 comprising the amino acid sequence of SEQ ID NO: 27; a nucleotide sequence encoding a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29; a nucleotide sequence encoding a VH FR3 comprising the amino acid sequence of SEQ ID NO: 31; a nucleotide sequence encoding a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33; a nucleotide sequence encoding a VH FR4 comprising the amino acid sequence of SEQ ID NO: 35; and / or a nucleotide sequence encoding a scFv linker comprising the amino acid sequence of SEQ ID NO: 37.
[0360] For example, in one embodiment, the nucleotide sequence encoding VL FR1 comprises the nucleotide sequence of SEQ ID NO: 6; the nucleotide sequence encoding VL CDR1 comprises the nucleotide sequence of SEQ ID NO: 8; the nucleotide sequence encoding VL FR2 comprises the nucleotide sequence of SEQ ID NO: 10; the nucleotide sequence encoding VL CDR2 comprises the nucleotide sequence of SEQ ID NO: 12; the nucleotide sequence encoding VL FR3 comprises the nucleotide sequence of SEQ ID NO: 14; the nucleotide sequence encoding VL CDR3 comprises the nucleotide sequence of SEQ ID NO: 16; the nucleotide sequence encoding VL FR4 comprises the nucleotide sequence of SEQ ID NO: 18; the nucleotide sequence encoding VH FR1 comprises the nucleotide sequence of SEQ ID NO: 22; the nucleotide sequence encoding VH CDR1 comprises the nucleotide sequence of SEQ ID NO: 24; the nucleotide sequence encoding VH FR2 comprises the nucleotide sequence of SEQ ID NO: 26; the nucleotide sequence encoding VH CDR2 comprises the nucleotide sequence of SEQ ID NO: 28; the nucleotide sequence encoding VH FR3 comprises the nucleotide sequence of SEQ ID NO: 30; the nucleotide sequence encoding VH The nucleotide sequence of CDR3 comprises the nucleotide sequence of SEQ ID NO:32; the nucleotide sequence encoding VH FR4 comprises the nucleotide sequence of SEQ ID NO:34; and / or the nucleotide sequence encoding the scFv linker comprises the nucleotide sequence of SEQ ID NO:36.
[0361] In one embodiment, the nucleic acid molecule encodes an antibody or antigen-binding fragment thereof comprising one or more mutations. For example, in one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding VL FR2, the VL FR2 comprising an amino acid sequence of SEQ ID NO: 39, wherein SEQ ID NO: 39 comprises a V→A point mutation relative to SEQ ID NO: 11. For example, in one embodiment, the nucleotide sequence encoding the mutant VL FR2 comprises a nucleotide sequence of SEQ ID NO: 38. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding VL CDR2, the VL CDR2 comprising an amino acid sequence of SEQ ID NO: 41, wherein SEQ ID NO: 41 comprises a G→E point mutation relative to SEQ ID NO: 13. For example, in one embodiment, the nucleotide sequence encoding the mutant VL CDR2 comprises a nucleotide sequence of SEQ ID NO: 40. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding VL FR4, the VL FR4 comprising an amino acid sequence of SEQ ID NO: 43, wherein SEQ ID NO: 43 comprises a V→A point mutation relative to SEQ ID NO: 19. For example, in one embodiment, the nucleotide sequence encoding a mutant VL FR4 comprises the nucleotide sequence of SEQ ID NO: 42. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a VH CDR1 comprising an amino acid sequence of SEQ ID NO: 45, wherein SEQ ID NO: 45 comprises an S→F point mutation relative to SEQ ID NO: 25. For example, in one embodiment, the nucleotide sequence encoding a mutant VH CDR1 comprises a nucleotide sequence of SEQ ID NO: 44. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a VH FR3 comprising an amino acid sequence of SEQ ID NO: 47, wherein SEQ ID NO: 47 comprises an I→V point mutation relative to SEQ ID NO: 31. For example, in one embodiment, the nucleotide sequence encoding a mutant VH FR3 comprises a nucleotide sequence of SEQ ID NO: 46. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a VH CDR3 comprising an amino acid sequence of SEQ ID NO: 49, wherein SEQ ID NO: 49 comprises a D→G point mutation relative to SEQ ID NO: 33. For example, in one embodiment, the nucleotide sequence encoding the mutant VH CDR3 comprises the nucleotide sequence of SEQ ID NO:48.In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a VH FR4 comprising the amino acid sequence of SEQ ID NO: 51, wherein SEQ ID NO: 51 comprises a G→E point mutation relative to SEQ ID NO: 35. For example, in one embodiment, the nucleotide sequence encoding a mutant VH FR4 comprises the nucleotide sequence of SEQ ID NO: 50.
[0362] In one embodiment, the nucleic acid molecule encodes an antibody fragment comprising an scFv represented herein as Mut-gy1-st. In one embodiment, the nucleic acid molecule encoding Mut-gy1-st comprises: a nucleotide sequence encoding VL FR2, wherein the VL FR2 comprises an amino acid sequence of SEQ ID NO: 39; a nucleotide sequence encoding VH CDR1, wherein the VHCDR1 comprises an amino acid sequence of SEQ ID NO: 45, and a nucleotide sequence encoding VH FR4, wherein the VH FR4 comprises an amino acid sequence of SEQ ID NO: 51. In one embodiment, the nucleic acid molecule encoding Mut-gy1-st comprises: a nucleotide sequence encoding VL FR1, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO: 7; a nucleotide sequence encoding VL CDR1, wherein the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 9; a nucleotide sequence encoding VL FR2, wherein the VL FR2 comprises the amino acid sequence of SEQ ID NO: 39; a nucleotide sequence encoding VL CDR2, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 13; a nucleotide sequence encoding VL FR3, wherein the VL FR3 comprises the amino acid sequence of SEQ ID NO: 15; a nucleotide sequence encoding VLCDR3, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 17; a nucleotide sequence encoding VL FR4, wherein the VL FR4 comprises the amino acid sequence of SEQ ID NO: 19; a nucleotide sequence encoding VH FR1, wherein the VH FR1 comprises the amino acid sequence of SEQ ID NO: 23; a nucleotide sequence encoding VH CDR1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:45; a nucleotide sequence encoding VH FR2, wherein the VH FR2 comprises the amino acid sequence of SEQ ID NO:27; a nucleotide sequence encoding VH CDR2, wherein the VH CDR2 comprises the amino acid sequence of SEQ ID NO:29; a nucleotide sequence encoding VH FR3, wherein the VH FR3 comprises the amino acid sequence of SEQ ID NO:31; a nucleotide sequence encoding VH CDR3, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO:33; a nucleotide sequence encoding VH FR4, wherein the VH FR4 comprises the amino acid sequence of SEQ ID NO:51; and / or a nucleotide sequence encoding a scFv linker, wherein the scFv linker comprises the amino acid sequence of SEQ ID NO:37.
[0363] In one embodiment, the nucleotide sequence encoding VL FR1 comprises the nucleotide sequence of SEQ ID NO: 6; the nucleotide sequence encoding VL CDR1 comprises the nucleotide sequence of SEQ ID NO: 8; the nucleotide sequence encoding VL FR2 comprises the nucleotide sequence of SEQ ID NO: 38; the nucleotide sequence encoding VL CDR2 comprises the nucleotide sequence of SEQ ID NO: 12; the nucleotide sequence encoding VL FR3 comprises the nucleotide sequence of SEQ ID NO: 14; the nucleotide sequence encoding VL CDR3 comprises the nucleotide sequence of SEQ ID NO: 16; the nucleotide sequence encoding VL FR4 comprises the nucleotide sequence of SEQ ID NO: 18; the nucleotide sequence encoding VH FR1 comprises the nucleotide sequence of SEQ ID NO: 22; the nucleotide sequence encoding VH CDR1 comprises the nucleotide sequence of SEQ ID NO: 44; the nucleotide sequence encoding VH FR2 comprises the nucleotide sequence of SEQ ID NO: 26; the nucleotide sequence encoding VH CDR2 comprises the nucleotide sequence of SEQ ID NO: 28; the nucleotide sequence encoding VH FR3 comprises the nucleotide sequence of SEQ ID NO: 30; the nucleotide sequence encoding VH The nucleotide sequence of CDR3 comprises the nucleotide sequence of SEQ ID NO:32; the nucleotide sequence encoding VH FR4 comprises the nucleotide sequence of SEQ ID NO:50; and / or the nucleotide sequence encoding the scFv linker comprises the nucleotide sequence of SEQ ID NO:36.
[0364] For example, in one embodiment, the composition comprises a nucleic acid molecule encoding an antibody fragment comprising an scFv represented herein as Mut-gy1-2. In one embodiment, the nucleic acid molecule encoding Mut-gy1-2 comprises: a nucleotide sequence encoding VL CDR2 comprising an amino acid sequence of SEQ ID NO: 41; a nucleotide sequence encoding VL FR4 comprising an amino acid sequence of SEQ ID NO: 43; a nucleotide sequence encoding VH CDR1 comprising an amino acid sequence of SEQ ID NO: 45, and / or a nucleotide sequence encoding VH FR3 comprising an amino acid sequence of SEQ ID NO: 47.
[0365] In one embodiment, the nucleic acid molecule encoding Mut-gy1-2 comprises: a nucleotide sequence encoding VL FR1, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO: 7; a nucleotide sequence encoding VL CDR1, wherein the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 9; a nucleotide sequence encoding VL FR2, wherein the VL FR2 comprises the amino acid sequence of SEQ ID NO: 11; a nucleotide sequence encoding VL CDR2, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 41; a nucleotide sequence encoding VL FR3, wherein the VL FR3 comprises the amino acid sequence of SEQ ID NO: 15; a nucleotide sequence encoding VL CDR3, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 17; a nucleotide sequence encoding VL FR4, wherein the VL FR4 comprises the amino acid sequence of SEQ ID NO: 43; a nucleotide sequence encoding VH FR1, wherein the VH FR1 comprises the amino acid sequence of SEQ ID NO: 23; a nucleotide sequence encoding VH CDR1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:45; a nucleotide sequence encoding VH FR2, wherein the VH FR2 comprises the amino acid sequence of SEQ ID NO:27; a nucleotide sequence encoding VHCDR2, wherein the VH CDR2 comprises the amino acid sequence of SEQ ID NO:29; a nucleotide sequence encoding VH FR3, wherein the VH FR3 comprises the amino acid sequence of SEQ ID NO:47; a nucleotide sequence encoding VH CDR3, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO:33; a nucleotide sequence encoding VH FR4, wherein the VH FR4 comprises the amino acid sequence of SEQ ID NO:35; and / or a nucleotide sequence encoding a scFv linker, wherein the scFv linker comprises the amino acid sequence of SEQ ID NO:37.
[0366] In one embodiment, the nucleotide sequence encoding VL FR1 comprises the nucleotide sequence of SEQ ID NO: 6; the nucleotide sequence encoding VL CDR1 comprises the nucleotide sequence of SEQ ID NO: 8; the nucleotide sequence encoding VL FR2 comprises the nucleotide sequence of SEQ ID NO: 10; the nucleotide sequence encoding VL CDR2 comprises the nucleotide sequence of SEQ ID NO: 40; the nucleotide sequence encoding VL FR3 comprises the nucleotide sequence of SEQ ID NO: 14; the nucleotide sequence encoding VL CDR3 comprises the nucleotide sequence of SEQ ID NO: 16; the nucleotide sequence encoding VL FR4 comprises the nucleotide sequence of SEQ ID NO: 42; the nucleotide sequence encoding VH FR1 comprises the nucleotide sequence of SEQ ID NO: 22; the nucleotide sequence encoding VH CDR1 comprises the nucleotide sequence of SEQ ID NO: 44; the nucleotide sequence encoding VH FR2 comprises the nucleotide sequence of SEQ ID NO: 26; the nucleotide sequence encoding VH CDR2 comprises the nucleotide sequence of SEQ ID NO: 28; the nucleotide sequence encoding VH FR3 comprises the nucleotide sequence of SEQ ID NO: 46; the nucleotide sequence encoding VH The nucleotide sequence of CDR3 comprises the nucleotide sequence of SEQ ID NO:32; the nucleotide sequence encoding VH FR4 comprises the nucleotide sequence of SEQ ID NO:34; and / or the nucleotide sequence encoding the scFv linker comprises the nucleotide sequence of SEQ ID NO:36.
[0367] In one embodiment, the nucleic acid molecule encodes an antibody fragment comprising an scFv represented herein as Mut-gy1-3. In one embodiment, the nucleic acid molecule encoding Mut-gy1-3 comprises: a nucleotide sequence encoding VH CDR1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 45, and a nucleotide sequence encoding VH CDR3, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 49. In one embodiment, Mut-gy1 comprises: a nucleotide sequence encoding VL FR1, wherein the VL FR1 comprises the amino acid sequence of SEQ ID NO:7; a nucleotide sequence encoding VL CDR1, wherein the VLCDR1 comprises the amino acid sequence of SEQ ID NO:9; a nucleotide sequence encoding VL FR2, wherein the VL FR2 comprises the amino acid sequence of SEQ ID NO:11; a nucleotide sequence encoding VL CDR2, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO:13; a nucleotide sequence encoding VL FR3, wherein the VL FR3 comprises the amino acid sequence of SEQ ID NO:15; a nucleotide sequence encoding VLCDR3, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17; a nucleotide sequence encoding VL FR4, wherein the VL FR4 comprises the amino acid sequence of SEQ ID NO:19; a nucleotide sequence encoding VH FR1, wherein the VH FR1 comprises the amino acid sequence of SEQ ID NO:23; a nucleotide sequence encoding VH CDR1, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:45; a nucleotide sequence encoding a VH FR2 comprising the amino acid sequence of SEQ ID NO:27; a nucleotide sequence encoding a VH CDR2 comprising the amino acid sequence of SEQ ID NO:29; a nucleotide sequence encoding a VH FR3 comprising the amino acid sequence of SEQ ID NO:31; a nucleotide sequence encoding a VH CDR3 comprising the amino acid sequence of SEQ ID NO:49; and / or a nucleotide sequence encoding a VH FR4 comprising the amino acid sequence of SEQ ID NO:35.
[0368] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence encoding a scFv linker comprising the amino acid sequence of SEQ ID NO:37. In one embodiment, the nucleotide sequence encoding VL FR1 comprises the nucleotide sequence of SEQ ID NO: 6; the nucleotide sequence encoding VL CDR1 comprises the nucleotide sequence of SEQ ID NO: 8; the nucleotide sequence encoding VLFR2 comprises the nucleotide sequence of SEQ ID NO: 10; the nucleotide sequence encoding VL CDR2 comprises the nucleotide sequence of SEQ ID NO: 12; the nucleotide sequence encoding VL FR3 comprises the nucleotide sequence of SEQ ID NO: 14; the nucleotide sequence encoding VLCDR3 comprises the nucleotide sequence of SEQ ID NO: 16; the nucleotide sequence encoding VL FR4 comprises the nucleotide sequence of SEQ ID NO: 18; the nucleotide sequence encoding VH FR1 comprises the nucleotide sequence of SEQ ID NO: 22; the nucleotide sequence encoding VHCDR1 comprises the nucleotide sequence of SEQ ID NO: 44; the nucleotide sequence encoding VH FR2 comprises the nucleotide sequence of SEQ ID NO: 26; the nucleotide sequence encoding VH CDR2 comprises the nucleotide sequence of SEQ ID NO: 28; the nucleotide sequence encoding VHFR3 comprises the nucleotide sequence of SEQ ID NO: 30; the nucleotide sequence encoding VH The nucleotide sequence of CDR3 comprises the nucleotide sequence of SEQ ID NO: 48; and / or the nucleotide sequence encoding VH FR4 comprises the nucleotide sequence of SEQ ID NO: 34. In some embodiments, the nucleotide sequence encoding the scFv linker comprises the nucleotide sequence of SEQ ID NO: 36.
[0369] In some embodiments, the nucleic acid molecule encodes a PSMAb or a polypeptide chain thereof. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain, the heavy chain comprising the amino acid sequence of SEQ ID NO: 68. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain, the heavy chain having a signal peptide, wherein the heavy chain having a signal peptide comprises the amino acid sequence of SEQ ID NO: 53. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain signal peptide, the heavy chain signal peptide comprising the amino acid sequence of SEQ ID NO: 55. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain variable region, the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain constant region of SEQ ID NO: 59. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a light chain, the light chain comprising the amino acid sequence of SEQ ID NO: 69. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a light chain, the light chain having a signal peptide, wherein the light chain having a signal peptide comprises the amino acid sequence of SEQ ID NO: 61. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a light chain signal peptide, the light chain signal peptide comprising an amino acid sequence of SEQ ID NO: 63. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a light chain variable region, the light chain variable region comprising an amino acid sequence of SEQ ID NO: 65. In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a light chain constant region of SEQ ID NO: 67. In one embodiment, the nucleotide sequence encoding a heavy chain with a signal peptide comprises a nucleotide sequence of SEQ ID NO: 52. In one embodiment, the nucleotide sequence encoding a heavy chain signal peptide comprises a nucleotide sequence of SEQ ID NO: 54. In one embodiment, the nucleotide sequence encoding a heavy chain variable region comprises a nucleotide sequence of SEQ ID NO: 56. In one embodiment, the nucleotide sequence encoding a heavy chain constant region comprises a nucleotide sequence of SEQ ID NO: 58. In one embodiment, the nucleotide sequence encoding a light chain with a signal peptide comprises a nucleotide sequence of SEQ ID NO: 60. In one embodiment, the nucleotide sequence encoding a light chain signal peptide comprises a nucleotide sequence of SEQ ID NO: 62. In one embodiment, the nucleotide sequence encoding a light chain variable region comprises a nucleotide sequence of SEQ ID NO: 64. In one embodiment, the nucleotide sequence encoding the light chain constant region comprises the nucleotide sequence of SEQ ID NO:66.
[0370] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having homology to one or more nucleotide sequences described herein. For example, in some embodiments, the nucleic acid molecule comprises a nucleotide sequence having 70% or more, 75% or more, 80% or more, 82% or more, 85% or more, 87% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more homology to a nucleotide sequence described herein.
[0371] In another aspect, the present disclosure also provides methods for expressing or producing recombinant proteins of anti-PSMA antibodies or antigen-binding fragments thereof using various protein expression systems.
[0372] In one embodiment, the present invention also provides transformed cells and their offspring, and nucleic acid molecules encoding antibodies or antigen binding fragments are introduced therein by recombinant DNA technology in vitro, in vitro or in vivo. The transformed cells (eukaryotic cells or prokaryotic cells) can be used to produce recombinant antibodies or their antigen binding fragments for purification or for in situ or secretory expression (e.g., diagnosis or treatment of tumors) for various purposes. The transformed cells can be propagated, the nucleic acids introduced by transcription, or the encoded proteins can be expressed. It is understood that daughter cells may be different from parental cells because mutations may exist during replication. Transformed cells include, but are not limited to, prokaryotic and eukaryotic cells, such as bacteria, fungi, plants, insects, and animals (e.g., mammals, including humans) cells. The cell can be present in a culture, in a cell, tissue or organ in vitro, or in an object.
[0373] Typically, cell transformation employs a vector. The term "vector" refers to, for example, a plasmid, a virus (e.g., a viral vector), or other medium known in the art, which can be manipulated by inserting or incorporating nucleic acids for genetic manipulation (i.e., a "cloning vector"), or can be used to transcribe or translate an inserted polynucleic acid (i.e., an "expression vector"). Such vectors can be used to introduce nucleic acids, including nucleic acids encoding antibodies operably linked to expression control elements, and to express the encoded protein in vitro (e.g., in solution or in solid phase), in cells, or in vivo.
[0374] In one embodiment, the expression vector is transferred to a host cell by conventional techniques, and the transfected cells are then cultured by conventional techniques to produce antibodies or antigen-binding fragments of the present invention. Therefore, the present invention includes host cells containing polynucleic acids encoding antibodies of the present invention (e.g., complete antibodies, heavy chains or light chains thereof, or portions thereof, or single-chain antibodies, or fragments or variants thereof), which are operably connected to heterologous promoters. In other embodiments, in order to express complete antibody molecules, vectors encoding heavy and light chains are co-expressed in host cells to express complete immunoglobulin molecules.
[0375] A variety of host-expression vector systems can be utilized to express the antibody molecules of the present invention. Such host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells that can express the antibody molecules of the present invention in situ when transformed or transfected with the appropriate nucleic acid coding sequences. These include, but are not limited to, phage particles engineered to express antibody fragments or variants thereof (single-chain antibodies), microorganisms such as bacteria (e.g., E. coli, Bacillus subtilis) transformed with recombinant phage DNA, plasmid DNA, or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., yeast, Pichia pastoris) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant viral expression vectors (e.g., baculovirus) containing antibody coding sequences; aMV; tobacco mosaic virus, TMV) or a plant cell system transformed with a recombinant plasmid expression vector (e.g., Ti plasmid) containing an antibody coding sequence; or a mammalian cell system (e.g., COS, CHO, BHK, 293, 3T3, NS0 cells) containing a recombinant expression construct, the recombinant expression construct containing a promoter derived from the mammalian cell genome (e.g., metallothionein promoter) or from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, CMV promoter or EF1α promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially eukaryotic cells for expressing complete recombinant antibody molecules, are used to express recombinant antibody molecules. For example, mammalian cells (e.g., Chinese hamster ovary cells (CHO)) in combination with vectors (e.g., major intermediate early gene promoter elements from human cytomegalovirus) are effective expression systems for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio / Technology 8:2 (11990); Bebbington et al., Bio / Techniques 10:169 (1992); Keen and Hale, Cytotechnology 18:207 (1996)). The entire contents of these references are incorporated herein by reference.
[0376] The vector or host-expression vector used to transform cells usually contains at least a replication origin for propagation in the cell. The control elements comprising the expression control elements described herein present in the vector are included to promote transcription and translation. The term "expression control element" is intended to include at least one or more components whose presence can affect expression, and may include components other than promoters or enhancers, for example, leader sequences and fusion partner sequences, internal ribosome binding site (IRES) elements for producing polygenes, or polycistronic, messenger, splicing signals for introns, maintaining the correct reading frame of the gene to allow translation in the reading frame of the mRNA, polyadenylation signals to provide suitable polyadenylation of the transcript of the gene of interest, stop codons, etc.
[0377] The vector can include a selection marker. As known in the art, a "selection marker" refers to a gene that allows the selection of cells containing the gene. "Positive selection" refers to a process in which cells containing only the selection marker will survive when exposed to positive selection. Drug resistance is an example of a positive selection marker; cells containing the marker will survive in a culture medium containing a selection drug, while cells without the marker will die. Such markers include drug resistance genes, such as neo, which confers resistance to G418, hygr, which confers resistance to hygromycin, or puro, which confers resistance to puromycin, etc. Other positive selection marker genes include genes that allow identification or screening of cells containing the marker. These genes include fluorescent protein (GFP) genes, lacZ genes, alkaline phosphatase genes, and surface markers (e.g., CD8), etc.
[0378] The vector may contain a negative selection marker. "Negative selection" refers to the process of killing cells containing negative selection markers when exposed to an appropriate negative selection agent. For example, cells containing the herpes simplex virus thymidine kinase (HSV-tk) gene (Wigler et al., Cell 11: 223 (1977))) are sensitive to the drug ganciclovir (GANC). Similarly, the gpt gene makes cells sensitive to 6-thioxanthine.
[0379] Mammalian expression systems also include vectors specifically designed for in vivo and ex vivo expression. Such systems include adeno-associated virus (AAV) vectors (U.S. Patent No. 5,604,090). AAV vectors have previously been shown to provide expression of factor IX in humans and mice at levels sufficient to obtain therapeutic benefits (Kay et al., Nat. Genet. 24: 257 (2000); Nakai et al., Blood 91: 4600 (1998)). Adenoviral vectors (U.S. Pat. Nos. 5,700,470, 5,731,172, and 5,928,944), herpes simplex virus vectors (U.S. Pat. No. 5,501,979), and retroviral (e.g., lentiviral vectors can be used to infect dividing as well as non-dividing cells and foamy viruses) vectors (U.S. Pat. Nos. 5,624,820, 5,693,508, 5,665,577, 6,013,516, and 5,674,703 and WIPO publications WO92 / 05266 and WO92 / 14829) and papillomavirus vectors (e.g., human and bovine papillomavirus) have all been used for gene therapy (U.S. Pat. No. 5,719,054). Vectors also include cytomegalovirus (CMV)-based vectors (U.S. Pat. No. 5,561,063). Vectors that effectively deliver genes to intestinal cells have been developed and can also be used (see, e.g., U.S. Patent Nos. 5,821,235, 5,786,340, and 6,110,456). In yeast, for example, vectors that promote integration of exogenous nucleic acid sequences into chromosomes by homologous recombination are known in the art and can be used. When the inserted nucleic acid is too large (e.g., greater than about 12 kb) for more conventional vectors, yeast artificial chromosomes (YACs) are typically used.
[0380] In one embodiment, the phagemid vectors used for the present invention include any vectors available in the art suitable for producing antibodies / antibody templates / FR libraries of the present invention, and include phagemid vectors pCB04, pIT1, pIT2, CANTAB6, pComb 3HS. The methods for constructing filamentous vectors and phagemids are described in, for example, U.S. Patent No. 6,054,312 and U.S. Patent No. 6,803,230, each of which is incorporated herein by reference. Phage display systems involving non-filamentous phage vectors referred to as cytoplasmic phages or lytic phages can also be used, such as, for example, as described in U.S. Patent No. 5,766,905, which is incorporated herein by reference.
[0381] Suitable bacterial expression constructs for use in the present invention include, but are not limited to, pCAL, pUC, pET, pETBlue TM(Novagen), pBAD, pLEX, pTrcHis2, pSE280, pSE380, pSE420 (Invitrogen), pKK223-2 (Clontech), pTrc99A, pKK223-3, pRIT2T, pMC1871, pEZZ 18 (Pharmacia), pBluescript IISK (Stratagene), pALTER-Ex1, pALTER-Ex2, pGEMEX (Promega), pFivE (MBI), pQE (Qiagen) commercially available expression constructs, and their derivatives and other expression constructs known in the art. In some embodiments, the construct may also include a virus, a plasmid, a bacmid, a phagemid, a cosmid or a bacteriophage.
[0382] The use of liposomes for introducing various compositions (including nucleic acids) into cells is known to those skilled in the art (see, e.g., U.S. Pat. Nos. 4,844,904, 5,000,959, 4,863,740, and 4,975,282). Carriers comprising natural polymers, or derivatives or hydrolyzates of natural polymers, are described in WO 94 / 20078 and U.S. Pat. No. 6,096,291, and are suitable for mucosal delivery of molecules (e.g., polypeptides and polynucleic acids). It is also known that zwitterionic cationic lipids based on piperazine are useful for gene therapy (see, e.g., U.S. Pat. No. 5,861,397). Cationic lipid systems are also known (see, e.g., U.S. Pat. No. 5,459,127). Therefore, viral and non-viral vector means for delivery to cells or tissues in vitro, in vivo, and ex vivo are included.
[0383] In one embodiment, nucleotide sequence can be "operably connected", that is, positioned to ensure the function of expression control sequence. These expression constructs can be replicated in cells as episomes or as components of cell chromosome DNA usually, and can contain the appropriate replication origin of the corresponding prokaryotic strain for expression. Usually, expression construct contains selection marker, such as tetracycline resistance, ampicillin resistance, kanamycin resistance or chloramphenicol resistance, so that those bacterial cells transformed with the desired nucleotide sequence are detected and / or selected (see, for example, U.S. Patent number 4,704,362). However, these markers are not exclusive, and many other markers can be used, as known to those skilled in the art. In some embodiments, expression construct comprises positive and negative selection markers.
[0384] Similarly, a reporter gene may be incorporated into the expression construct to facilitate identification of the transcription product. Thus, in one embodiment of the invention, the reporter gene used is selected from the group consisting of β-galactosidase, chloramphenicol acetyltransferase, luciferase and fluorescent protein.
[0385] Prokaryotic promoter sequences regulate the expression of the polynucleic acid sequences encoded, and in some embodiments of the present invention, are operably linked to polynucleic acids encoding polypeptides of the present invention. In other embodiments of the present invention, these promoters are constitutive or inducible, and provide means for high and low level expression of polypeptides of the present invention, and in some embodiments, provide means for regulating expression of multiple polypeptides of the present invention, which are expressed as fusion proteins in some embodiments.
[0386] Many well-known bacterial promoters can be used, including T7 promoter system, lactose promoter system, tryptophan (Trp) promoter system, Trc / Tac promoter system, β-lactamase promoter system, tetA promoter system, arabinose regulated promoter system, phage T5 promoter or promoter system from phage λ, and others, as well, and including embodiments of the present invention. The promoter will generally control expression, optionally together with an operator sequence, and may include a ribosome binding site sequence, for example, for initiating and completing transcription and translation. According to additional embodiments, the vector may also contain expression control sequences, enhancers that can regulate the transcriptional activity of the promoter, appropriate restriction sites that promote the cloning of inserted sequences near the promoter, and other necessary information processing sites, such as RNA splicing sites, polyadenylation sites, and transcription termination sequences, as well as any other sequences that can promote the expression of the inserted nucleic acid.
[0387] In another embodiment, the present invention includes methods of using the polynucleic acids, vectors, antibodies and / or fragments thereof and / or compositions comprising the same as described herein in treatment, inhibition or prevention.
[0388] PSMA-targeted antibody drug conjugates
[0389] In one embodiment, the present invention provides an antibody drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent (e.g., a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or a fragment thereof), or a radioactive isotope (i.e., a radioconjugate). In a specific embodiment, the drug includes, but is not limited to, tubulin inhibitors and DNA cleavage agents, such as maytansinoids, auristatins, dolastatins, and calicheamicin. In another embodiment, the present invention further provides methods of using the ADC. In one aspect, the ADC comprises any of the above PSMA antibodies or antibody fragments covalently linked to a cytotoxic agent or a detectable agent.
[0390] Antibody drug conjugates are used for local delivery of cytotoxic or cytostatic agents, i.e., drugs that kill or inhibit tumor cells in cancer therapy (Syrigos and Epenetos (1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drg Del. Rev. 26:151-172; U.S. Pat. No. 4,975,278) allowing targeted delivery of drug moieties to tumors, as well as intracellular accumulation therein, where systemic administration of these unconjugated agents can result in unacceptable levels of toxicity to normal cells as well as to the tumor cells sought to be eliminated (Baldwin et al., (1986) Lancet pp. (Mar. 15, 1986):603-05; Thorpe, (1985) "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical applications, A. Pinchera et al. (ed.s), pp. 475-506). Thus, maximum efficacy with minimal toxicity is sought. Both polyclonal and monoclonal antibodies have been reported to be useful in these strategies (Rowland et al., (1986) Cancer Immunol. Immunother., 21: 183-87). Drugs used in these methods include daunorubicin, doxorubicin, methotrexate, and vindesine sulfate (Rowland et al., (1986) supra).Toxins used in antibody-toxin conjugates include bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin (Mandler et al. (2000) Jour. of the Nat. Cancer Inst. 92(19):1573-1581; Mandler et al. (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al. (2002) Bioconjugate Chem. 13:786-791), maytansine compounds (EP 1391213; Liu et al., (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), and calicheamicin (Lode et al. (1998) Cancer Res. 58:2928; Hinman et al. (1993) Cancer Res. 53:3336-3342). Toxins can affect their cytotoxic and cytostatic effects through mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition. Some cytotoxic drugs tend to be inactive or less active when coupled to large antibodies or protein receptor ligands.
[0391] Examples of antibody drug conjugates include ZEV (ibritumomab tiuxetan, Biogen / Idec), which is an antibody-radioisotope conjugate consisting of a murine IgG1κ monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes and an 111In or 90Y radioisotope bound via a thiourea linker-chelator (Wiseman et al. (2000) Eur. Jour. Nucl. Med. 27(7):766-77; Wiseman et al. (2002) Blood 99(12):4336-42; Witzig et al. (2002) J. Clin. Oncol. 20(10):2453-63; Witzig et al. (2002) J. Clin. One al. 20(15):3262-69).
[0392] In addition, MYLOTARG TM(gemtuzumab ozogamicin, Wyeth Pharmaceuticals), an antibody-drug conjugate consisting of a human CD33 antibody linked to calicheamicin, was approved in 2000 for the treatment of acute myeloid leukemia by injection (Drugs of the Future (2000) 25(7):686; U.S. Pat. Nos. 4,970,198; 5,079,233; 5,585,089; 5,606,040; 5,693,762; 5,739,116; 5,767,285; 5,773,001).
[0393] Finally, auristatin peptides (e.g. monomethyl auristatin E (MMAE), a synthetic analog of dolastatin) have been conjugated to chimeric monoclonal antibodies cBR96 (specific for Lewis Y on cancer) and cAC10 (specific for CD30 on hematological malignancies) (Doronina et al. (2003) Nature Biotechnology 21(7):778-784). cAC10 is under therapeutic development.
[0394] In addition, chemotherapeutic agents for producing ADCs are described herein. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, α-sarcin, Aleurites fordii protein, dianthin protein, Phytolaca americana protein (PAPI, PAPII and PAP-S), bitter melon inhibitor, curcin, crotonin, saponin inhibitor, gelonin, milinomycin, restrictocin, phenomycin, enomycin and tricothecenes. See, for example, WO 93 / 21232, published on October 28, 1993. There are a variety of radionuclides that can be used to produce radio-conjugated antibodies. Examples include 212Bi, 131I, 131In, 90Y and 186Re. Conjugates of antibodies and cytotoxic agents can be prepared using various bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimide HCL), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bisdiazo derivatives (e.g., bis(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate) and bisactive fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al (1987) Science, 238:1098. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelator for conjugation of radionucleic acids to antibodies (WO 94 / 11026).
[0395] Conjugates of antibodies and one or more small molecule toxins (e.g., calicheamicin, maytansines, dolastatins, auristatins, trichothecenes, and CC1065), as well as toxin-active derivatives of these toxins, are also contemplated herein.
[0396] Maytansinoids:
[0397] Maytansinoid compounds suitable for use as the drug moiety of maytansinoid compounds are well known in the art and can be isolated from natural sources according to known methods, produced using genetic engineering techniques (see Yu et al. (2002) PNAS 99:7968-7973), or maytansinol and maytansinol analogs can be prepared synthetically according to known methods.
[0398] Exemplary maytansine drug moieties include those with modified aromatic rings, such as: C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared by reduction of ansamytocin P2 with lithium aluminum hydride); C-20-hydroxy (or C-20-demethyl) + / - C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016) (prepared by demethylation using Streptomyces or Actinomycetes or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), + / -dechloro (U.S. Pat. No. 4,294,757) (prepared by acylation using acyl chlorides), as well as those with modifications at other positions.
[0399] Exemplary maytansine drug moieties also include those with modifications, such as: C-9-SH (U.S. Pat. No. 4,424,219) (prepared by reaction of maytansinol with H2S or P2S5); C1-14-alkoxymethyl (demethoxy / CH2OR) (U.S. Pat. No. 4,331,598); C-14-hydroxymethyl or acyloxymethyl (CH2OH or CH2OAc) (U.S. Pat. No. 4,450,254) (prepared from Nocardia); C-15-hydroxy / acyloxy (U.S. Pat. No. 4,364,866) (prepared by transformation of maytansinol by Streptomyces); C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (isolated from Trewianudlflora); C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (prepared by demethylation of maytansinol by Streptomyces); and 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared by titanium trichloride / LAH reduction of maytansinol).
[0400] ADCs containing maytansine compounds, methods for their preparation, and their therapeutic uses are disclosed in, for example, U.S. Patent Nos. 5,208,020; 5,416,064; 6,441,163 and European Patent EP 0425 235B1, the disclosures of which are expressly incorporated herein by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) describes an ADC comprising a maytansine compound called DM1 linked to a monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic to cultured colon cancer cells and showed antitumor activity in an in vivo tumor growth assay. Chari et al., Cancer Research 52:127-131 (1992) described ADCs in which maytansine compounds were conjugated via disulfide bonds to murine antibody A7, which binds to an antigen on a human colon cancer cell line, or to another murine monoclonal antibody TA.1, which binds to the HER-2 / neu oncogene. The cytotoxicity of the TA.1 maytansine compound conjugate was tested in vitro on the human breast cancer cell line SK-BR-3, which expresses 3×10 5 HER-2 surface antigen. The drug conjugate achieved a similar degree of cytotoxicity as the free maytansine drug, which could be increased by increasing the number of maytansine molecules per antibody molecule. The A7 maytansine conjugate showed low systemic cytotoxicity in mice.
[0401] An exemplary maytansinoid embodiment is DM1 (wherein the wavy line indicates the covalent attachment to the linker (L) of the antibody drug conjugate).
[0402]
[0403] Auristatins and dolastatins:
[0404] In some embodiments, the ADC comprises an antibody of the invention coupled to dolastatin or dolastatin peptide analogs and derivatives, and auristatin (U.S. Pat. Nos. 5,635,483; 5,780,588). Dolastatin and auristatin have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cell division (Woyke et al. (2001) Antimicrob. Agents and Chemother. 45 (12): 3580-3584) and have anticancer effects (U.S. Pat. No. 5,663,149) and antifungal activity (Pettit et al. (1998) Antimicrob. Agents Chemother. 42: 2961-2965). The dolastatin or auristatin drug moiety can be linked to the antibody via the N (amino) terminus or the C (carboxyl) terminus of the peptide drug moiety (WO 02 / 088172).
[0405] Exemplary auristatin embodiments include N-terminally linked monomethyl auristatin drug moieties DE and DF, which are disclosed in "Senter et al., Proceedings of the American Association for Cancer Research, Volume 45, Abstract Number 623, filed March 28, 2004, and described in U.S. Patent Publication No. 2005 / 0238649, the disclosures of which are expressly incorporated herein by reference in their entirety.
[0406] ADCs using MMAE and MMAF with various linker components have been disclosed (US 2005 / 0238649, US08968742).
[0407] An exemplary auristatin embodiment is MMAE (wherein the wavy line indicates the covalent attachment to the linker (L) of the antibody drug conjugate).
[0408]
[0409] Another exemplary auristatin embodiment is MMAF, wherein the wavy line indicates the covalent attachment to the linker (L) of the antibody drug conjugate (US2005 / 0238649):
[0410]
[0411] Typically, a peptide-based drug moiety can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such a peptide bond can be prepared, for example, according to a liquid phase synthesis method known in the field of peptide chemistry (see E. Schroder and K. Lubke, "The Peptides," volume 1, pp 76-136, 1965, Academic Press). The auristatin / dolastatin drug moiety can be prepared according to the following methods: U.S. Patent No. 5,635,483; U.S. Patent No. 5,780,588; Pettit et al. (1989) J. Am. Chem. Soc. 111:5463-5465; Pettit et al. (1998) Anti-Cancer Drug Design 13:243-277; Pettit, GR, et al. Synthesis, 1996, 719-725; Pettit et al. (1996) J. Chem. Soc. Perkin Trans. 1 5:859-863; and Doronina (2003) Nat Biotechnol 21(7):778-784.
[0412] Calcheamicin:
[0413] In other embodiments, the ADC comprises an antibody of the invention coupled to one or more calicheamicin molecules. The calicheamicin family of antibiotics is capable of producing double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001 and 5,877,296 (all belonging to American Cyanamid Company). Structural analogs of calicheamicin that can be used include, but are not limited to, γ1I, α2I, α3I, N-acetyl-γ1I, PSAG, and θ1I (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research 58:2925-2928 (1998) and the above-mentioned U.S. patents for U.S. cyanamide). Another anti-tumor drug to which the antibody can be coupled is QFA, which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not easily cross the plasma membrane. Therefore, the cellular uptake of these agents by antibody-mediated internalization greatly enhances their cytotoxic effects.
[0414] Other cytotoxic agents:
[0415] Other anti-tumor agents that can be conjugated to the antibodies of the invention include BCNU, streptozotocin, vincristine and 5-fluorouracil, the family of agents collectively referred to as LL-E33288 complex described in US Pat. Nos. 5,053,394, 5,770,710, and esperamicin (US Pat. No. 5,877,296).
[0416] Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, α-sarcin, tung oil protein, dianthin protein, pokeweed protein (PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, saponin, gelonin, milincomycin, restrictocin, phenomycin, enomycin and trichothecenes. See, for example, WO 93 / 21232 published on October 28, 1993.
[0417] The present invention further contemplates ADCs formed between an antibody and a compound having nucleolytic activity (eg, a ribonuclease or a DNA endonuclease, such as a deoxyribonuclease; DNase).
[0418] In order to selectively destroy tumors, antibodies can contain highly radioactive atoms. A variety of radioactive isotopes can be used to produce radioactively coupled antibodies. Examples include radioactive isotopes of At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and Lu. When the conjugate is used for detection, it can contain radioactive atoms (e.g., tc99m or I123) for scintigraphic studies, or spin labels (e.g., iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron) for nuclear magnetic resonance (NMR) imaging (also referred to as magnetic resonance imaging (MRI)).
[0419] Radioactive labels or other labels can be incorporated into the conjugate in a known manner. For example, the peptide can be biosynthesized, or can be synthesized by chemical amino acid synthesis using suitable amino acid precursors (including, for example, fluorine-19 instead of hydrogen). Labels such as tc99m or I123, Re186, Re188 and In111 can be connected by cysteine residues in the peptide. Yttrium-90 can be connected by lysine residues. The IODOGEN method (Fraker et al (1978) Biochem.Biophys.Res.Commun.80:49-57) can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes other methods in detail.
[0420] PSMA-targeted ADC compounds:
[0421] The present invention provides, inter alia, antibody drug conjugate compounds for targeted drug delivery. The inventors have found that the antibody drug conjugate compounds have effective cytotoxic and / or cytostatic activity against cells expressing PSMA. The antibody drug conjugate compounds comprise an antibody unit covalently linked to at least one drug unit. The drug unit can be covalently linked directly or through a linker unit (-LU-).
[0422] In some embodiments, the antibody drug conjugate compound has the following formula:
[0423] Ab-(LU-D)p
[0424] or a pharmaceutically acceptable salt or solvate thereof; wherein:
[0425] Ab is an antibody unit, such as a complete antibody or an antigen-binding fragment thereof derived from Mut-gy1 or a mutant variant thereof of the present invention, such as PSMAb, and
[0426] (LU-D) is a Linker unit-Drug unit moiety, wherein:
[0427] Lu- is the linker unit, and
[0428] -D is a drug unit having cytostatic or cytotoxic activity on target cells; and
[0429] p is an integer from 1 to 20.
[0430] In some embodiments, p is 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p is 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In other embodiments, p is 1, 2, 3, 4, 5, or 6. In some embodiments, p is 2 or 4.
[0431] In some embodiments, the antibody drug conjugate compound has the following formula:
[0432] Ab-(A a -W w —Y y -D)p
[0433] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0434] Ab is an antibody unit, such as a complete antibody or an antigen-binding fragment thereof derived from Mut-gy1 or a mutant variant thereof of the present invention, such as PSMAb; and
[0435] -A a -W w —Y y - is a connection subunit (LU), where:
[0436] -A- is the extension unit,
[0437] a is 0 or 1,
[0438] Each —W— is independently an amino acid unit,
[0439] w is an integer from 0 to 12,
[0440] —Y— is a self-decomposing spacer unit,
[0441] y is 0, 1, or 2;
[0442] -D is a drug unit having cytostatic or cytotoxic activity on target cells; and
[0443] p is an integer from 1 to 20.
[0444] In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0, 1 or 2. In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0 or 1. In some embodiments, p is 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p is 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In other embodiments, p is 1, 2, 3, 4, 5, or 6. In some embodiments, p is 2 or 4. In some embodiments, when w is not zero, y is 1 or 2. In some embodiments, when w is 1 to 12, y is 1 or 2. In some embodiments, w is 2 to 12, and y is 1 or 2. In some embodiments, a is 1 and w and y are 0.
[0445] For compositions comprising multiple antibodies, drug loading is represented by p, and p is the average number of drug molecules of each antibody. The drug loading of each antibody can be 1 to 20 drugs (D). The average number of drugs of each antibody in the preparation of coupled reaction can be characterized by conventional methods (such as mass spectrometry, ELISA determination and HPLC). The quantitative distribution of antibody drug conjugates can also be determined by p. In some cases, the separation, purification and characterization of similar antibody drug conjugates can be achieved by methods such as reversed-phase HPLC or electrophoresis, wherein p is a specific value from an antibody drug conjugate with other drug loadings. In an exemplary embodiment, p is 2 to 8.
[0446] The production of antibody drug conjugate compounds can be completed by any technique known to those skilled in the art. In short, the antibody drug conjugate compound comprises a complete antibody or antigen-binding fragment derived from Mut-gy1 or its mutant variant of the present invention as an antibody unit, a drug, and an optional linker for connecting the drug and the binding agent. In a preferred embodiment, the antibody is an antibody or antigen-binding fragment derived from Mut-gy1 or its variant with point mutations, as described elsewhere herein. Many different reactions can be used for the covalent connection of the drug and / or linker to the binding agent. This is usually completed by the reaction of the amino acid residues of the binding agent (e.g., antibody molecules, including the amine group of lysine, the free carboxylic acid groups of glutamic acid and aspartic acid, the sulfhydryl group of cysteine and various groups of aromatic amino acids). One of the most commonly used non-specific methods of covalent connection is the carbodiimide reaction of connecting the carboxyl (or amino) group of the compound to the amino (or carboxyl) group of the antibody. In addition, bifunctional agents such as dialdehydes or imidoesters have been used to connect the amino group of the compound to the amino group of the antibody molecule. Schiff base reaction can also be used for the connection of drugs to binding agents. The method involves periodate oxidation of drugs containing ethylene glycol or hydroxyl groups to form aldehydes which then react with the binding agent. The connection is made via a Schiff base to the composition of the amino group of the binding agent. Isothiocyanates can also be used as coupling agents to covalently link the drug to the binding agent. Other techniques are known to those skilled in the art and are within the scope of the present invention.
[0447] In some embodiments, the intermediate as a precursor of the linker is reacted with the drug under appropriate conditions. In some embodiments, the reactive group is used for the drug and / or the intermediate. The reaction product or the derived drug between the drug and the intermediate is then reacted with the complete antibody or antigen-binding fragment thereof derived from Mut-gy1 or its variant under appropriate conditions.
[0448] PSMA-targeted CAR-T or CAR-NK
[0449] Recent development of autologous T cell (CART) therapy modified with chimeric antigen receptor (CAR), which relies on redirecting T cells to appropriate cell surface molecules on cancer cells such as B cell malignancies, has shown promising results in treating B cell malignancies and other cancers using the power of the immune system (see, e.g., Sadelain et al., Cancer Discovery 3:388-398 (2013)). Clinical results of mouse CART19 (i.e., "CTL019") have shown the prospect of establishing complete remission in patients with CLL as well as childhood ALL (see, e.g., Kalos et al., Sci Transl Med 3:95ra73 (2011), Porter et al., NEJM 365:725-733 (2011), Grupp et al., NEJM 368:1509-1518 (2013)). In addition to the chimeric antigen receptor recognition and destruction of target cells on genetically modified T cells, successful therapeutic T cell therapy needs to have the ability to proliferate and continue over time, and further monitoring of leukemia cell escape is required.The variable quality of T cells, whether it is energy, suppression or exhaustion results, will have an impact on the performance of CAR-modified T cells, but the current skilled practitioners are limited in the control of this situation.In order to be effective, the patient T cells of CAR transformation need to continue and maintain the ability to proliferate in response to CAR antigens.It has been shown that ALL patient T cells can achieve this with CART19 comprising mouse scFv (see, e.g., Grupp et al., NEJM 368:1509-1518 (2013)).
[0450] The present invention controls the patient's immune response by providing fully human antibody fragments (e.g., scFv) that bind to PSMA integrated into chimeric antigen receptor (CAR) constructs that redirect engineered T cells to recognize and kill PSMA-positive tumor cells.
[0451] Therefore, on the one hand, the present invention relates to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or an antigen binding fragment thereof, the antibody or its antigen binding fragment comprising a PSMA binding domain, a transmembrane domain and an intracellular signaling domain (e.g., an intracellular signaling domain comprising a co-stimulatory domain and / or a primary signaling domain). In one embodiment, the CAR comprises an antibody or its antigen binding fragment, the antibody or its antigen binding fragment comprising a fully human anti-PSMA binding domain as described herein, a transmembrane domain as described herein, and an intracellular signaling domain as described herein (e.g., an intracellular signaling domain comprising a co-stimulatory domain and / or a primary signaling domain).
[0452] In one embodiment, the encoded human anti-PSMA binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a fully human anti-PSMA binding domain described herein, and / or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a fully human anti-PSMA binding domain described herein, e.g., a fully human anti-PSMA binding domain comprises one or more (e.g., all three) LC CDRs and / or one or more (e.g., all three) HC CDRs. In one embodiment, the encoded light chain variable region comprises one, two, three, or all four framework regions described herein. In one embodiment, the encoded heavy chain variable region comprises one, two, three, or all four framework regions described below. In one embodiment, the encoded fully human anti-PSMA binding domain comprises a human light chain variable region described below and / or a human heavy chain variable region described below. In one embodiment, the encoded anti-PSMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence described herein. In one embodiment, the anti-PSMA binding domain (e.g., scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of the amino acid sequence of the light chain variable region provided below, or a sequence having 95% to 99% identity with the amino acid sequence described below; and / or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions) of the amino acid sequence of the heavy chain variable region provided below, or a sequence having 95% to 99% identity with the amino acid sequence described below. In one embodiment, the encoded human anti-PSMA binding domain comprises the following sequence, or a sequence with 95-99% identity thereof. In one embodiment, the nucleic acid sequence encoding the human anti-PSMA binding domain comprises the following sequence, or a sequence with 95-99% identity thereof. In one embodiment, the encoded human anti-PSMA binding domain is a scFv, and the light chain variable region is connected to the heavy chain variable region by a linker (e.g., a linker described herein). In one embodiment, the encoded human anti-PSMA binding domain includes a (Gly4-Ser)n linker, wherein n is 1, 2, 3, 4, 5 or 6, preferably 3 or 4. In another embodiment, the encoded human anti-PSMA binding domain contains the linker sequence set forth in SEQ ID NO: 37. The light chain variable region and heavy chain variable region of the scFv can be, for example, in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.
[0453] In some embodiments, the anti-PSMA binding domain comprises an antibody or antigen-binding fragment thereof described elsewhere herein. For example, in some embodiments, the anti-PSMA binding domain comprises Mut-gy1, Mut-gy1-st, Mut-gy1-2, Mut-gy1-3, or PSMAbLm, as described elsewhere herein.
[0454] PSMA-targeted bispecific antibodies
[0455] Different from natural antibodies, bispecific antibodies (BsAb) are artificial antibodies with dual specificity, targeting two different tumor antigens, or one on tumor cells, the other on effector cells, which can effectively recruit immune effector cells to tumor sites and activate them to specifically kill tumor cells. The former example, i.e., the BsAb targeting two different tumor-associated antigens is bH1, which simultaneously combines Her2 and VEGF (Bostrom J1 et al. 2009, Science 323: 1610-4), or ErBb2 / ErBb3 dual-targeting bispecific scFv (Robinson MK et al. 2008, Br J Cancer 99: 1415-25). Both tumor-associated antigens can be expressed on tumor cells, or one is expressed on tumor cells, and the other is expressed on tumor cell-related cells, such as tumor microenvironment cells, such as fibroblasts, vascular cells, endothelial cells, pericytes or immune cells (macrophages, B cells, T cells, etc.) in the tumor microenvironment. An example of the latter, i.e., a BsAb targeting a tumor-associated antigen and an immune active antigen is a BsAb having one arm targeting a tumor antigen (e.g., Her2, CD19, or CD123) and another arm targeting an immune active antigen (e.g., CD3 or CD16) (Kontermann RE, et al. 2015, Drug Discovery Today 20:838-847), which can engage tumor cells and immune cells (e.g., T cells, NK cells, or macrophages, etc.).
[0456] BsAbs containing anti-CD3 antibodies will bind T cells and tumor cells together, leading to the killing of tumor cells (Muller and Kontermann, BioDrugs 2010; 24: 89-98, Baeuerle and Reinhardt 2009, Cancer Research 96: 4941) activated T cells. Belinto (Bargou et al., Science 2008, 321: 974-976) is a single-chain antibody construct named BiTE, which induces cytotoxicity by targeting CD19 and CD3. Other T cell binding bispecifics based on antibody fragments have been described (Moore et al. 2011, Blood 117: 4542-4551, Baeuerle et al. Current Opinion in Molecular Therapeutics 2009, 11: 22-30). BiTE TM The format is a bispecific single-chain antibody construct that connects the variable domains derived from two different antibodies. However, belinto monoclonal antibody has a poor half-life in vivo and is difficult to manufacture in terms of production and stability. Therefore, there is a need for an improved bispecific antibody that can target T cells to tumor cells and has improved manufacturability.
[0457] BsAb is a hybrid protein that can be produced by chemical crosslinking, hybridoma technology or genetic methods. In the chemical crosslinking method, two monoclonal antibodies and fragments thereof are dissociated by a reducing agent to produce monovalent antibodies and fragments thereof. The BsAb produced is constructed by chemical crosslinking of two monovalent antibodies and fragments thereof from different parent antibodies. This strategy can be used for large-scale rapid production of BsAb, but BsAb is sometimes inactivated during the crosslinking process, and it is difficult to ensure the homogeneity of the product. Another strategy for producing BsAb is hybridoma technology, by which an established hybridoma cell line secreting a monoclonal antibody is fused to a spleen cell immunized with another antigen, or two established hybridoma cell lines secreting two different monoclonal antibodies are fused to each other to produce hybrid hybridomas. The aforementioned hybridomas produced are referred to as dimerization hybridomas and tetramerization hybridomas. Generally, the BsAb produced by hybridoma technology maintains high biological activity. However, this method is tedious and time-consuming, and is not easy to separate BsAb from other inactive and unwanted antibodies produced simultaneously. These BsAb formats encounter another foreseeable problem: the excessive size and the murine components contained in the BsAb are immunogenic in patients and will induce the production of human anti-mouse antibodies (HAMA), which may prevent the reuse of these BsAbs in clinical practice. In addition, the production and purification of these forms of BsAbs are expensive, which limits the clinical application of BsAbs. Replacing these traditional methods with genetic recombination methods has accelerated progress in this field. Based on small molecule antibody technology, the production of BsAbs by genetic engineering has advantages over the above methods, such as process stability, large-scale production, low cost and ease of use. Genetic engineering has led to the development of various small molecule BsAb formats by connecting two different types of scFv. The three BsAb formats are classified by different connections. (1) Miniantibodies are heterodimers that are assembled by connecting two scFv fragments with an oligomerization domain (e.g., a leucine zipper motif derived from Fos or Jun transcription factors). (2) A bivalent antibody is a non-covalently bound dimer assembled from two single chains, VH1-VL2 and VH2-VL1, each of which is connected by a short linker that is too short to allow pairing between V domains from the same chain. Therefore, each chain alone cannot bind to the antigen, but co-expression of the two chains (VH1-VL2 and VH2-VL1) leads to the assembly of a heterodimeric bivalent antibody that can bind to two antigens. (3) ScBsAb: An intermediate linker used to connect two different scFvs with different specificities, and the ScBsAb is expressed as a single polypeptide in the host cell. The intermediate linker between the two domains within the scFv is usually (Gly4Ser)3. There are two strategies for designing the intermediate linker between the two scFvs.To avoid mispairing between heterologous variable regions, the intermediate linker is usually a short peptide linker with less than 10 amino acid residues, such as Gly4Ser. Another strategy is to select a longer linker for the intermediate linker. In summary, the most important thing in designing the intermediate linker is to ensure proper pairing between the variable domains and the folding of the protein, thereby forming a BsAb that maintains biological activity and stability. Some new properties should be introduced to facilitate purification and extend plasma half-life.
[0458] BsAb-mediated immunotherapy plays a promising role in clinical biotherapy of tumors. The tumor killing effect mediated by BsAb is based on stimulating the immune system, is highly specific to tumors and has no MHC restriction. Therefore, BsAb-mediated therapy is a supplement to traditional methods such as surgery, radiotherapy and chemotherapy. BsAb can not only cure tumors, but also stimulate the immune system to provide and maintain long-term immune protection. Based on the results of experiments in mice and clinics, the best BsAb prepared for experimental use should have at least five of the following characteristics: 1): It has high specificity and affinity to target relevant tumor antigens; 2): It can bind to trigger factors on effector cells-cytotoxic cells, and only when BsAb binds to tumor antigens will it cause cross-linking; 3): BsAb can promote effective cytotoxicity and inflammation selectively produced by the corresponding leukocyte population at the tumor site; 4): BsAb must be humanized to minimize the induction of human anti-mouse responses after repeated use; Finally, 5): BsAb should not only be small enough to penetrate the tumor, but also large enough to remain in the circulation for a long enough time.
[0459] Based on the above points, in the past few years, many BsAbs that trigger multiple immune effector cells and target different tumor cells have been developed, among which effector cells include T lymphocytes, NK cells, monocytes, macrophages, neutrophils, LAK cells (lymphokine-activated cytotoxic cells) and TIL cells (tumor-infiltrating lymphocytes), etc. T cells are generally considered to be the main specific cells of immune response. CD3 expressed on the surface of all mature T cells is a common surface marker of T cells. CD3 non-covalently binds to TCR to form a complete TCR-CD3 complex and participates in the immune response to antigen stimulation. CD3 is now the most widely and successfully used surface triggering molecule on immune effector cells. After the anti-CD3 antibody in BsAb binds to the CD3 molecule on the surface of T cells, many effects will be produced to kill tumor cells. These effects include: (1) T cell proliferation and differentiation. First, BsAb can activate the remaining T cells, resulting in Th cells and Tc cells derived from immature effector T cells with CD4+ or CD8+. Secondly, BsAb can activate a large number of memory cells to proliferate and differentiate into effector T cells that will attack and kill tumor cells. The number of effector cells is directly related to the rate of tumor clearance. (2) Cytokine release: CD4+Th cells activated by BsAb can secrete a large amount of IL-2. IL-2 not only stimulates the proliferation of Th cells in autocrine, but also activates the initial CD8+T cells in paracrine to become Tc cells, resulting in increased cytotoxicity of Tc cells. In addition, IL-2 is a co-stimulatory signal for activating T cells. Therefore, IL-2 plays a vital role in the immune effect mediated by BsAb. Some other cytokines, such as TNF-α and IFN-γ, are produced during T cell activation and can produce a "bystander" effect by inhibiting the growth of "bystander" tumor cells through intercellular mediators. (3) Cytotoxicity: In vitro experiments have shown that through BsAb mediation, CD8+Tc directly interacts with tumor cells, releases cytotoxic substances through granule exocytosis and lyses target cells, which usually occurs rapidly within 4 to 6 hours after targeting tumor cells. The main components of cytotoxic materials are perforin and serine esterase or granzyme. Perforin can attack the plasma membrane and form ion channels, thereby causing a large number of ions and water to enter, leading to cell lysis and necrosis, while granzyme is similar to lymphotoxin and can activate DNA enzymes in cells, thereby causing nuclear DNA lysis and leading to apoptosis of target cells.
[0460] Currently, Fv fragments are widely used to construct BsAbs because they are the smallest unit with a complete antigen binding site, small (about 1 / 6 of a complete antibody), lack an Fc domain, have low immunogenicity, and easily penetrate blood vessel walls and solid tumors. However, Fv is unstable and easily dissociated in vivo because the covalent bond between the VH and VL domains cannot be generated. In order to improve the stability of the Fv fragment, a polypeptide intermediate linker between the VH and VL domains is used to form a so-called ScFv. The intermediate linker is typically a short flexible peptide with a length of 15 amino acid residues, such as (Gly4Ser)3. In one embodiment of the present invention, an intermediate linker is used for anti-CD3 scFv, and a different intermediate linker is used for anti-PSMA scFv.
[0461] Bispecific antibodies with a standard IgG format can be challenging to produce because they include four different polypeptide chains. The efficacy of smaller, more easily produced bispecific molecules has been clinically demonstrated in non-Hodgkin's lymphoma. See, e.g., Bargou et al. (2008), Science 321(5891):974-977.
[0462] Due to the short in vivo half-life of this small single-chain molecule, chronic administration by continuous intravenous infusion was used to achieve these results. Therefore, there is a need in the art for bispecific therapeutics that retain similar therapeutic efficacy, have a straightforward to manufacture format, and have favorable pharmacokinetic properties, including a longer half-life.
[0463] As described herein, bispecific Fc (Bs-Fc) can bind to two different proteins and contain the Fc region of an antibody or a portion thereof. Relative to the bispecific single-chain molecules lacking the Fc region, Bs-Fc can have favorable pharmacokinetic properties. A protein bound by Bs-Fc can be expressed on immune effector cells (e.g., T cells, NK cells, neutrophils, or macrophages), while another protein can be expressed on target cells (e.g., cancer cells, cells infected by pathogens, or cells mediating diseases, such as fibroblasts causing fibrosis). Bs-Fc molecules described herein can cause activation of immune effector cells in the presence of target cells and / or kill target cells in the presence of immune effector cells.
[0464] In some embodiments, the anti-PSMA binding domain comprises an antibody or antigen-binding fragment thereof described elsewhere herein. For example, in some embodiments, the anti-PSMA binding domain comprises Mut-gy1, Mut-gy1-st, Mut-gy1-2, Mut-gy1-3, or PSMAbLm, as described elsewhere herein.
[0465] Treatment
[0466] In another aspect, the present disclosure further provides a method for preventing or treating a proliferative disease associated with PSMA expression in a subject. In some embodiments, the method comprises administering to the subject an effective amount of an antibody or antigen-binding fragment thereof, or a variant thereof, a bispecific or multispecific antibody or antigen-binding fragment thereof, a CAR, a nucleic acid molecule, a vector, a cell, or a composition described herein. In some embodiments, the subject is a mammal, such as a human.
[0467] In some embodiments, the method further comprises administering a second agent or treatment to the subject. In some embodiments, the second agent or treatment comprises an anticancer agent. In some embodiments, the second agent or treatment is administered to the subject before, after, or simultaneously with an antibody or antigen-binding fragment thereof, or variant thereof, a bispecific or multispecific antibody or antigen-binding fragment thereof, a CAR, a nucleic acid molecule, a vector, a cell, or a composition as described herein.
[0468] In one embodiment, the present invention provides a method for treating a solid tumor with abnormal PSMA expression in a subject (e.g., prostate cancer or a solid tumor with high PSMA expression in the neovasculature), the method comprising the step of targeting PSMA high-expressing cells with an antibody or antigen-binding fragment. In some embodiments, the method comprises administering a composition comprising an antibody or an antigen-binding fragment thereof to a subject having a tumor associated with high PSMA expression.
[0469] In one embodiment, the antibody or its antigen binding fragment is operably linked to a bioactive agent or a combination of these agents, wherein the agent is a toxin, a radioisotope, a nanoparticle or a bioactive peptide. These tumors include, but are not limited to, prostate cancer, lung cancer, liver cancer, pancreatic cancer, colon cancer, gastric cancer, breast cancer, ovarian cancer, kidney cancer, prostate cancer, bladder cancer, melanoma, glioma, etc.
[0470] In one embodiment, provided herein is a method of inhibiting or controlling a tumor in a subject. In another embodiment, the method comprises the step of administering an effective amount of an antibody or antigen-binding fragment described herein.
[0471] In another embodiment, provided herein is a method for delaying the progression of a solid tumor in a subject. In another embodiment, the method comprises administering to the subject an effective amount of an antibody or antigen-binding fragment thereof provided herein. In another embodiment, the subject produces an immune response to the vascular system of the solid tumor, thereby delaying the progression of the solid tumor in the subject.
[0472] In one embodiment, the term "operably linked" refers to the positioning / linking of two or more molecules or sequences in such a way as to ensure proper function or expression of the molecules and sequences.
[0473] In one embodiment, the term "therapeutically effective amount" refers to an amount that provides a therapeutic effect for a given condition and administration regimen. In the present invention, the therapeutic effect is to prevent or inhibit tumor growth, infiltration, spread, metastasis or recurrence, or preferably reduce tumor burden, or improve patient outcomes.
[0474] In one embodiment, the term "prevent or treat" refers to any one or more of the following: delaying the onset of symptoms, reducing the severity of symptoms, reducing the severity of acute episodes, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, preventing disease recurrence, reducing the number or frequency of recurrent episodes, increasing the latency between symptom onsets, increasing the time to sustained progression, accelerating remission, inducing remission, enhancing remission, accelerating recovery, or increasing resistance to alternative treatments or reducing resistance to alternative treatments. In one embodiment, "treating" refers to both therapeutic treatment and prophylactic or preventive measures, wherein the purpose is to prevent or alleviate the target pathological condition or disorder as described above.
[0475] In another embodiment, a "symptom" is a manifestation of a disease or pathological condition as described above.
[0476] In one embodiment, the composition of the invention comprises a polypeptide, antibody or antigen-binding fragment of the invention alone or in some embodiments in combination with a second pharmaceutically active agent. In another embodiment, the composition further comprises a proteolytic inhibitor, a pharmaceutical carrier, a diluent and an adjuvant.
[0477] In one embodiment, the term "pharmaceutical active agent" refers to any drug that meets a specified purpose. In some embodiments, pharmaceutical active agents include, but are not limited to, chemotherapeutic drugs, radiotherapeutic drugs, angiogenesis inhibitors, tumor imaging probes, immunomodulators, or any other tumor treatment and / or imaging drugs / agents, etc.
[0478] In another embodiment, provided herein is a method of delivering a bioactive agent and an antibody or antigen binding fragment of the invention to treat a tumor in a subject. In another embodiment, the method comprises the step of administering the bioactive agent and the antibody or antigen binding fragment simultaneously but separately. In another embodiment, the method comprises the step of administering the bioactive agent and the antibody or antigen binding fragment separately.
[0479] In one embodiment, the antibodies or antigen-binding fragments provided herein are themselves "biologically active", meaning that they are able to exert the biological effects or enhanced effects of their corresponding parent antibodies even after modification, particularly in binding to target antigens, inhibiting ligand binding to receptors, and further in regulating, particularly inhibiting antigen-mediated signal transduction and preventing or treating antigen-mediated diseases. The term "biological activity" when used to refer to any biologically active agent described herein also refers to the ability of an agent to modulate an immune response in a manner that can result in a preventive, diagnostic or therapeutic effect as will be understood by those skilled in the art. In some embodiments, agents used to achieve this biological activity include, but are not limited to, cytokines, enzymes, chemokines, radioactive isotopes, enzyme-active toxins, therapeutic nanoparticles or chemotherapeutic agents, as will be understood by those skilled in the art.
[0480] In another embodiment, the polypeptide of the antibody is coupled or operably connected so as to act with an enzyme in its intended purpose so as to adopt antibody-dependent enzyme-mediated prodrug therapy (ADEPT). ADEPT can be used by coupling or operably connecting an antibody or Fc fusion to a prodrug activating enzyme that converts a prodrug (e.g., a peptide-based chemotherapeutic agent) into an active anticancer drug. The enzyme component of the immunoconjugate for ADEPT includes any enzyme that can act on the prodrug in this way to convert it into its more active cytotoxic form. Other additional modifications of the modified molecules provided herein are contemplated herein. For example, the polypeptide / antibody can be connected to one of various non-protein polymers, such as polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylene, or a copolymer of polyethylene glycol and polypropylene glycol.
[0481] In another embodiment, the antibodies / polypeptides provided herein are administered together with one or more immunomodulators. Such agents can increase or decrease the production of one or more cytokines, upregulate or downregulate autoantigen presentation, mask MHC antigens, or promote the proliferation, differentiation, migration or activation state of one or more types of immune cells. Immunomodulators include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, celecoxib, diclofenac, etodolac, fenoprofen, indomethacin, ketoric acid, oxaprozin, nabumetone, sulindac, tolmetin, rofecoxib, naproxen, ketoprofen and nabumetone; steroids (e.g., glucocorticoids, dexamethasone, cortisone, hydroxycortisone, methylprednisolone, prednisone, prednisolone, trimesotropin, azulfidine icosanoids such as prostaglandins, thromboxanes, and leukotrienes; and topical steroids such as anthralin, calcipotriene, clobetasol, and tazarotene); cytokines such as TGFβ, IFNα, IFNβ, IFNγ, IL-2, IL-4, IL-10; cytokine, chemokine, or receptor antagonists, including antibodies, soluble receptors, and receptor-Fc fusions directed against BATF, B7, CCR2, CCR5, CD2, CD 3. CD4, CD6, CD7, CD8, CD11, CD14, CD15, CD17, CD18, CD20, CD23, CD28, CD40, CD40L, CD44, CD45, CD52, CD64, CD80, CD86, CD147, CD152, complement factors (C5, D), CTLA4, eosinophil chemokine, Fas, ICAM, ICOS, IFN-αIF N-β, IFN-γ, IFNAR, IgE, IL-1, IL-2, IL-2R, IL-4, IL-5R, IL-6, IL-8, IL-9, IL-12, IL-13, IL-13 R1, IL-15, IL-18R, IL-23, integrins, LFA-1, LFA-3, MHC, selectins, TGF-β, TNF-α, TNF-β, TNF-R1, T cell receptors, including (etanercept), (Adalimumab), (infliximab), PD1 antibody ( (Nivolumab), (pembrolizumab) or PD-L1 antibody (durvalumab, MPDL3280A); xenologous antilymphocyte globulin; other immunomodulatory molecules, such as anti-idiotypic antibodies to 2-amino-6-aryl-5-substituted pyrimidines, MHC-binding peptides and MHC fragments, azathioprine, brequinar, bromocriptine, cyclophosphamide, cyclosporine A, D-penicillamine, deoxyspergualin, FK506, glutaraldehyde, gold, hydroxychloroquine, leflunomide, malononitrile amides (e.g., leflunomide), methotrexate, minocycline, mizoribine, mycophenolate mofetil, rapamycin, and sulfasalazine.
[0482] In another embodiment, the antibodies of the invention are administered with a cytokine. "Cytokine" as used herein refers to a general term for proteins released by one cell population that act as intercellular mediators on another cell. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-α and tumor necrosis factor-β; substances that inhibit moles; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factor such as NGF-β; platelet growth factor; transforming growth factor (TGFβ), such as TGF-α and TGF-β; insulin-like growth factor-I and insulin-like growth factor-II; erythropoietin (EPO); osteoinductive factors; interferons, such as interferon-α, interferon- β and interferon-γ; colon stimulating factor (CSF), such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (IL), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, tumor necrosis factor, such as TNF-α or TNF-β; and other polypeptide factors, including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or recombinant cell culture, as well as biologically active equivalents of native sequence cytokines.
[0483] Chemotherapeutic agents or other cytotoxic agents can be administered as prodrugs. The term "prodrug" refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells than the parent drug and can be enzymatically activated or converted into a more active parent form. See, for example, Wilman, 1986, Biochemical Society Transactions, 615th Meeting Belfast, 14: 375-382; and Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery," Directed Drug Delivery, Borchardt et al., (ed.): 247-267, Humana Press, 1985. Prodrugs for use in the compositions and methods provided herein include, but are not limited to, phosphate-containing prodrugs, phosphorothioate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs, which can be converted into more active non-cytotoxic drugs. Examples of cytotoxic drugs that can be derived into prodrug forms of antibodies / polypeptides for use in the compositions and methods provided herein include, but are not limited to, any of the above-mentioned chemotherapeutic agents.
[0484] In some embodiments, antibodies / polypeptides can be used with any combination of the above-mentioned bioactive agents, i.e., cytokines, enzymes, chemokines, radioactive isotopes, enzyme-active toxins, or chemotherapeutic agents. In another embodiment, antibodies / polypeptides can be operably linked to bioactive agents and used in the methods described herein, or antibodies / polypeptides provided herein can be used only in combination with bioactive agents in a manner that the two are administered separately (i.e., not coupled) to achieve the desired preventive, diagnostic, or therapeutic effect.
[0485] Combination therapy
[0486] Compositions comprising antibodies, antibody fragments, ADCs, CAR-expressing cells or bispecific antibodies described herein can be used in combination with other known drugs and treatments. "Combination" as used herein refers to delivering two (or more) different treatments to an object during the course of an object suffering from a disease, for example, after the object has been diagnosed with the disease and before the disease has been cured or eliminated or before the treatment has stopped for other reasons, two or more treatments are delivered. In some embodiments, the delivery of one treatment still occurs at the beginning of the delivery of the second treatment, so that there is overlap in the administration. This is sometimes referred to as "simultaneous" or "parallel delivery" in this article. In other embodiments, the delivery of one treatment ends before the delivery of another treatment begins. In some embodiments of either case, due to combined administration, the treatment is more effective. For example, compared with the administration of the second treatment in the absence of the first treatment, the second treatment is more effective, for example, an equivalent effect is observed in the case of less treatment of the second treatment, or the second treatment alleviates the symptoms to a greater extent, or a similar situation is observed in the case of the first treatment. In some embodiments, delivery causes a reduction in symptoms or other parameters related to the disease greater than that observed for a treatment delivered in the absence of another. The effects of the two treatments can be partially additive, completely additive, or greater than additive. The delivery may be such that when the second therapeutic agent is delivered, the effect of the first therapeutic agent delivered is still detectable.
[0487] Compositions comprising antibodies, antibody fragments, ADCs, CAR-expressing cells or bispecific antibodies described herein and at least one additional therapeutic agent can be administered simultaneously, in the same or separate compositions or sequentially. For sequential administration, cells expressing CAR described herein can be administered first, additional agents can be administered secondly, or the order of administration can be reversed.
[0488] In a further aspect, compositions comprising antibodies, antibody fragments, ADCs, cells expressing CARs, or bispecific antibodies described herein can be used in combination with surgery, chemotherapy, radiation, immunosuppressants (e.g., cyclosporine, azathioprine, methotrexate, mycophenolic acid, and FK506), antibodies, or other immunoablative agents (e.g., CAMPATH) for treatment regimens. Anti-CD3 antibodies or other antibody treatments, cytotoxins, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and radiation. Peptide vaccines, such as described in Izumoto et al. 2008 J Neurosurg 108: 963-971.
[0489] In one embodiment, a composition comprising an antibody, antibody fragment, ADC, CAR-expressing cell, or bispecific antibody described herein may be used in combination with a chemotherapeutic agent. Exemplary chemotherapeutic agents include anti-androgens (androgen antagonists), anthracyclines (e.g., doxorubicin (e.g., liposomal doxorubicin)), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, dacarbazine, melphalan, ifosfamide, temozolomide), immune cell antibodies (e.g., alemtuzumab, gemtuzumab, rituximab, tositumomab), antimetabolites (including, for example, folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors (e.g., fludarabine)), mTOR inhibitors, TNFR glucocorticoid-induced TNFR-related protein (GITR) agonists, proteasome inhibitors (e.g., aclarubicin A, neurotoxin or bortezomib), immunomodulators such as thalidomide or thalidomide derivatives (e.g., lenalidomide). General chemotherapeutic agents contemplated for combination therapy include anastrozole Bicalutamide Bleomycin sulfate Busulfan Busulfan Injection Capecitabine N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin Carmustine Chlorambucil Cisplatin Cladribine Cyclophosphamide ( or ), cytarabine, cytarabine Cytarabine liposome injection Dacarbazine Actinomycin (Actinomycin D, Cosmegan), daunorubicin hydrochloride Daunorubicin citrate liposome injection Dexamethasone, docetaxel Doxorubicin Hydrochloride Etoposide Fludarabine phosphate 5-Fluorouracil Flutamide Tezatibine, gemcitabine (difluorodeoxycytidine), hydroxyurea Idabi Ifosfamide Irinotecan L-Asparaginase Calcium folinate, melphalan 6-Mercaptopurine Methotrexate Mitoxantrone Melotak, paclitaxel phoenix (Yttrium90 / MX-DTPA), pentostatin, polyfeproban 20 with carmustine implant Tamoxifen citrate Teniposide 6-thioguanine, thiotepa, tirapazamine Topotecan Hydrochloride for Injection Vinblastine Vincristine Vinorelbine
[0490] Exemplary anti-androgen (androgen antagonist) agents include bicalutamide, goserelin acetate SR Depo.
[0491] Exemplary alkylating agents include, but are not limited to, nitrogen mustards, aziridine derivatives, alkyl sulfonates, nitrosoureas, and triazenes: Aminouracil Uracil Nitrogen ), methyl chloride Cyclophosphamide ( Revimmune TM ), ifosfamide Melphalan Krobru Pipobrom Triethylenemelamine Triethylenethiophosphoramide, Temozolomide Thiotepa Busulfan Carmustine Lomustine Chain Zoxing and dacarbazine (DTIC- ). Additional exemplary alkylating agents include, but are not limited to, oxaliplatin Temozolomide ( and ); actinomycin (also known as actinomycin-D,
[0493] ); Melphalan (also known as L-PAM, L-myoflavone, and phenylalanine mustard,
[0494] ); Aletramine (also known as hexamethylmelamine (HMM), ); Carmustine Bedamustine Busulfan and ); Carboplatin Lomustine (also known as CCNU, ); cisplatin (also known as CDDP, and -AQ); chlorambucil Cyclophosphamide ( and ); Dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, ); Aletramine (also known as hexamethylmelamine (HMM),
[0495] ); ifosfamide Prednimustine; Procarbazine Dichloromethyldiethylamine (also known as nitrogen mustard, mustard and methylchloroethylamine hydrochloride, ); Chain Zoxin Thiotepa (also known as thiophosphoramide, TESPA, and TSPA,
[0496] ); Cyclophosphamide ( and bedamustine hydrochloride
[0497] Exemplary mTOR inhibitors include, for example, temozolomide; dafimozolomide (formally known as deferolimus, (1R, 2R, 4S)-4-[(2R)-2[(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28Z, 30S, 32S, 35R)-1,18-dihydroxy-19,30-dimethoxy- 15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaza-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03 / 064383); everolimus ( or RAD001); rapamycin (AY22989, ); simapimod (CAS164301-51-3); (5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7-yl}- 7(8H)-one (PF04691502, CAS1013101-36-4); and N2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholin-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-asparagine-L-serine, inner salt (SF1126, CAS936487-67-1), and XL765.
[0498] Exemplary immunomodulators include, for example, atuzumab (available from ); pegfilgrastim Lenalidomide (CC-5013, ); thalidomide actimid (CC4047); and IRX-2 (a mixture of human cytokines including interleukin 1, interleukin 2, and interferon gamma, CAS 951209-71-5, available from IRX Therapeutics).
[0499] Exemplary anthracyclines include, for example, doxorubicin ( and ); Bleomycin Daunorubicin (doxorubicin hydrochloride, daunorubicin and rubicin hydrochloride ); daunorubicin liposomes (daunorubicin citrate liposomes, ); Mitoxantrone (DHAD, ); Ellence TM ); Idabi ( Idamycin ); Milindacrycin C Geldanamycin; oxadiazine; revampicin; and desacetyl revampicin.
[0500] Exemplary vinca alkaloids include, for example, vinorelbine tartrate Vincristine Vindesine Vinblastine (also known as vinblastine sulfate, vinblastine, and VLB, Alkaban- and ); and vinorelbine
[0501] Exemplary proteosome inhibitors include bortezomib Carfilzomib (PX-171-007, (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetylamino)-4-phenylbutyrylamino)-pentanamide); Marizomib (NPI -0052); ixazomib citrate (MLN-9708); dilanzomib (CEP-18770); and O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide (ONX-0912).
[0502] Exemplary GITR agonists include, for example, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as, for example, GITR fusion proteins described in U.S. Pat. No. 6,111,090, European Patent No. 090505B1, U.S. Pat. No. 8,586,023, PCT Publication Nos. WO 2010 / 003118 and 2011 / 090754, or anti-GITR antibodies described in, for example, U.S. Pat. No. 7,025,962, European Patent No. 1947183B1, U.S. Pat. No. 7,812,135, U.S. Pat. No. 8,388,967, U.S. Pat. No. 8,591,886, European Patent No. EP 1866339, PCT Publication No. WO 2011 / 028683, PCT Publication No. WO 2013 / 039954, PCT Publication No. WO2005 / 007190, PCT Publication No. WO2007 / 133822, PCT Publication No. WO2005 / 055808, PCT Publication No. WO99 / 40196, PCT Publication No. WO2001 / 03720, PCT Publication No. WO99 / 20758, PCT Publication No. WO2006 / 083289, PCT Publication No. WO2005 / 115451, U.S. Patent No. 7,618,632 and PCT Publication No. WO 2011 / 051726.
[0503] In one embodiment, an agent that reduces or ameliorates side effects associated with the administration of a naked antibody or antigen-binding fragment thereof, an ADC, a CAR-expressing cell, or a bispecific antibody can be administered to a subject.
[0504] In one embodiment, an agent that enhances the activity of a naked antibody or its antigen-binding fragment, ADC, a cell expressing CAR, or a bispecific antibody can be administered to a subject. For example, in one embodiment, an agent can be an agent that inhibits an inhibitory molecule. In some embodiments, inhibitory molecules, such as programmed death 1 (PD1), can reduce the ability of cells expressing CAR to cause immune effector responses. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, Tim3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFRβ. The inhibition of inhibitory molecules, such as inhibition at the DNA, RNA, or protein level, can optimize the performance of naked antibodies or their antigen-binding fragments, ADC, cells expressing CAR, or bispecific antibodies. In an embodiment, an inhibitory nucleic acid, such as an inhibitory nucleic acid, such as dsRNA, such as siRNA or shRNA, can be used to inhibit the expression of inhibitory molecules in CAR-expressing cells or bispecific Ab-reactive cells. In one embodiment, the inhibitor is shRNA. In one embodiment, an inhibitor of an inhibitory signal can be, for example, an antibody or its antigen-binding fragment that binds to an inhibitory molecule. For example, the agent can be an antibody or antigen-binding fragment thereof that binds to PD1, PD-L1, PD-L2, or CTLA4 (e.g., ipilimumab (also known as MDX-010 and MDX-101, and as Sold by Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody obtained from Pfizer, formerly known as ticilimumab, CP-675,206). ). In one embodiment, the agent is an antibody or antigen-binding fragment thereof that binds to Tim3. In one embodiment, the agent is an antibody or antigen-binding fragment thereof that binds to LAG3.
[0505] PD1 is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS and BTLA. PD1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 Int. Immunol 8: 765-75). It has been shown that the two ligands of PD1, PD-L1 and PD-L2 downregulate T cell activation when bound to PD1 (Freeman et al. 2000 J Exp Med 192: 1027-34; Latchman et al. 2001 Nat Immunol 2: 261-8; Carter et al. 2002 Eur J Immunol 32: 634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81: 281-7; Blank et al. 2005 Cancer Immunol. Immunother 54: 307-314; Konishi et al. 2004 Clin Cancer Res 10: 5094). Immunosuppression can be reversed by inhibiting the local interaction of PD1 with PD-L1. Antibodies, antibody fragments, and other inhibitors of PD1, PD-L1, and PD-L2 are available in the art and can be used in combination with naked antibodies or antigen-binding fragments thereof, ADCs, cells expressing CAR, or bispecific antibodies described herein targeted by PSMA. For example, nivolumab (also referred to as BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody that specifically blocks PD1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD1 are disclosed in U.S. Pat. No. 8,008,449 and WO2006 / 121168. Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD1, and other humanized anti-PD1 monoclonal antibodies are disclosed in WO2009 / 101611. Lambrotuzumab (also known as MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD1. Pembrolizumab and other humanized anti-PD1 antibodies are disclosed in U.S. Pat. No. 8,354,509 and WO2009 / 114335. MDPL3280A (Genentech / Roche) is a human Fc-optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies against PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and U.S. Publication No. 20120039906.Other anti-PD-L1 binding agents include YW243.55.S70 (heavy and light chain variable regions are shown in SEQ ID NO 20 and SEQ ID NO 21 in WO2010 / 077634) and MDX-1105 (also referred to as BMS-936559, and anti-PD-L1 binding agents disclosed, for example, in WO2007 / 005874). AMP-224 (B7-DCIg; Amplimmune; disclosed, for example, in WO2010 / 027827 and WO2011 / 066342 is a PD-L2Fc fusion soluble receptor that blocks the interaction between PD1 and B7-H1. Other anti-PD1 antibodies include AMP 514 (Amplimmune), etc., for example, the anti-PD1 antibodies disclosed in U.S. Pat. Nos. 8,609,089, US2010028330 and / or US20120114649.
[0506] In some embodiments, the agent that enhances the activity of cells expressing CAR can be, for example, a fusion protein comprising a first domain and a second domain, wherein the first domain is an inhibitory molecule or a fragment thereof, and the second domain is a polypeptide associated with a positive signal, for example, a polypeptide comprising an intracellular signaling domain as described herein. In some embodiments, the polypeptide associated with a positive signal may include a co-stimulatory domain of CD28, CD27, ICOS, such as an intracellular signaling domain of CD28, CD27 and / or ICOS, and / or a primary signaling domain of CD3ζ, such as described herein. In one embodiment, the fusion protein is expressed by the same cell expressing CAR. In another embodiment, the fusion protein is expressed by a cell, for example, a T cell that does not express anti-PSMACAR.
[0507] Formulations and routes of administration
[0508] The antibodies, ADCs, cells expressing CAR or bispecific antibodies of the present invention can be found for a variety of products. In one embodiment, the antibodies, ADCs, cells expressing CAR or bispecific antibodies of the present invention are therapeutic, diagnostic or research reagents. In one embodiment, the antibodies ADCs, CAR-expressing cells or bispecific antibodies of the present invention are therapeutic agents. In some embodiments, the antibodies or antigen-binding fragments thereof, ADCs, cells expressing CAR or bispecific antibodies of the present invention are used for industrial purposes. The antibodies of the present invention can be used for monoclonal or polyclonal antibody compositions. The antibodies of the present invention can be agonists, antagonists, neutralizers, inhibitors or stimulants. In one embodiment, the antibodies or antibody fragments, ADCs, cells expressing CAR or bispecific antibodies of the present invention are used to kill target cells carrying target antigens, such as cancer cells. In another embodiment, the antibodies of the present invention are used to block, antagonize or excite target antigens. In another embodiment, the antibodies of the present invention are used to block, antagonize or excite target antigens and kill target cells carrying target antigens. In another embodiment, the target cell is a tumor cell or its new vasculature. In one embodiment, the new vasculature plays an important role in angiogenesis and is also considered to be the target of antibodies or antibody fragments, ADCs, cells expressing CAR or bispecific antibodies provided herein.
[0509] The present disclosure further provides a kit, which includes one or more compositions of the present invention (including pharmaceutical preparations) packaged into suitable packaging materials. In another embodiment, the kit includes nucleic acids encoding antibodies or antigen-binding fragments of the present invention, Car T or Car NK cells or their bispecific antibodies. In another embodiment, the kit includes nucleic acids further including expression control elements; expression vectors; viral expression vectors; adeno-associated virus expression vectors; adenovirus expression vectors; and retroviral expression vectors. In another embodiment, the kit includes cells expressing antibodies or antigen-binding fragments thereof of the present invention, such as Car T or Car NK cells.
[0510] In another embodiment, the kit includes a label or a package insert including instructions for expressing the antibody or bispecific antibody or encoding the antibody, antigen binding fragment or its bispecific antibody in vitro, in vivo or in vitro cells. In another embodiment, the kit includes a label or a package insert including instructions for treating a subject (e.g., a subject suffering from asthma or at risk of suffering from asthma) with an antibody or its antigen binding fragment, ADC, CAR expressing cell or its bispecific antibody of the present invention in vivo or in vitro.
[0511] As used herein, the term "packaging material" refers to the physical structure that holds the components of the kit. The packaging material can hold the components aseptically and can be made of materials commonly used for such purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampoules, etc.). The label or package insert may include appropriate written instructions, e.g., to practice the methods of the invention, e.g., to treat the common cold. The kit may additionally include instructions for using the kit components in the methods of the invention.
[0512] The instructions may include instructions for implementing any of the methods of the invention described herein. Thus, the pharmaceutical compositions of the invention may be included in a container, package or dispenser along with instructions for administration to a subject. The instructions may additionally include satisfactory clinical endpoints or indications of any adverse symptoms that may occur, or additional information required by the Food and Drug Administration for use on human subjects.
[0513] In one embodiment, the polypeptides of the invention are administered as part of a vaccine.In some embodiments, the term vaccine is understood to include any immunomodulatory composition, and such vaccines may contain adjuvants, antigens, immunomodulatory compounds, or combinations thereof in addition to the polypeptides of the invention.
[0514] In some embodiments, adjuvants may include, but are not limited to: (A) aluminum compounds (e.g., aluminum hydroxide, aluminum phosphate, aluminum hydroxyphosphate, aluminum oxyhydroxide, orthophosphates, sulfates, etc.) [e.g., see Sections 8 and 9 of Reference 96]), or mixtures of different aluminum compounds, wherein the compound takes any suitable form (e.g., gel, crystalline, amorphous, etc.), and adsorption is preferred; (B) MF59 (5% squalene, 0.5% Tween 80 and 0.5% Span85, formulated into submicron particles using a microfluidizer); (C) liposomes; (D) ISCOM, which may not contain additional detergent; (E) SAF, containing 10% squalane, 0.4% Tween 80, 5% Pluronic block polymer L121 and thr-MDP, microfluidized into a submicron emulsion or vortexed to produce an emulsion of larger particle size; (F) RibiTM Adjuvant System (RAS), (Ribi Immunochem), which contains 2% squalene, 0.2% Tween 80 and one or more bacterial cell wall components selected from monophospholipid A (MPL), trehalose dimycoate (TDM) and cell wall skeleton (CWS), preferably MPL + CWS (Detox TM ); (G) saponin adjuvants, such as QuilA or QS21, also known as Stimulon TM; (H) chitosan; (I) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (J) cytokines, such as interleukins (such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (such as interferon-γ), macrophage colony stimulating factor, tumor necrosis factor, etc.; (K) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL)]; (L) 3dMPL in combination with, for example, QS21 and / or an oil-in-water emulsion; (M) an oligonucleic acid containing a CpG motif, i.e., containing at least one CG dinucleic acid, optionally using 5-methylcytosine instead of cytosine; (N) polyoxyethylene ethers or polyoxyethylene esters; (O) a polyoxyethylene sorbitan ester surfactant in combination with octylphenoxy alcohol, or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional nonionic Surfactants such as octylphenoxy alcohol combinations; (P) immunostimulatory oligonucleotides (e.g., CpG oligonucleotides) and saponins; (Q) particles of immunostimulatory agents and metal salts; (R) saponins and oil-in-water emulsions; (S) saponins (e.g., QS21) + 3dMPL + IL12 (optionally + sterols); (T) Escherichia coli heat-labile enterotoxin ("LT") or detoxification mutants thereof, such as K63 or R72 mutants; (U) cholera toxin ("CT"), or diphtheria toxin ("DT") or detoxification mutants thereof; (V) double-stranded RNA; (W) monophosphoryl lipid A mimetics, such as aminoalkyl aminoglucosidase phosphate derivatives (e.g., RC-529); (X) polyphosphazenes (PCPP); or (Y) bioadhesives such as esterified hyaluronic acid microspheres or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrrolidone, polysaccharides and carboxymethyl cellulose.
[0515] In some embodiments, the administration of the antibody or antigen-binding fragment thereof is intended to reduce the severity of a pathological condition. The term "reducing the severity of a pathological condition" should be understood that any reduction by the methods, compounds, and compositions disclosed herein should be considered to be included in the present invention. In some embodiments, the reduction in severity can include an enhancement of survival, or in another embodiment, stopping disease progression, or in another embodiment, delaying disease progression.
[0516] In one embodiment, dosing depends on the cellular response to the administered molecule / compound or composition comprising the same. Generally, dosages for the above purposes will vary, but will be in an effective amount to exert the desired effect, as determined by one skilled in the art. As used herein, the term "pharmaceutically effective amount" refers to an amount of a compound as described herein that will produce a desired alleviation of symptoms or other desired phenotype in a patient.
[0517] In one embodiment, the concentration of the antibody or antigen-binding fragment thereof will depend on various factors, including the nature of the condition to be treated, the condition of the patient, the route of administration, and individual tolerability of the composition.
[0518] In some embodiments, any composition of the invention will consist essentially of an antibody or antigen-binding fragment thereof as described herein. In some embodiments, the term "comprising" refers to comprising the active agent indicated, e.g., an antibody or antigen-binding fragment thereof of the invention, and comprising other active agents and pharmaceutically acceptable carriers, excipients, lubricants, stabilizers, etc., as known in the pharmaceutical industry.
[0519] In some embodiments, the composition of the present invention is essentially composed of polypeptides / polynucleic acids / vectors as described herein. In some embodiments, the term "essentially composed of..." refers to a composition, the active ingredient of which only a specific type of medicament is the active ingredient shown, however, other compounds directly related to the therapeutic effect of the active ingredient shown may be included. In some embodiments, the term "essentially composed of..." refers to such a composition, the active ingredient that only targets a specific mechanism or acts via a specific pathway is the indicated active ingredient, however, other compounds directly related to the therapeutic effect of the indicated active ingredient may be included, which, for example, has a mechanism of action related to the action of the indicated medicament but not directly related to the action of the indicated medicament. In some embodiments, the term "essentially composed of..." refers to a composition whose only active ingredient is the active ingredient shown. However, other compounds for stabilizing, preserving, etc. preparations may be included, but not directly related to the therapeutic effect of the active ingredient shown. In some embodiments, the term "essentially composed of..." may refer to a component that promotes the release of the active ingredient. In some embodiments, the term "essentially composed of..." refers to a composition containing an active ingredient and a pharmaceutically acceptable carrier or excipient.
[0520] It will be appreciated that the actual amount of the antibody or antigen-binding fragment in a particular case will vary depending on the particular composition formulated, the mode of application, and the particular condition and organism being treated. The dosage for a given host can be determined using conventional considerations, such as by routine comparison of the different activities of the subject compound and known agents, such as by appropriate conventional pharmacological protocols.
[0521] In one embodiment, the compounds of the invention are administered acutely for acute treatment of temporary conditions, or may be administered chronically, particularly in the case of progressive, relapsing or degenerative diseases. In one embodiment, one or more compounds of the invention may be administered simultaneously, or in another embodiment, they may be administered in a staggered manner. In one embodiment, the staggered manner may be determined by the stage or phase of the disease.
[0522] Parenteral vehicles (for subcutaneous, intravenous, intra-arterial or intramuscular injection) include sodium chloride solution, Ringer's dextrose, dextrose, sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutritional supplements, electrolyte supplements such as those based on Ringer's dextrose, etc. Examples are sterile liquids, such as water and oils, with or without surfactants and other pharmaceutically acceptable adjuvants. Typically, water, saline, dextrose aqueous solutions and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. The example of oil is oil of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil and cod liver oil.
[0523] In one embodiment, the route of administration can be parenteral, or a combination thereof. In another embodiment, the approach can be intraocular, conjunctival, topical, transdermal, intradermal, subcutaneous, intraperitoneal, intravenous, intraarterial, vaginal, rectal, intratumoral, paracancer, transmucosal, intramuscular, intravascular, intraventricular, intracranial, inhalation (aerosol), nasal inhalation (spray), intranasal (drops), sublingual, oral, aerosol or suppository or a combination thereof. In one embodiment, the administration regimen will be determined by a skilled clinician based on factors such as the exact nature of the illness being treated, the severity of the illness, the age of the patient and general physical condition, body weight and the response of individual patients.
[0524] For intranasal administration or administration by inhalation, a solution or suspension of the compound is mixed and aerosolized or nebulized in the presence of a suitable carrier. Such an aerosol may contain any of the agents described herein.
[0525] For parenteral use, particularly suitable are injectable sterile solutions, preferably oily or aqueous solutions, and suspensions, emulsions or implants, including suppositories and enemas. Ampoules are convenient unit doses. Such suppositories may contain any of the agents described herein.
[0526] Sustained or directed release compositions can be formulated, such as liposomes or those in which antibodies or antigen binding fragments are protected with differentially degradable coatings, such as by microencapsulation, multiple coatings, etc. Such compositions can be formulated for immediate or slow release. The novel compound can also be freeze-dried and the lyophilized material obtained can be used, for example, for the preparation of injectable products. For liquid preparations, pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions, emulsions, or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Examples of oils are oils of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and cod liver oil.
[0527] In one embodiment, the composition of the inventive method or the composition for the inventive method can be used alone or in the composition. In another embodiment, the composition of the present invention can be used with conventional excipients, i.e., suitable for parenteral, enteral (e.g., oral) or topical pharmaceutically acceptable organic or inorganic carrier material mixing, which does not have a harmful reaction with the active compound. In one embodiment, suitable pharmaceutically acceptable carriers include but are not limited to water, saline solution, alcohol, gum arabic, vegetable oil, benzyl alcohol, polyethylene glycol, gelatin, carbohydrates (e.g., lactose), straight-chain starch or starch, magnesium stearate, talc, silicic acid, viscous paraffin, white paraffin, glycerol, alginate, hyaluronic acid, collagen, spice oil, fatty acid monoglyceride, and diglyceride, pentaerythritol fatty acid ester, hydroxymethyl cellulose, polyvinyl pyrrolidone, etc. In another embodiment, the pharmaceutical preparations can be sterilized and, if necessary, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants, flavorings and / or aromatic substances, etc., which do not react harmfully with the active compounds. In another embodiment, they can also be combined with other active agents (e.g., vitamins) when necessary.
[0528] Pharmaceutical compositions include "pharmaceutically acceptable" and "physiologically acceptable" carriers, diluents or excipients. In one embodiment, the terms "pharmaceutically acceptable" and "physiologically acceptable" refer to any safe formulation and provide appropriate delivery for the desired route of administration of an effective amount of at least one antibody or antigen-binding fragment used in the present invention. The term also refers to the use of buffered formulations, in which the pH is maintained at a specific desired value from pH 4.0 to pH 9.0, depending on the stability of the compound and the route of administration. The term includes solvents (aqueous or non-aqueous), solutions, emulsions, dispersion media, coatings, isotonic agents, and absorption promoters or delay agents that are compatible with drug administration. Such formulations may be contained in liquids; emulsions, suspensions, syrups or elixirs, or solid forms; tablets (coated or uncoated), capsules (hard or soft), powders, granules, crystals or microbeads. Supplementary active compounds (e.g., preservatives, antibacterial agents, antiviral agents, and antifungal agents) may also be incorporated into the composition.
[0529] The pharmaceutical compositions of the present invention may include one or more other chemotherapeutic agents selected from nitrogen mustards (e.g., cyclophosphamide and ifosfamide), aziridines (e.g., thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine and streptozotocin), platinum complexes (e.g., carboplatin and cisplatin). Non-classical alkylating agents (e.g., dacarbazine and temozolomide), folate analogs (e.g., methotrexate), purine analogs (e.g., fludarabine and mercaptopurine), adenosine analogs (e.g., cladribine and pentostatin), pyrimidine analogs (e.g., fluorouracil (alone or in combination with folinic acid) and gemcitabine), substituted ureas (e.g., hydroxyurea), antitumor antibiotics (e.g., bleomycin and doxorubicin), epipodophyllotoxins (e.g., etoposide and teniposide), microtubule The invention relates to cancer treatment with a variety of therapeutic agents, including but not limited to, leukocyte antigen 2 (EGFR) and leukocyte antigen 2 (EGFR) agonists (e.g., docetaxel and paclitaxel), camptothecin analogs (e.g., irinotecan and topotecan), enzymes (e.g., asparaginase), cytokines (e.g., interleukin-2 and interferon-α), monoclonal antibodies (e.g., trastuzumab and bevacizumab), recombinant toxins and immunotoxins (e.g., recombinant cholera toxin-B and TP-38), cancer gene therapy, physical therapy (e.g., hyperthermia, radiation therapy, and surgery), and cancer vaccines (e.g., vaccines against telomerase).
[0530] The compositions of the invention (e.g., antibodies, bispecific molecules) can also be administered with complement. Thus, within the scope of the invention are compositions comprising human antibodies, multispecific or bispecific molecules and serum or complement. These compositions are advantageous because complement is in close proximity to the human antibodies, multispecific or bispecific molecules. Alternatively, the human antibodies, multispecific or bispecific molecules of the invention and complement or serum can be administered separately.
[0531] The pharmaceutical composition can be formulated to be compatible with a specific local or systemic route of administration. Therefore, the pharmaceutical composition includes a carrier, diluent or excipient suitable for use by a specific route. The specific non-limiting example of the route of administration for the composition of the present invention is suction or intranasal delivery. Additional approaches include parenteral administration, such as intravenous, intradermal, subcutaneous, oral, transdermal (topical), transmucosal and rectal administration.
[0532] Solutions or suspensions for parenteral, intradermal or subcutaneous application may include: a sterile diluent, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for adjusting tonicity, such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
[0533] Pharmaceutical compositions for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and a suitable mixture thereof. For example, fluidity can be maintained by using a coating such as lecithin, by maintaining the desired particle size in the case of dispersion, and by using a surfactant. Antibacterial and antifungal agents include, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. Isotonic agents, such as sugars, polyols (e.g., mannitol, sorbitol), sodium chloride can be included in the composition. Including agents that delay absorption, such as aluminum monostearate and gelatin can prolong the absorption of the injectable composition.
[0534] Sterile injectable solutions can be prepared by incorporating the antibody or antigen-binding fragment thereof in the desired amount in an appropriate solvent together with one or a combination of the above-mentioned ingredients, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the antibody or antigen-binding fragment thereof into a sterile carrier containing a basic dispersion medium and the above-mentioned other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, preparation methods include, for example, vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution thereof.
[0535] For transmucosal or transdermal administration, penetrants suitable for barrier penetration are used in the formulation. Such penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays, inhalation devices (e.g., aspirators) or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gels, or creams generally known in the art.
[0536] Antibodies of the present invention, including subsequences and modified forms and nucleic acids encoding them, can be prepared with carriers that protect against rapid elimination from the body, such as controlled release formulations or time-delay materials, such as glyceryl monostearate or glyceryl stearate. Implants and microencapsulated delivery systems can also be used to deliver the composition to achieve local or systemic sustained delivery or controlled release.
[0537] Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such preparations are obvious to those skilled in the art. These materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to cells or tissues using antibodies or viral coat proteins) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0538] Other pharmaceutical formulations suitable for use in the compositions administered in the methods of the invention are known in the art (see, e.g., Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing Co., Easton, Pa.; The Merck Index (1996) 12th ed., Merck Publishing Group, Whitehouse, NJ; and Pharmaceutical Principles of Solid Dosage Forms, Technonic Publishing Co., Inc., Lancaster, Pa., (1993)). Pharmaceutical formulations may be packaged in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" as used herein refers to physically discrete units suitable as unitary dosages for the subject to be treated; each unit contains a predetermined quantity of antibody or antigen-binding fragment thereof calculated to produce the desired therapeutic effect, in association with a pharmaceutically acceptable carrier or excipient.
[0539] Although the pharmaceutical compositions provided herein are primarily directed to pharmaceutical compositions suitable for administration to humans, it will be appreciated by those skilled in the art that such compositions are generally suitable for administration to animals of all kinds. In order to make the compositions suitable for administration to various animals, modifications to pharmaceutical compositions suitable for administration to humans are well understood, and pharmacologists of ordinary skill can design and perform such modifications with little or no experimentation. It is contemplated that subjects to whom the pharmaceutical compositions of the present invention may be administered include, but are not limited to, humans and other primates and other mammals.
[0540] It is to be understood that any amino acid sequence, whether obtained naturally or synthetically by any means, which shows sequence, structural or functional homology to the polypeptides described herein is considered to be part of the present invention.
[0541] It should be understood that any reference to a publication, patent application, or issued patent is considered to be fully incorporated herein by reference in its entirety.
[0542] It will be appreciated that any assay for measuring a specific activity modulated by a therapeutic compound may be used as a means of determining the efficacy of the compound, in one embodiment determining optimal loading of the compound, in another embodiment determining timing and dosage, and in another embodiment determining a combination of the foregoing factors.
[0543] Methods for detecting PSMA
[0544] It will be appreciated by those skilled in the art that the antibodies, antigen-binding fragments or compositions provided herein can be used in diagnostic or therapeutic procedures.
[0545] In one embodiment, provided herein is a method for diagnosing the presence of a tumor or cancer growth in a subject. In another embodiment, the method comprises sampling a tissue sample isolated from a subject with a composition comprising an antibody or antigen binding fragment provided herein, whereby specific binding of the antibody or antigen binding fragment to the tissue sample indicates the presence of a tumor or cancer growth in the subject.
[0546] In another embodiment, the method further comprises detecting a second agent that specifically binds to the antibody or antigen-binding fragment but does not antagonize binding of the antibody or antigen-binding fragment to its target. In another embodiment, the "second agent" is a photoactivator, an enzyme, a tag, a label, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, or a fluorescent peptide.
[0547] In one embodiment, the terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma), neuroendocrine tumors, mesothelioma, schwannoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies.
[0548] In one embodiment, the term "cancer" includes but is not limited to ovarian cancer, breast cancer, glioblastoma, gastrointestinal cancer. In another embodiment, the cancer is prostate cancer.
[0549] In another embodiment, "sampling" includes the step of testing or analyzing a sample using a detection assay that enables detection of a second reagent that is complexed or coupled to the antibody or antigen-binding fragment, and when the antibody or antigen-binding fragment specifically binds to the target, it emits a detectable "signal." In another embodiment, detection is achieved using assays routinely used in the art, such as, but not limited to, immunoassays (e.g., immunohistochemistry, ELISA, etc.) or microscopic imaging.
[0550] In one embodiment, the term "labeled" refers to an antibody of the present invention that has one or more attached elements, isotopes or compounds to enable detection in screening. Generally, labels are divided into three categories: a) immunolabeling, which can be an epitope incorporated as a fusion partner that is recognized by the antibody, b) isotope labels, which can be radioactive or heavy isotopes, and c) small molecule labels, which can include fluorescent and calorimetric dyes or molecules, such as biotin that can enable other labeling methods. In one embodiment, the antibody of the present invention is labeled with biotin. In other related embodiments, the biotinylated antibodies of the present invention can be used as, for example, imaging agents or means for identifying one or more ligand molecules. In another embodiment, the marker can be a nanoparticle that can be detected or visualized once it is bound to the antibody or antigen binding fragment. The marker can be incorporated into the compound at any position and can be incorporated in vitro or in vivo during protein expression.
[0551] In one embodiment, the conjugates formed by the antibodies or antigen-binding fragments provided herein and the second agent are used in various applications, such as, but not limited to, flow cytometry, ELISA, Western blot, immunohistochemistry, membrane assays, and diagnostic and therapeutic methods as further described herein or as routinely used in the art.
[0552] Imaging of Tumors with Aberrant PSMA Expression
[0553] In one embodiment, the compositions of the invention are administered to a subject suffering from a disease involving inappropriate expression of a target antigen, protein, or other molecule. For example, in one embodiment, a composition comprising an antibody or antigen-binding fragment thereof that binds to PSMA is administered to detect the presence, abundance, location, or a combination thereof of PSMA in a subject. Within the scope of the present disclosure are diseases and conditions characterized by abnormal proteins, which are attributed to, for example, changes in the amount of protein present, protein localization, post-translational modifications, conformational states, the presence of mutants or pathogenic proteins, etc. Similarly, the disease or condition may be characterized by changes in molecules, including but not limited to polysaccharides and gangliosides. The excess may be due to any reason, including but not limited to overexpression at the molecular level, prolonged or accumulated appearance at the site of action, or increased activity relative to normal protein. Included within this definition are diseases and conditions characterized by a decrease in protein. This decrease may be due to any reason, including but not limited to reduced expression at the molecular level, shortened or reduced appearance at the site of action, mutant forms of the protein, or reduced activity of the protein relative to normal. Such excess or reduction of a protein can be measured relative to normal expression, appearance or activity of the protein, and this measurement can play an important role in the development and / or clinical testing of the antibodies of the invention.
[0554] In one embodiment, the disclosed antibodies or antigen-binding fragments thereof bind to an antigen expressed on a tumor cell, such as a prostate cancer cell, when administered to a subject. In another embodiment, the antibody or antigen-binding fragment thereof administered to a subject binds to an antigen expressed on the neovasculature of a solid tumor (e.g., a tumor with PSMA-positive neovasculature), including but not limited to lung cancer, liver cancer, pancreatic cancer, colon cancer, gastric cancer, breast cancer, ovarian cancer, kidney cancer, prostate cancer, bladder cancer, melanoma, glioma, etc.
[0555] In one embodiment, provided herein is a method for imaging a tumor containing PSMA. In some embodiments, the method comprises administering an antibody or antigen binding fragment thereof described herein to a subject or contacting a tissue sample with the antibody or antigen binding fragment thereof. In another embodiment, once the antibody or antigen binding fragment has bound to its target, such as a tissue or organ containing PSMA, a prostate or other type of solid tumor can be observed. In some embodiments, the antibody or antigen binding fragment thereof is operably linked to a second agent. In another embodiment, the second agent comprises a photoactivator, an enzyme, a label, a marker, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, or a fluorescent peptide. Non-limiting examples of second agents are provided below.
[0556] In one embodiment, the detectable label or a second agent linked thereto includes a label such as, but not limited to, a fluorescent label (e.g., fluorescein, isothiocyanate (FITC), cyanine dye, etc.), an affinity label (e.g., biotin, avidin, protein A, etc.), an enzyme label (e.g., horseradish peroxidase or alkaline phosphatase), or an isotopic label (e.g., 124I) or any other such detectable moiety to allow detection and separation of the antibody.
[0557] The detection method for identifying the binding species in the variable region population of the change can be direct or indirect, and can include the measurement of luminescence, radioisotopes, calorimetric dyes and fluorescent dyes, for example. Direct detection includes the method of operating to evaluate the amount of the antigen or ligand combined without an intermediate or secondary measurement procedure. Such a method usually uses a ligand that is itself labeled with, for example, a radioactive, luminescent or fluorescent moiety. On the contrary, indirect detection includes the method of operating by an intermediate or secondary measurement procedure. These methods usually use molecules that react with antigen or ligand specificity, and they themselves can be directly labeled or detected by a second reagent. For example, a second antibody that can interact with the first antibody of ligand specificity can be used, and the above-mentioned detection method for direct detection is used again to detect the antibody of ligand specificity. Indirect methods can additionally adopt enzyme-labeled detection. In addition, for the specific example of the screening of catalytic antibodies, the disappearance of the substrate or the appearance of the product can be used as an indirect measurement of binding affinity or catalytic activity.
[0558] In some embodiments, the antibody or antigen-binding fragment thereof is labeled with a near-infrared dye. For example, the antibody or antigen-binding fragment thereof can be labeled with IRDye800CW or indocyanine green (ICG).
[0559] In some embodiments, the antibody or antigen-binding fragment thereof is linked to a macrocyclic chelator for coupling radioactive metal ions to a polypeptide, including but not limited to 111In, 177Lu, 90Y, 166Ho, 153Sm, 215Bi and 225Ac. In some embodiments, the radioactive metal ion associated with the macrocyclic chelator attached to the antibody of the invention is 111In. In some embodiments, the radioactive metal ion associated with the macrocyclic chelator attached to the antibody polypeptide of the invention is 90Y. In a specific embodiment, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA). In a specific embodiment, the macrocyclic chelator is orthogonal-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraaza-cyclododecane-1,4,7,10-tetraacetic acid. In other specific embodiments, DOTA is linked to the antibody of the invention via a linker molecule. Examples of linker molecules for coupling macrocyclic chelators such as DOTA to polypeptides are well known in the art; see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90, 1998; Peterson et al., Bioconjug. Chem. 10(4):553-7, 1999; and Zimmerman et al., Nucl. Med. Biol. 26(8):943-50, 1999, the entireties of which are incorporated herein by reference. In addition, U.S. Pat. Nos. 5,652,361 and 5,756,065 disclose chelators that can be coupled to antibodies and methods for their preparation and use, the entireties of which are incorporated herein by reference.
[0560] definition
[0561] To aid understanding of the detailed description of compositions and methods according to the present disclosure, some clear definitions are provided to facilitate clear disclosure of various aspects of the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the field to which the present disclosure belongs.
[0562] As used herein, the term "conjugate" or "conjugated" or "linked" as used herein refers to the connection of two or more entities to form one entity. Conjugates include peptide-small molecule conjugates and peptide-protein / peptide conjugates.
[0563] The term "substantial identity" or "substantially identical", when referring to a nucleic acid or fragment thereof, means that when optimally aligned with another nucleic acid (or its complementary strand) for appropriate nucleotide insertions or deletions, there is nucleotide sequence identity in at least about 90%, or at least about 95%, 96%, 97%, 98%, or 99% of the nucleotide bases. As measured by any well-known sequence identity algorithm, such as FASTA, BLAST, or GAP, as described below. In some cases, a nucleic acid molecule having substantial identity to a reference nucleic acid molecule can encode a polypeptide having an amino acid sequence that is identical or substantially similar to a polypeptide encoded by the reference nucleic acid molecule.
[0564] When applied to polypeptides, the term "substantial similarity" or "substantially similar" means that two peptide sequences, when optimally aligned, for example by using the program GAP or BESTFIT with default gap weights, share at least 90% sequence identity or at least 95%, 98% or 99% sequence identity. Preferably, non-identical residue positions differ by conservative amino acid substitutions. "Conservative amino acid substitutions" are amino acid substitutions in which an amino acid residue is substituted by another amino acid residue with a side chain (R group) of similar chemical properties (e.g., charge or hydrophobicity). Typically, conservative amino acid substitutions do not substantially change the functional properties of a protein. In the case where two or more amino acid sequences differ from each other by conservative substitutions, the percentage or degree of similarity can be adjusted upward to correct for the conservative nature of the substitution. Means for performing such adjustments are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference. Examples of amino acid groups with side chains of similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxy side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine and methionine. In some embodiments, conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, conservative substitutions are any changes with positive values in the log-likelihood matrix, which are disclosed in Gonnet et al. (1992) Science 256: 1443 45, incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
[0565] The sequence similarity of polypeptide is usually measured using sequence analysis software. Protein analysis software uses similarity measures assigned to various substitutions, deletions and other modifications (including conservative amino acid substitutions) to match similar sequences. For example, GCG software includes programs such as GAP and BESTFIT, which can use default parameters to determine the sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from organisms of different species or sequence homology or sequence identity between wild-type proteins and their mutant proteins. See, for example, GCG Version 6.1. FASTA can also be used to compare polypeptide sequences under default or recommended parameters; a program in GCG 6.1 version. FASTA (for example, FASTA2 and FASTA3) provides comparison and sequence identity percentage of the best overlapping region between query and search sequence (Pearson (2000) the same). When the sequence of the present invention is compared with a database containing a large number of sequences from different organisms, another preferred algorithm is a computer program BLAST using default parameters, especially BLASTP or TBLASTN. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is incorporated herein by reference.
[0566] The term "Kassoc" or "Ka" as used herein refers to the association rate of a specific antibody-antigen interaction, while the term "Kdis" or "Kd" as used herein refers to the dissociation rate of a specific antibody-antigen interaction. The term "KD" as used herein refers to the dissociation constant, which is obtained by the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). The KD value of an antibody can be determined using methods known in the art. As an example, a method for determining the KD of an antibody is by using surface plasmon resonance, preferably using a biosensor system, such as a BIACORE system.
[0567] As used herein, the term "detectable label" refers to a detectable molecule, including but not limited to radioisotopes, fluorescent agents, chemiluminescent agents, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands (e.g., biotin, avidin, streptavidin or haptens), intercalating dyes, etc. The term "fluorescent agent" refers to a substance or a portion thereof that is capable of exhibiting fluorescence in a detectable range.
[0568] In many embodiments, the terms "object" and "patient" are used interchangeably, regardless of whether the object has or is currently experiencing any form of treatment. As used herein, the terms "object (subject)" and "subjects (subjects)" may refer to any vertebrate, including but not limited to mammals (e.g., cattle, pigs, camels, llamas, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats and mice, non-human primates (e.g., monkeys, such as cynomolgus monkeys (cynomolgus monkeys), chimpanzees, etc.) and people). Objects can be people or non-human. In more exemplary aspects, mammals are people. As used herein, expression "objects in need" or "patients in need" means showing one or more symptoms or indications of illness (e.g., neuronal illness, autoimmune disease and cardiovascular disease) and / or people or non-human mammals diagnosed with inflammatory conditions. In some embodiments, an object is a mammal. In some embodiments, an object is a person.
[0569] As used herein, the term "disease" is intended to be generally synonymous and may be used interchangeably with the terms "disorder" and "condition...
Claims
1. An antibody or an antigen-binding fragment thereof or a variant thereof, which specifically binds to prostate-specific membrane antigen (PSMA), wherein the antibody or antigen-binding fragment thereof comprises: a light chain variable region (LCVR) comprising three light chain complementarity determining regions (LCDRs) (LCDR1, LCDR2, and LCDR3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:9, the LCDR2 comprises the amino acid sequence of SEQ ID NO:13 or SEQ ID NO:41, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:17; and / or a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 25 or SEQ ID NO: 45, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 29, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 49, wherein the variant comprises one or more conservative amino acid substitutions in the LCDR1, the LCDR2, the LCDR3, the HCDR1, the HCDR2 or the HCDR3.
2. The antibody or antigen-binding fragment thereof or variant thereof according to claim 1, wherein: (a) the LCDR1 comprises the amino acid sequence of SEQ ID NO: 9, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; the HCDR1 comprises the amino acid sequence of SEQ ID NO: 25, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 29, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 33; (b) the LCDR1 comprises the amino acid sequence of SEQ ID NO: 9, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 17; the HCDR1 comprises the amino acid sequence of SEQ ID NO: 45, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 29, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 33; (c) the LCDR1 comprises the amino acid sequence of SEQ ID NO:9, the LCDR2 comprises the amino acid sequence of SEQ ID NO:41, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:17; the HCDR1 comprises the amino acid sequence of SEQ ID NO:45, the HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:33; or (d) the LCDR1 comprises the amino acid sequence of SEQ ID NO:9, the LCDR2 comprises the amino acid sequence of SEQ ID NO:13, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:17; the HCDR1 comprises the amino acid sequence of SEQ ID NO:45, the HCDR2 comprises the amino acid sequence of SEQ ID NO:29, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:
49.
3. The antibody or antigen-binding fragment or variant thereof according to any one of claims 1 to 2, wherein the light chain variable region comprises one or more of the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 39, SEQ ID NO: 43, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67 and SEQ ID NO:
69.
4. The antibody or antigen-binding fragment or variant thereof according to any one of claims 1 to 4, wherein the heavy chain variable region comprises one or more of the amino acid sequences of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59 and SEQ ID NO:
68.
5. The antibody or antigen-binding fragment thereof or variant thereof according to any one of the preceding claims, wherein: (a) the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 5, or comprises the amino acid sequence of SEQ ID NO: 5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 21, or comprises the amino acid sequence of SEQ ID NO: 21; (b) the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 70, or comprises the amino acid sequence of SEQ ID NO: 70; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 72, or comprises the amino acid sequence of SEQ ID NO: 72; (c) the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 71, or comprises the amino acid sequence of SEQ ID NO: 71; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO: 73, or comprises the amino acid sequence of SEQ ID NO: 73; or (d) the light chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:5, or comprises the amino acid sequence of SEQ ID NO:5; and / or the heavy chain variable region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:74, or comprises the amino acid sequence of SEQ ID NO:
74.
6. The antibody or antigen-binding fragment or variant thereof according to any one of the preceding claims, wherein the light chain variable region and the heavy chain variable region comprise the LCVR and HCVR amino acid sequence pairs of SEQ ID NO: 5 and SEQ ID NO: 21, SEQ ID NO: 70 and SEQ ID NO: 72, SEQ ID NO: 71 and SEQ ID NO: 73, or SEQ ID NO: 5 and SEQ ID NO:
74.
7. An antibody or antigen-binding fragment or variant thereof according to any one of the preceding claims, comprising a heavy chain / light chain sequence pair of SEQ ID NO: 75 and SEQ ID NO: 77, SEQ ID NO: 76 and SEQ ID NO: 78, SEQ ID NO: 69 and SEQ ID NO: 68, or SEQ ID NO: 75 and SEQ ID NO:
79.
8. The antibody or antigen-binding fragment thereof or variant thereof according to any one of the preceding claims, comprising at least one of the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO:
37.
9. An antibody or antigen-binding fragment thereof or variant thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is selected from IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD and IgE; or has a wild-type or aglycosylated immunoglobulin constant region and / or variable region of IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD and IgE.
10. An antibody or antigen-binding fragment thereof or variant thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof (i) is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, a mixture of monoclonal and / or polyclonal antibodies, a human antibody, a humanized antibody or a chimeric antibody, and / or (ii) is conjugated to a cytotoxic agent, a drug, a growth inhibitory agent, a toxin, an enzyme, a tag, a label, a radioisotope or a nanoparticle.
11. A bispecific or multispecific antibody or antigen-binding fragment thereof, which binds to two or more different epitopes on the same or different antigens, wherein one of the epitopes is on human prostate-specific membrane antigen (PSMA), and the bispecific or multispecific antibody comprises the light chain variable region and / or the heavy chain variable region of the antibody or antigen-binding fragment thereof or variant thereof according to any one of the preceding claims.
12. An isolated chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antigen-binding fragment thereof or a variant thereof according to any one of claims 1 to 10, a transmembrane domain, and an intracellular signaling domain comprising one or more stimulatory domains.
13. A nucleic acid molecule encoding a polypeptide chain of an antibody or antigen-binding fragment thereof or a variant thereof according to any one of claims 1 to 10, a bispecific or multispecific antibody or antigen-binding fragment thereof according to claim 11, or a CAR according to claim 12.
14. A vector comprising the nucleic acid molecule according to claim 13.
15. A cell comprising the nucleic acid molecule according to claim 13 or the vector according to claim 14.
16. A method for preparing an antibody or an antigen-binding fragment thereof, comprising: Obtaining the cell according to claim 15; culturing the cells in a culture medium under conditions that allow expression of the polypeptide encoded by the nucleic acid molecule and assembly of the antibody or fragment thereof; as well as The antibody or fragment is purified from the cultured cells or the culture medium of the cells.
17. A composition comprising an antibody or antigen-binding fragment thereof or a variant thereof according to any one of claims 1 to 10, a bispecific or multispecific antibody or antigen-binding fragment thereof according to claim 11, a CAR according to claim 12, a nucleic acid molecule according to claim 13, a vector according to claim 14 or a cell according to claim 15, and optionally a pharmaceutically acceptable carrier.
18. A kit comprising an antibody or antigen-binding fragment thereof or a variant thereof according to any one of claims 1 to 10, a bispecific or multispecific antibody or antigen-binding fragment thereof according to claim 11, a CAR according to claim 12, a nucleic acid molecule according to claim 13, a vector according to claim 14, a cell according to claim 15, or a composition according to claim 17.
19. Use of the composition of claim 17 in the preparation of a medicament for the diagnosis, prevention, treatment, or a combination thereof of a condition caused by a proliferative disease associated with PSMA expression in a subject.
20. A method for preventing or treating a proliferative disease associated with PSMA expression in a subject, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof or variant thereof according to any one of claims 1 to 10, the bispecific or multispecific antibody or antigen-binding fragment thereof according to claim 11, the CAR according to claim 12, the nucleic acid molecule according to claim 13, the vector according to claim 14, the cell according to claim 15, or the composition according to claim 17.
21. The method of claim 20, further comprising administering a second agent or treatment to the subject.
22. The method of claim 21, wherein the second agent or treatment comprises an anti-cancer agent.
23. A method of identifying a subject having a disease or condition associated with PSMA expression, comprising: providing a tissue sample from the subject; contacting the sample with the antibody or antigen-binding fragment thereof or variant thereof according to any one of claims 1 to 10; and Binding of the antibody, or antigen-binding fragment thereof, or variant thereof to the tissue sample is determined, wherein binding of the antibody, or antigen-binding fragment thereof, or variant thereof to the tissue sample indicates the presence of a disease condition associated with PSMA expression in the subject.
24. A method of imaging targeted to PSMA, comprising administering to a subject in need thereof an antibody or antigen-binding fragment thereof or variant thereof according to any one of claims 1 to 10 or a composition according to claim 17, wherein the antibody or antigen-binding fragment thereof or variant thereof is linked to an agent.
25. The method of claim 24, wherein the agent comprises a photoactivator, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, a fluorescent peptide, an imaging contrast agent, an enzyme, a nuclear magnetic resonance active agent, or a nanoparticle.
26. The method of any one of claims 20 to 25, wherein the disease comprises cancer.
27. The method of claim 26, wherein the cancer comprises prostate cancer.
Citation Information
Patent Citations
Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it
EP0090505B1
Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0425235B1
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1391213A1
Mammalian cell surface antigens; related reagents
EP1947183B1
Monomethylvaline compounds capable of conjugation to ligands
US20050238649A1
